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ABSTRACT 
Mesoderm induction early response 1 (mi-er1), previously called er1, was first 
isolated as a novel fibroblast growth factor-regulated early-response gene from Xenopus 
embryonic cells induced to differentiate into mesoderm. The human orthologue of xmi-
er 1, hmi-er 1, was found to have ubiquitous, but low level, expression in normal human 
tissues (Paterno et al., 1998; Paterno et al., 2002). Breast carcinoma cell lines and 
tumours, on the other hand, showed elevated levels (Paterno et al., 1998), suggesting that 
hmi-er 1 expression is associated with the neoplastic state in human breast carcinoma. 
Structurally, hMI-ERl has conserved domains found in a number of transcriptional 
regulators, including an acid activation domain (Paterno et al., 1997), an ELM2 domain 
(Solari et al., 1999) and a signature SANT domain (Aasland et al., 1996). 
My hypothesis is that hMI-ER1 may be a potent transcriptional regulator, and 
deregulation of its expression and/or functions may contribute to tumorigenesis. The 
purpose of this project was to: (1) isolate and characterize the hmi-er1 promoters; (2) 
investigate the role of hMI-ER1 in transcriptional regulation; and (3) identify and 
characterize hMI-ER1-interacting proteins. 
Cloning and sequence analysis of one of the hmi-er 1 promoters, P2, showed the 
absence of a TATA box, but presence of a CpG island, multiple Sp1 binding sites, and 
other factor binding sites which may be important in the regulation of gene expression. 
Functional characterization of the promoter revealed that Sp 1 binds to the promoter and 
plays a positive role in the regulation of the P2 promoter activity of hmi-er1. hMI-ER1 
1 
was found to function as transcriptional repressor on the GSTKCAT promoter by 
recruitment of HDACl via the ELM2 domain. hMI-ERla and p also function as 
transcriptional repressors on their own P2 promoter, through interaction with Sp 1 and 
interference with the Spl-DNA binding via the SANT domain. In order to better 
understand the function of hMI-ERl, an attempt was made to identify more hMI-ERl 
interacting proteins by yeast two-hybrid eDNA library screening. HSP40 and TRABID 
were identified as proteins that interact specifically with hMI-ERla and p. Furthermore, 
hMI-ERla and P were found to interact with the tumour suppressor RB and may 
participate in cell growth regulation. These results suggest that hMI-ERl may function 
as a transcriptional regulator, through distinct mechanisms, to regulate cellular functions. 
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SECTION I 
CHAPTER 1 GENERAL INTRODUCTION 
1.1 Development of cancer 
In mammals and other multicellular organisms, normal cells are controlled by 
their surroundings through signals such as growth factors, extracellular matrix 
components or ligands on neighbouring cells that dictate their behaviour: to grow, to stop 
growing, to die and so on. A normal cell also has its own signal transduction network to 
integrate and respond to the external messages so that the cell is in harmony with its 
environment (reviewed in Hanahan and Weinberg, 2000). Misregulated signal 
transduction pathways can result in the development of cancer, which is characterized by 
the uncontrolled growth of cells (reviewed in Hanahan and Weinberg, 2000). 
Cancer is a genetic disease caused by accumulation of mutations. Genetic 
mutation leading to cancer development comes from DNA damage or errors made by the 
DNA replication machinery (reviewed in Hoeijmakers, 2001). A mutation(s) in a single 
cell may cause the cell to divide abnormally, forming a mass of localized benign tumor 
cells. Subsequent mutations in a subset of the benign tumor cells may generate a 
malignant tumor cell, and this cell continues to divide and the progeny may invade the 
basal lamina that surrounds the tissue. Some of these tumor cells spread into blood 
vessels that will distribute them to other sites in the body. Some of the tumor cells may 
exit from the blood vessels and grow at distant sites; a patient with such a tumor is said to 
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have cancer. It is thought that cancer development in humans is a multi-step process 
caused by the progressive accumulation of lesions in multiple genes governing vital 
cellular functions (reviewed in Hanahan and Weinberg, 2000; Vogelstein and Kinzler, 
1993). 
Normal cells have the ability not only to identify and repair DNA damage 
(reviewed in Hoeijmakers, 2001), but also to prevent the expansion of mutation-laden 
daughter cells by cell growth arrest (see section 1.2) or apoptosis (see section 1.3). As 
such, cells maintain genomic stability and prevent mutation accumulation. Evidence 
suggests that the acceleration of the development of cancer lies in the disruption of those 
genes maintaining genomic stability (reviewed in Hoeijmakers, 2001; Shiloh, 2003). 
Once these genes are inactivated, further mutations would easily follow (Loeb, 2001). 
fudeed, genetic defects that disrupt DNA-damage response and repair systems, have been 
shown to cause severe syndromes that are characterized by the predisposition to cancer 
(reviewed in Hoeijmakers, 2001). Disruption of the DNA-damage response and repair 
systems result in genomic instability, which may also develop during tumour progression. 
For instance, the ability of tumour cells to evade cell grow arrest (see section 1.2) or 
apoptosis (see section 1.3) is associated with genomic instability. The increasing 
frequency of mutational events accompanying tumour progression provides a driving 
force for several of the properties of malignancy, such as self-sufficient growth signals 
(see section 1.1), limitless replicative potential (see section 1.4), sustained angiogenesis 
(see section 1.5), tissue invasion and metastasis (see section 1.6). 
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1.1.1 Self-sufficient growth signals 
It is thought that a normal somatic cell proliferates only in response to growth 
signals such as growth factors. In a cancer cell, the requirement for growth signals from 
their surroundings can be circumvented by three common molecular strategies: (1) 
enabling the cell to produce its own mitogenic signals; (2) through mutations activating 
growth factor receptors which lead to signalling in the absence of ligand; or, (3) through 
mutations in genes encoding components of the intracellular signalling network that 
translate those signals into action. The mutant forms of ras gene which encodes a 
constitutive activated protein, for example, is found in perhaps one quarter of all tumours 
in humans (reviewed in McCormick, 1991). These mutations release cells from 
dependence on exogenously derived signals and thus disrupt a critically important 
homeostatic mechanism that normally operates to ensure the appropriate behaviour of the 
various cell types within a tissue. 
1.1.2 Disrupted growth regulatory circuits 
Normal somatic cell proliferation not only depends on mitogenic signals, but is 
also usually limited by growth regulatory networks, such as the p16INK4A-cyclin D-RB 
pathway and the p19ARF-MDM2-p53 pathway (reviewed in Harbour and Dean, 2000; 
Sharpless and DePinho, 2002). 
At the heart of the p16INK4A-cyclin D-RB pathway is transcription factor E2F. 
E2F transcription factors regulate the expression of a number of genes that act in the G 1 
and S phases of the cell cycle. E2F activity is negatively regulated by RB through 
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multiple mechanisms (reviewed in Stevens and LaThangue, 2003). In turn, the ability of 
RB to inhibit the E2F activity is regulated through phosphorylation of RB by complexes 
consisting of cyclin dependent kinases (CDK) -4 and -6 and D type cyclins. Furthermore, 
the activity of CDK4 and 6 is negatively regulated by the CDK inhibitor p16INK4A. 
Disruption of the RB pathway results in inactivating the RB protein that releases E2Fs 
and thus allows cell proliferation (reviewed in Harbour and Dean, 2000). Inactivation of 
RB is associated with a significant proportion of human cancers including familial 
retinoblastoma, cervical carcinomas, prostate carcinomas, and breast carcinomas 
(reviewed in Sellers and Kaelin, Jr., 1997). Moreover, in a number of cancers, functional 
inhibition ofRB is achieved through inactivation of the pl6INK4A gene, by genetic lesions 
or by pl6INK4A promoter methylation (Sharpless and DePinho, 1999; Sherr, 2001). 
Overexpression of cyclin D1 has also been shown to inhibit RB (reviewed in Sicinski and 
Weinberg, 1997). Thus, the p16INK4A-cyclin D-RB pathway is a central growth 
regulatory pathway. When this pathway is inactivated, cells acquire a selective growth 
advantage during oncogenic transformation. 
p53 can arrest cell proliferation or induce apoptosis in response to DNA damage 
or inappropriate cell growth signals (reviewed in Sherr, 1998). p53 functions as a 
transcription factor that can activate the expression of a group of cellular genes involved 
in cell cycle arrest and induction of apoptosis. The importance of p53 in tumour 
suppression is underscored by the fact that p53 is probably the most frequently mutated 
gene in human cancer (reviewed in Sharpless and DePinho, 2002). Activity of p53 is 
negatively regulated by MDM2, a protein that has been detected in various human 
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tumours (reviewed in Momand and Zambetti, 1997). The p19ARF protein can bind 
MDM2, thereby preventing MDM2 from acting as a negative regulator of p53. 
Mutations involving the pl~ gene are again common events in cancer development. 
Impairment of p53 function by mutation, p19ARF inactivation, or by MDM2 
overexpression is associated with increased tumour incidence (reviewed in Sharpless and 
DePinho, 2002). Thus, the p19ARF-MDM2-p53 pathway is another central growth 
regulatory pathway whose inactivation is strongly selected for during oncogenic 
transformation. 
1.1.3 Evasion of apoptosis 
Apoptotic cell death can be characterized morphologically by blebbing of the 
plasma membrane, chromatin condensation, and phagocytosis by neighbouring cells 
(reviewed in Kerr et a/., 1972; Savill and Fadok, 2000). Along with the obvious 
morphological changes, distinct biochemical alterations are also associated with 
apoptosis. The most prominent is the induced activation of a family of cysteine proteases 
called caspases which cleave a variety of specific protein substrates (reviewed in Shi, 
2002; Thornberry and Lazebnik, 1998). Caspases are crucial components of apoptosis 
pathways. They are normally present in the cell as zyrnogens that require proteolysis for 
activation of enzymatic activity. The mammalian caspases have been divided into 
upstream initiator caspases such as caspase-8 and caspase-9, and downstream effector 
caspases such caspase-3, based on their sites of action in the proteolytic caspase cascade 
(reviewed in Shi, 2002; Thornberry and Lazebnik, 1998). Binding of initiator caspase 
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precursors to activator molecules appears to promote procaspase oligomerization and 
autoactivation by enzymatic cleavage of the procaspase into fragments. Enzymatic 
activation of initiator caspases leads to proteolytic activation of downstream effector 
caspases and then cleavage of a set of proteins, resulting in destruction of the cell 
(reviewed in Shi, 2002; Thornberry and Lazebnik, 1998). 
Two main apoptotic pathways leading to the execution of apoptosis have been 
identified: a mitochondria-dependent pathway and a parallel pathway involving 
activation of cell death receptors, such as those involved in Fas and tumour necrosis 
factor (TNF) receptor signalling (reviewed in Reed, 2000b ). Some cytokines, such as 
TNF-q can bind to their receptors on the plasma membrane, causing trimerization of the 
receptors. Trimerized cell death receptors interact with death adaptor proteins such as 
TNF receptor-1 (TNFR1)-associated death domain protein (TRADD), which can cause 
activation of initiator caspases such as caspase-8 (Baker and Reddy, 1998; Nunez et al., 
1998). 
The mitochondria-dependent pathway includes the release of the intermembrane 
space proteins such as cytochrome c (reviewed in Gross et al., 1999). Once binding to 
cytochrome c, the apoptotic proteinase activating factor-1 (APAF-1) can form a complex 
with and then activate initiator caspase-9 (Li et al., 1997; Zou et al., 1997). The 
mitochondrial pathway is governed by bcl-2 family proteins (reviewed in Coultas and 
Strasser, 2003). 
In multicellular organisms, homeostasis is maintained through a balance between 
cell proliferation and cell death (reviewed in Thompson, 1995). Mounting evidence 
6 
suggests that decreased cell death, especially by apoptosis, may result in an abnormal 
accumulation of cells during some of the tumour progression (reviewed in Reed, 2000a; 
Thompson, 1995). For example, studies in transgenic mice have confirmed the notion 
that the tumour suppressor role of p53 in vivo is closely linked to its ability to induce 
apoptosis by regulating the expression of members of the Bcl-2 family (Donehower et al., 
1995; Symonds et al., 1994). A number of viral oncoproteins have also been shown to 
play roles in regulating apoptosis. Examples are the E1B of adenovirus and E6 of human 
papillomavirus (HPV). E1B and E6 can disable the p53 pathway in apoptosis, interfering 
with the RB-mediated cell death response to E1A or E7, respectively (Debbas and White, 
1993; White, 1996). 
1.1.4 Limitless replicative potential 
The end of the human chromosome, the telomere, comprises an array of tandem 
repeats of the hexanucleotide 5 -TTAGGG-3 and its binding proteins (reviewed in 
Blackburn, 2001). These nucleoprotein structures function to anchor chromosomes 
within the nucleus, to protect chromosomes against exonucleases and ligases, and to 
prevent the activation of DNA-damage checkpoints (reviewed in DePinho and Wong, 
2003; Maser and DePinho, 2002). Moreover, telomeres assist the replication of 
chromosomes. Conventional DNA replication machinery utilizes an RNA primer to 
initiate DNA synthesis. The removal of the terminal RNA primer after DNA synthesis is 
complete, results in the absence of the 5 end of the daughter DNA strand. The 
incompletely replicated telomeres will then be inherited by the daughter cells. fu the 
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absence of a molecular mechanism to overcome this end replication problem , the 
telomeres progressively shorten as cells proceed through successive cell divisions. 
Eventually, the telomeres will be too short to continue to function as protective caps of 
the chromosomes, which are necessary for maintaining genomic stability (reviewed in 
DePinho and Wong, 2003; Maser and DePinho, 2002). Telomere shortening has been 
proposed as the mitotic clock marking the progress of a cell toward the end of its 
replicative life span, a process is evident by the consistent shortening of telomeres with 
aging of human tissues (Allsopp et al., 1992). However, telomere maintenance is evident 
in virtually all types of cancer cells (Shay and Bacchetti, 1997). Ongoing maintenance of 
telomeres is thought to be a prerequisite for the indefinite proliferation of cells - the 
phenotype of cell immortalization - and is thus clearly an intrinsic part of the 
tumorigenesis (Sharpless and DePinho, 2004). The majority of cancers succeed in 
maintaining telomeres by upregulating expression of the telomerase enzyme, which adds 
the telomeric TTAGGG hexanucleotide repeats de novo onto the ends oftelomeric DNA 
(Artandi and DePinho, 2000; Masutomi and Hahn, 2003). The remainder of cancer cells 
maintain telomeres though an alternative telomere (AL T) mechanism via recombination-
based interchromosomal exchanges of sequence information, which in tum permits 
unlimited multiplication of descendant cells (Artandi and DePinho, 2000; Masutomi and 
Hahn, 2003). 
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1.1.5 Sustained angiogenesis 
The process of new blood vessel formation is called angiogenesis. Angiogenesis 
is a complex multi-step process, which begins with local degradation of the basement 
membrane surrounding capillaries and then is followed by invasion of the surrounding 
stroma by the underlying endothelial cells in the direction of the angiogenic signals. 
Endothelial cell migration is accompanied by the proliferation of endothelial cells and 
their organization into three-dimensional structures that join with other structures to form 
a new blood vessel in tissues (Auerbach and Auerbach, 1994; Bussolino et al., 1997). 
The oxygen and nutrients in blood supplied by the vasculature are crucial for the 
survival of both normal and tumour cells. Tumour cells induce angiogenesis through 
their ability to release angiogenic signals which attract and stimulate endothelial cells. 
Tumours appear to induce angiogenesis by upregulating pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGFs), while 
downregulating anti-angiogenic factors such as thrombospondin-1 (Fidler et al., 2000; 
Hanahan and Folkman, 1996). These signals stimulate the endothelia cells which, in 
turn, construct capillaries within the tumour. 
1.1.6 Tissue invasion and metastasis 
Metastases are the major causes of human cancer deaths (Sporn, 1996). 
Metastasis is defined as the formation of secondary tumour foci at sites discontinuous 
from the primary lesion. The metastatic process is a complex composed of many steps in 
which tumour cells will: (1) detach from the primary tumour; (2) invade through the 
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ECM; (3) invade into the bloodstream; (4) migrate to the target site; (5) attach to target 
endothelium; (6) invade into the target tissue; and, (7) progressively growing secondary 
tumour. To invade and metastasize to other parts of the body, the cancer cell must have 
acquired altered expression of genes involved in the regulation of cell-cell and cell-matrix 
interactions. For example, E-cadherin function is lost in a majority of epithelial cancers 
(Christofori and Semb, 1999), while ECM degrading proteases are upregulated in tumour 
cells (Coussens and Werb, 1996). 
In summary, cancer development Is a multiple step process, and the 
transformation of a normal cell into a cancerous one requires deregulation of multiple 
distinct control mechanisms and the acquisition of multiple properties, which results from 
changes in cellular gene expression pattern. Gene expression is mainly controlled by 
transcription regulation (see below). 
1.2 Transcription regulation 
There are major differences in the gene expression patterns between cell types, 
despite the fact that all have the same set of inherited genes. The temporal and spatial 
control of gene expression encompasses many layers of complex mechanisms. The 
genetic information for proteins is encoded in DNA sequences. In order to produce 
proteins, the cell needs first to transcribe the DNA code into a sequence of messenger 
RNA (mRNA) molecules. This process is called transcription. Transcription is followed 
by translation, the synthesis of proteins according to the m.RNA sequence. Eukaryotic 
cells utilize a many intricate mechanisms, which is mostly centered at the transcriptional 
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regulation, to ensure that gene expression is properly regulated (reviewed in Alberts et 
al., 2002). In eukaryotic cells, transcription is controlled by interactions among the 
general transcriptional machinery, sequence-specific transcriptional regulators, 
mediators, DNA cis-acting regulatory elements, and unique local chromatin structure at 
cis-acting regulatory elements (see below). 
1.2.1 General transcription machinery and gene transcription 
Transcription involves several separate stages, including: (1) template 
recognition; (2) initiation of transcription; (3) elongation of transcription; and (4) 
termination of transcription. Transcriptional regulation is centered at promoter 
recognition and initiation (reviewed in Alberts et al., 2002). 
Eukaryotic genes are transcribed by three distinct RNA polymerases, namely 
RNA polymerase I, RNA polymerase II and RNA polymerase III (reviewed in Alberts et 
al., 2002). RNA polymerase I transcribes genes encoding the ribosomal RNAs, while 
RNA polymerase ill transcribes genes encoding the transfer RNAs and small nuclear 
RNAs (reviewed in Alberts et al., 2002). 
RNA polymerase II is the core protein of the enzyme complex responsible for all 
mRNA synthesis (reviewed in Alberts et al., 2002). The core eukaryotic RNA 
polymerase II enzyme requires a set of proteins called general transcription factors, 
which must be assembled at the promoter before transcription can begin. The term 
general refers to the fact that these proteins assemble on all promoters transcribed by 
RNA polymerase II. Therefore, they differ from sequence-specific transcriptional 
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regulatory proteins (section 1.2.2), which act only at particular gene promoters and/or 
enhancers (Alberts et al., 2002). The general transcription factors together with RNA 
polymerase constitute the basal transcription machinery, which is sufficient to mediate 
basal transcription. The general transcription factors for RNA polymerase II are called 
TFII (for Transcription factor for RNA polymerase ID, including TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH (Alberts et al., 2002). They are required for the initiation and 
elongation of mRNA (Alberts et al., 2002). The in vitro assembly scheme was shown in 
the Figure 1.1. Firstly, the core TATA box is recognized by the components of the 
TFIID complex (Figure 1.1A and B), including TATA-binding protein {TBP), and TBP-
associated factors (TAFs) (Alberts et al., 2002). TBP binds TFIIA and TFIIB (Figure 
1.1C), which further recruits the RNA polymerase II-TFIIF complex to the promoter 
(Figure 1.1D) (Alberts et al., 2002). Initiation of transcription additionally requires the 
binding ofTFIIE and TFIIH (Alberts et al., 2002). 
Although the general transcription factors and RNA polymerase II assemble in a 
stepwise order in vitro (see above), there are cases in living cells where some of them are 
brought to the promoter as a large pre-assembled complex that is called the RNA 
polymerase IT holoenzyme (Figure 1.2A and B) (reviewed in Alberts et al., 2002). In 
addition to some of the general transcription factors and RNA polymerase II, the 
holoenzyme typically contains a multi-subunit protein complex called the mediator (see 
section 1.2.3), which was first identified as being required to activate transcription by 
sequence-specific transcription regulators (see section 1.2.2). 
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Figure 1.1 Initiation of transcription of a eukaryotic gene by RNA polymerase II in 
vitro (adapted from Alberts et al., 2002). 
(A) To begin transcription, RNA polymerase requires a number of general transcription 
factors. First, TBP binds the TATA box. (B) The TATA box is recognized and bound by 
transcription factor TFIID, which then enables the adjacent binding of TFIIB (C). For 
simplicity, the DNA distortion produced by the binding of TFIID is not shown. (D) The 
rest of the general transcription factors including TFIIE, TFilli and TFIIF, as well as the 
RNA polymerase itself, assemble at the promoter. TFilli then uses ATP to pry apart the 
DNA double helix at the transcription start point, allowing transcription to begin. The 
assembly s~heme shown in the figure was deduced from experiments performed in vitro. 
Promoter 
A 
B 
c 
D 
Figure 1.2 Transcription of a eukaryotic gene by RNA polymerase TI in cells. 
(A) To begin transcription, transcriptional activators bind to cis-regulatory elements in 
promoters. (B) RNA polymerase II is brought to the promoter as a large pre-assembled 
complex that is called the RNA polymerase II holoenzyme, which also contains 
transcriptional regulator called mediator. For simplicity, the alterations of the chromatin 
structure are not shown. (C) Not only does the polymerase transcribe DNA into RNA, but 
it also carries a few critical components of pre-mRNA-processing proteins on its tail 
when it is phosphorylated late in the processing of transcription initiation. These 
components ofpre-mRNA-processing proteins then transferred to the nascent RNA at the 
appropriate time. Once transferred to an RNA molecule, they serve as a nucleation site 
for the remaining components. 
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Transcription in vivo 
Elongation of transcription is a stage during which the polymerase continues its 
movement along the DNA template as the precursor-rnRNA chain (pre-mRNA) grows. It 
is regulated by specific elongation factors as well as by phosphorylation of the RNA 
polymerase II tail, the C-terminal domain (CTD) of the largest subunit of RNA 
polymerase II (Figure 1.2C) (Alberts et a/., 2002). The phosphorylation of the RNA 
polymerase II tail dissociates the RNA polymerase II from other proteins present at the 
start point of transcription, and recruits a few critical components of pre-mRNA-
processing proteins (Figure 1.2C). These components of pre-mRNA-processing proteins 
are then transferred to the nascent RNA at the appropriate time. Once transferred to an 
RNA molecule, they serve as a nucleation site for other related components. 
The RNA processing events, including 5 end capping, splicing, and 3 end 
formation, are tightly coupled to transcription elongation and termination (Alberts eta/., 
2002; Proudfoot et a/., 2002). The long C-terminal tail of the RNA polymerase 
coordinates these processes by transferring pre-mRNA-processing factors directly to the 
nascent RNA as the RNA emerges from the enzyme. 
As soon as RNA polymerase II has produced about 25 nucleotides of RNA, the 5 
end of the new pre-mRNA molecule is modified by addition of a cap structure that 
consists of a modified guanine nucleotide. The capping reaction is performed by a 
phosphatase, a guanyl transferase and a methyl transferase acting in succession (Alberts 
et a/., 2002; Proudfoot et al., 2002). 
A typical euykaryotic gene in the genome consists of short blocks of protein-
coding sequence (exons) separated by long non-protein-coding sequence (introns). Both 
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intron and exon sequences are transcribed into pre-mRNA. As the polymerase continues 
its traverses the DNA template, the spliceosome components assemble on the pre-mRNA 
and the intron sequences are removed through the process that is called RNA splicing 
(Alberts et al., 2002; Proudfoot et al., 2002). 
Termination of transcription is a complex process that is regulated by mRNA 
3 end processing. The specific signals in the pre-RNA are recognized by mRNA 3 end 
processing factors. A multisubunit protein complex called cleavage and polyadenylation 
specificity factor (CPSF) recognizes the highly conserved AAUAAA hexamer sequence 
in the pre-mRNA, while another protein complex called cleavage stimulation factor F 
(CstF) recognizes a downstream sequence element (DSE) which is aU- or GU-rich motif 
(Proudfoot et al., 2002). Both of CPSF and CstF protein complexes travel with the RNA 
polymerase tail and are transferred to the 3 end of pre-mRNA sequence as it emerges 
from the RNA polymerase II. Once CstF and CPSF bind to specific nucleotide sequences 
on an emerging RNA molecule, additional proteins assemble with them to perform the 
processing that creates the 3 end of the mRNA. The pre-mRNA is cleaved between the 
AAUAAA hexamer and the DSE and a polyadenosine [poly(A)] tail is added to the 3 
end of RNA upstream of the cleavage site by an poly-A polymerase enzyme, a process 
called as polyadenylation (reviewed in Alberts et al., 2002; Proudfoot et al., 2002). The 
mRNA is then transported out to the cytoplasm, where it serves as a template to translate 
information into protein. After the 3 end of a pre-mRNA molecule has been cleaved, the 
RNA polymerase II continues to transcribe, but soon releases from the template and 
transcription terminates. The piece of RNA downstream of the cleavage site is then 
16 
degraded in the cell nucleus. The phosphates on the RNA polymerase II tail are removed 
by soluble phosphatases, and it can reinitiate transcription. 
1.2.2 Sequence-specific transcriptional regulators 
RNA polymerase II and the general transcription factors are sufficient for the 
basal transcription (Alberts et al., 2002). However, gene selective transcriptional 
activation requires the action of sequence-specific transcription activators that bind to the 
cis-acting regulatory elements. Conversely, transcription can be inhibited by sequence-
specific transcription repressors which, when bound to their cis-acting regulatory DNA 
elements, prevent the transcriptional machinery from transcribing a gene. It is thought 
that transcription activators and repressors serve as critical components of the 
transcription regulatory network that ensures accurate transcription of a given gene 
according to the needs of a cell at the right time. 
The majority of sequence-specific transcription regulators recognize and bind to 
cis-acting regulatory elements on the DNA. These cis-acting regulatory elements are 
often parts of larger regulatory entities called promoters and/or enhancers (see section 
1.2.5). Transcriptional regulators can bind to the cis-acting regulatory elements in the 
core promoter region or in a distant enhancer region, but their role in the regulation of the 
accessibility and activity of transcription machinery is similar (Alberts et al., 2002). 
DNA can bend and form loops, and thus even those transcription factors located at a 
distance from the promoter can still make physical contacts with the basal transcription 
machinery. Sequence-specific transcription factors may interact with the basal 
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transcription machinery by recruiting mediator complexes or modify the chromatin 
structure by recruiting chromatin modification complexes (reviewed in Alberts et al., 
2002). 
Eukaryotic sequence-specific transcription regulators typically possess two 
characteristic domains: a DNA binding domain (DBD) that binds sequence-specific 
regulatory sites directly, and a second domain that exhibits transcriptional activation or 
repression potential. In some cases this dual requirement is shared by separate proteins in 
a complex, so that the sequence-specific binding domain and transcription activation 
domain and/or repression domain occur on separate proteins. In this case, transcription 
regulators without a DNA binding domain assemble on other DNA-bound protein 
complexes through protein-protein interactions. For example, RB has no DNA binding 
domain but can form complexes with members of E2F family on the E2F target gene 
promoters to repress gene expression from the E2F-target gene such as cyclin E 
(reviewed in Stevaux and Dyson, 2002). 
It is generally thought that sequence-specific transcription regulators serve as 
protein-protein interaction interfaces which recruit other transcription regulators, 
including mediator (section 1.2.3) and/or chromatin modifiers (section 1.3), to regulate 
transcription (Alberts et al., 2002). For example, RB can function as a transcriptional 
repressor by recruiting multiple chromatin remodelling and/or chromatin modifier 
complexes to the E2F target gene promoters (reviewed in Ferreira et al., 2001). 
Moreover, multiple transcription activator and/or repressor complexes may act 
simultaneously on a specific promoter/enhancer. If the activity of activator complexes 
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exceeds the activity of repressor complexes, promoter-proximal nucleosomes sequentially 
adopt an activation-specific modification profile, and vice versa (Berger, 2002; Daujat et 
al., 2002; Zhang and Reinberg, 2001). Therefore, multiple sequence-specific 
transcription regulatory protein complexes work together allow individual genes to be 
turned on or off to carry out a desired cellular response. Transcriptional regulatory 
proteins may be expressed differently in different cell types and thereby results in distinct 
gene expression profiles that give each cell type its unique characteristics. 
1.2.3 Mediator complexes 
Mediator complexes are general transcription machinery-interacting coactivator 
complexes, which transmit regulatory signals from sequence-specific transcriptional 
regulators to the general transcriptional machinery (Naar et al., 2001). It has been 
suggested that mediator complexes bridge between transcription regulators and the 
general transcription machinery and promote the formation of a stable pre-initiation 
complex at the promoter (Naar et al., 2001). Several mammalian mediator complexes, 
such as cofactor required for Sp 1 activation (CRSP), vitamin D receptor-interacting 
protein (DRIP), thyroid hormone receptor-associated protein (TRAP) and activator-
recruited cofactor (ARC) mediator complexes have been identified (Naar et al., 2001). 
These mediator complexes share a many subunits (Naar et al., 2001). It is thought, 
therefore, that there may be both core protein components which are shared by different 
mediator complexes and numerous variable components which are dependent on 
particular sequence-specific transcriptional regulators, and the composition and activity 
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of a mediator complex on a particular promoter may be regulated by specific signals and 
may also be dependent on the distinct cell type. 
1.2.4 Regulating the transcriptional regulators 
The transcriptional regulators themselves may also be subjected to multiple levels 
of regulation, in which their expression and/or activity is affected. The expressions of 
many of transcriptional regulators are regulated by specific signals (Brivanlou and 
Darnell, Jr., 2002). For example, the early-response gene Xbra encodes an embryonic 
mesoderm-specific transcriptional regulator whose expression can be induced by FGF 
(Smith et a/., 1991). Transcriptional regulators may be also subjected to post-
translational modifications such as phosphorylation (reviewed in Freiman and Tjian, 
2003). Phosphorylation of RB, for example, is mediated by cyclin-dependent kinases 
(CDKs) at the restriction site at later G1 of the cell cycle. Release of E2F following 
phosphorylation of RB allows for the transcription of E2F target genes (reviewed in 
Harbour and Dean, 2000). In addition, it has been recently shown that transcriptional 
regulator activities may also be regulated by acetylation (Gu and Roeder, 1997; hnhof et 
a/., 1997; Martinez-Balbas et al., 2000; Sartorelli et al., 1999). For example, acetylation 
of several lysine residues at the C terminus of p53 by p300 protein regulates its 
transcriptional activity (Barlev et al., 2001; Prives and Manley, 2001). Other potential 
post-translational modifications, such as ubiquitination and sumoylation, can also 
regulate the activity oftranscriptional regulators (Freiman and Tjian, 2003). 
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The activity of transcriptional regulators may also be subjected to regulation by 
subcellular localization. For example, eukaryotic cells are characterized by distinct 
nuclear and cytoplasmic compartments separated by the nuclear envelope. Active 
nuclear transport of transcriptional regulators is based on recognition of specific signals 
in the molecule that is being transported. Proteins carrying a nuclear localization signal 
(NLS) can be transported into the nucleus, while proteins carrying a nuclear export signal 
(NES) can be transported out of the nucleus (Moroianu, 1999). Moreover, the subcellular 
localization of proteins may also be regulated through other mechanisms, including 
piggy back transportation through interaction with other proteins, masking of transport 
signals, and subcellular department sequestration (Macara, 2001). For example, 
cytoplasmic retention has been described for some hormone nuclear receptors (J ans and 
Hubner, 1996; Vandromme et al., 1996). This form of regulation leads to the 
transportation and/or immobilization of a protein within a specific cellular compartment, 
thus ensuring that a precise presence and function of a protein in a given compartment at 
a given time. 
1.2.5 Cis-acting regulatory elements 
Eukaryotic promoters for RNA polymerase II contain a variety of core cis-acting 
regulatory elements required for promoter function. Some examples of these elements 
include but are not limited to the initiator (Inr), TATA box sequence, downstream 
promoter element (DPE) and the GC box (Alberts et al., 2002). Each of those elements is 
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found in only a subset of promoters, and any specific promoter may contain some, all, or 
none of them (Butler and Kadonaga, 2002). 
The efficiency and specificity of transcriptional activity from a promoter depends 
upon multiple cis-acting regulatory elements. The cis-acting regulatory elements found 
in any individual promoter differ in number, location, and orientation. In some cases, the 
activity of a promoter is also affected by the presence of cis-regulatory elements called 
enhancers located at a variable distance from the promoter. The enhancers are distinct 
from that of the promoters and have two distinguishing characteristics: (1) the position of 
the enhancers relative to the promoter can vary substantially; (2) they can function in 
either orientation. The DNA cis-acting regulatory elements can be recognized by a 
corresponding transcriptional regulator or by a number of a family of factors. Binding of 
the transcription regulators at these cis-acting regulatory elements may exert influence on 
the formation of the transcription initiation complex. There are usually multiple cis-
acting regulatory elements clustered in the promoter/enhancer, where protein-protein 
interactions between transcription regulators may play an important role in regulating the 
promoter activity. The activities of many transcription factors have shown to be 
regulated by other regulators bound nearby (reviewed in Alberts et a/., 2002). Thus, a 
single transcription factor can play distinct regulatory roles in different gene promoters. 
This context-dependent regulation of transcription allows cells to respond to a 
surprisingly diverse array of stimuli using the same factors (reviewed in Alberts eta/., 
2002). The cis-regulatory sequences usually contain binding sites for multiple 
transcription factors and thus allow each gene promoter to respond to multiple signalling 
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pathways and facilitate the precise control of gene transcription (reviewed in Alberts et 
a/., 2002). 
1.2.6 DNA methylation and transcriptional regulation 
Even though each individual has the same set of genes inherited in their somatic 
cells, the structure and function of these cells may still differ from each other. Tissue-
specific gene expression patterns are established and maintained by certain epigenetic 
'marks', such as DNA methylation, within the genome to provide an important 
mechanism for distinguishing genes that are active from those that are not (Li, 2002). 
DNA methylation is the enzymatic addition of methyl groups to cytosine nucleotides that 
is mediated by DNA methyltransferases (DNMTs) (Bestor, 1988). DNMTs, such as 
DNMT3a, DNMT3b, are enzymes that are responsible for the de novo methylation. Other 
DNMTs, such as DNMTl, are responsible for the maintenance of methylation (Newell-
Price eta/., 2000). The methylated form of cysteine, 5-methylcytosine (5-methyl C), has 
no effect on base-pairing. The methylation in DNA is restricted to cytosine (C) 
nucleotides in the sequence CpG, which is base-paired to exactly the same sequence in 
the opposite orientation on the other strand of the DNA helix. The existing pattern of 
DNA methylation can be inherited directly by the daughter DNA strands. 
These CpG sequences are found to be clustered as dense regions of CpGs, called 
CpG islands (Antequera and Bird, 1993). They are mainly in the 5'-regions of genes 
(Antequera and Bird, 1993). The state of gene promoter methylation is associated with 
transcriptional repression (Bird and Wolffe, 1999). The biological importance of CpG 
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methylation is directly demonstrated by the fact that mice lacking the dnmtl gene exhibit 
defects in embryogenesis at mid-gestation (Li et al., 1992). The transcriptional 
repression effects of CpG methylation are mainly mediated by methyl-CpG-binding 
domain (MBD)-containing proteins (reviewed in Ballestar and Wolffe, 2001). Much 
evidence has accumulated to indicate a close association between DNA methylation-
dependent repression and chromatin modification complexes (see section 1.3.6). 
1.3 Chromatin and transcription regulation 
Additional levels gene transcription regulatory complexity in eukaryotic cells are 
achieved by the folding of the DNA template into chromatin (Pazin and Kadonaga, 
1997). Thus, transcriptional regulation is not only dictated by the DNA sequence, but is 
also affected by the structure of chromatin, which controls the access of general 
transcription machinery to the promoter. The unique local chromatin structure at 
promoter and enhancer regions allows the cell to tightly control specific gene expression 
(Ashraf and Ip, 1998; Gregory and Horz, 1998; Torchia et al., 1998). 
1.3.1 Chromatin structure 
The basic building block of chromatin is the nucleosome. It consists of a short 
segment of DNA wrapped around an octamer of histones represented by two copies each 
of histone H2A, H2B, H3, and H4 (Alberts eta!., 2002). . Each nucleosome is connected 
to its neighbours by a short segment of linker DNA. This polynucleosome string is 
folded into a compact fibre which is stabilized by the binding H1 histone, to each 
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nucleosome and to its adjacent linker (Alberts et al., 2002). The DNA wound around the 
surface of the histone octamer is only partially accessible to other proteins and therefore 
provides a poor template for biochemical reactions such as transcription. 
The N-terminal tails of histones that protrude from the nucleosome (Davie and 
Chadee, 1998). The histone tails are unstructured and serve as targets for variable 
covalent post-translational modifications, including acetylation, phosphorylation, 
methylation, sumoylation, and ubiquitination (reviewed in Spencer and Davie, 1999; 
Strahl and Allis, 2000). This has led to the histone code hypothesis that the 
modification state of the histone termini make up a histone code , which can be read by 
other ptoeins proteins that modulate transitions between the different chromatin states 
(Jenuwein and Allis, 2001; Orphanides and Reinberg, 2002; Strahl and Allis, 2000). This 
histone code hypothesis suggests that the presence of a given modification on histone 
tails may dictate or prevent the occurrence of a second modification elsewhere on the 
chromatin. This histone code hypothesis thus predicts that histone modifications create 
binding sites for accessory proteins. In this way, these modifications serve as marks for 
the recruitment of different proteins or protein complexes to regulate gene expression 
(Jenuwein and Allis, 2001; Strahl and Allis, 2000; Thiagalingam et al., 2003). For 
instance, heterochromatin protein 1 (HP1) uses its chromodomain to recognize the 
histone H3 lysine 9 modification found in heterochromatin (Richards and Elgin, 2002). 
A number of studies have highlighted the important role of histone tails in chromatin 
folding and gene transcriptional regulation (Hayes and Hansen, 2001). The two most 
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important ways of locally altering chromatin structure are through nucleosome 
remodelling and covalent histone modification such as histone acetylation. 
1.3.2 Chromatin remodelling complexes and transcription regulation 
Chromatin remodelling factors use the energy derived from ATP hydrolysis to 
catalyze nucleosome mobilization, which involves a change in the position of the histone 
octamer on DNA. This change is believed to facilitate the access and function of key 
components of the transcriptional machinery to regulate gene transcription (Imbalzano et 
al., 1994). 
Chromatin remodelling complexes may be directed by transcription regulators to 
specific sites of a gene promoter to affect local chromatin structure (Peterson and 
Workman, 2000). For example, chromatin remodelling complexes can physically 
associate with nuclear receptors (Wallberg et al., 2000; Yoshinaga et a!., 1992). The 
transcription factor c-Myc was also shown to bind directly to subunits of mammalian 
SWI/SNF complexes (Cheng et al., 1999; Kowenz-Leutz and Leutz, 1999). Interestingly, 
chromatin remodelling complexes, such as the NURD complex, appear to be important 
not only for transcriptional activation, but also for transcriptional repression (Bird and 
Wolffe, 1999; Knoepfler and Eisenman, 1999). Moreover, the recruitment of a 
remodelling complex to the promoter may also facilitate binding of other transcriptional 
regulators whose binding sites were not previously exposed in the nucleosomes (Narlikar 
et al., 2002). 
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1.3.3 Histone acetyltransferase (HAT) complexes and transcription regulation 
Histone acetylation is a process in which acetyl groups are added to the a-groups 
at specific lysine residues in the N-tenninal regions of the core histone proteins. Histone 
acetylation is believed to destabilize nucleosomes, thereby causing the opening of the 
chromatin structure. With the opening of the chromatin structure, the transcription 
activators and the basal transcription machinery have better access to their specific 
binding sites in the gene promoter and/or enhancer sites (Figure 1.3A) (Ayer, 1999; 
Grunstein, 1997). Indeed, actively transcribed genes have been correlated with increased 
levels of histone acetylation (hyperacetylation), whereas silenced genes are generally 
associated with decreased levels of histone acetylation (hypoacetylation) (Roth et al., 
2001). 
Histone acetylation is catalyzed by HAT enzymes. Many studies have 
demonstrated the importance of HAT activity in the activator-dependent transcriptional 
activation (Roth et al., 2001). There is a direct functional link between the transcriptional 
machinery and HATs. Some HATs are actually tightly associated with the RNA 
polymerase II transcription machinery itself. For example, the TBP-associated factor, 
RNA polymerase II 251-KD {TAFII251) subunit ofTFIID, was found to contain intrinsic 
HAT activity (Mizzen et al., 1996). Moreover, a number of mammalian transcriptional 
regulators, primarily identified by interactions with activation domains of sequence-
specific transcription activators, have been found to exhibit HAT activity. Examples are 
the cAMP response element (CRE) binding protein (CREB)-binding protein (CBP) and 
the related adenovirus E1A-interacting protein p300 (Goodman and Smolik, 2000). 
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Figure 1.3 HAT and HDAC-dependent mechanisms of gene transcription 
regulation. 
Local alterations of chromatin structure on promoters are emerging as a mechanism of 
precise regulation of transcription. Numerous studies have linked post-translational 
histone modifications, particularly the acetylation and deacetylation of lysine residues in 
histone N-terminal tails, with the transcriptional capacity of chromatin. Acetylation and 
deacetylation are catalyzed by HATs and histone deacetylases (HDACs), respectively. 
(A) Acetylation is believed to destabilize nucleosomes, at least in part, and thus facilitate 
access of the general transcription machinery, thereby promoting transcription. (B) 
Deacetylation is likely to stabilize nucleosomes and/or the higher order structure of 
chromatin further and thus reinforces the inhibitory effect of chromatin. 
A 
Transcription 
B 
CBP/p300 is recruited by many transcription factors (Kornberg, 1999), and the action of 
CBP/p300 appears to require its HAT activity (Glass and Rosenfeld, 2000; McKenna et 
al., 1999). Different HATs were shown to exist in multisubunit complexes, and may 
have different subunit compositions (reviewed in Roth et al., 2001 ). For example, yeast 
GCN5p has been found in two distinct complexes, the SPT-ADA-GCN5-
acetyltransferase (SAGA) complexes and the adaptor (ADA) complexes (Grant et al., 
1997). Two mammalian homologs of GCN5p, hGCN5 and PCAF have been identified 
(Candau et al., 1996; Wang et al., 1997; Yang et al., 1996). Both hGCN5 and PCAF has 
been shown to be present in multisubunit complexes (Brand et al., 1999; Martinez et al., 
1998; Ogryzko et al., 1998; Wieczorek et al., 1998). 
1.3.4 Histone deacetylase complexes and transcription regulation 
The degree of acetylation of core histone tails has been shown to be dependent on 
the opposing activities of two types of enzymes, HATs and histone deacetylases 
(HDACs). Histone deacetylases (HDACs) are enzymes that remove the acetyl groups 
from the lysine residues of core histone proteins, influencing nucleosome structure in the 
opposite way to histone acetylation. Histone deacetylation, and hence histone 
hypoacetylation, is likely to stabilize nucleosomes and/or the higher order structure of 
chromatin, further reinforcing the inhibitory effect of chromatin structure on gene 
transcription (Figure 1.3B) (Braunstein et al., 1996; Lee et al., 1993a). 
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HDACs are subunits of large protein complexes such as mSin3A, NURD, and 
CoREST, that play important roles in transcription repression (reviewed in Thiagalingam 
et al., 2003). Many sequence-specific transcription factors form a complex with mSin3A, 
NURD and CoREST. For example, the transcription factor Snail recruit mSin3A-
HDAC112 complex to repress E-cadherin expression (Peinado et al., 2004). 
1.3.5 Interplay of distinct chromatin modification complexes and transcription 
regulation 
The modification of chromatin by acetylation/deacetylation to allow transcription 
is more complex than simple addition or removal of acetyl groups to histones. Recently, 
it has been suggested that there is interplay of histone modification with chromatin-
remodelling as well as with DNA methylation (see below). 
(a) Complexes containing chromatin remodelling enzymes and HDACs 
The chromatin-remodelling complexes play a major role in chromatin remodelling 
and are not only associated with activators but also found to form complexes with 
corepressors such as HDACs. fudeed, chromatin-remodelling complexes plays important 
roles in both regulation of transcription and gene repression (Neely and Workman, 2002). 
For example, the NURD complex :from HeLa human cervical carcinoma cells contains 
Mi-2, HDACl/2 and the RBAP46/48, MTA2 and MBD3 proteins (Guschin et al., 2000; 
Knoepfler and Eisenman, 1999). The ATPase activity ofMi-2 can increase the efficiency 
of histone deacetylation by NURD complexes in cell-free systems (Guschin et al., 2000; 
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Tong et al., 1998; Xue et al., 1998b). The nucleosome remodelling activity ofNURD is 
required for the deacetylation activity of NURD, which suggests that chromatin 
remodelling facilitates the access of the HDACs in NURD to the histone tails. 
(b) HAT-HDAC complex 
It is possible that some complexes possess both HAT and HDAC activity and 
therefore may be recruited for both transcriptional activation and repression, depending 
on the cellular context and under the appropriate stimuli. A recent study, for instance, 
showed that endogenous HDACs are associated with PCAF and GCN5 HATs, in HeLa 
cells (Yamagoe et al., 2003). These large multiprotein HAT-HDAC complexes were 
found to be distinct from the previously described mSin3A, CoREST and NURD 
complexes (Yamagoe et a!., 2003). The dynamic association with HAT-HDAC 
complexes may be regulated by distinct signals. For example, coactivator CBP and 
corepressor HDACs complexes have been shown to bind the homeodomain heterodimer 
PBX-HOX simultaneously, while protein kinase A (PKA) stimulation of CBP has been 
found to facilitate the switch from transcriptional repression to activation in this system 
(Asahara et al., 1999; Saleh et al., 2000). 
(c) Interplay of DNA methylation and HDAC complexes 
DNA methylation correlates with gene repression (section 1.2.2). A number of 
studies lead to the suggestion that DNA methyltransferases might be link to the histone 
deacetylation and gene transcriptional repression. The two repression mechanisms, 
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histone deacetylation and DNA methylation, are apparently connected by the methyl-CpG 
binding proteins (MBPs), such as MeCP2, MBDl, MBD2, MBD3, and MBD4. MBPs 
are believed to recruit chromatin remodelling and modification complexes, including the 
NURD complex (Ng et al., 1999; Tyler and Kadonaga, 1999; Zhang et al., 1999). It has 
been proposed that DNA methylation and histone deacetylation might work together in 
some gene promoters to establish a repressive chromatin environment and silence gene 
expression (Cameron et al., 1999). 
1.4 Xenopus mesoderm induction early-response gene (xmi-erl) 
1.4.1 FGF signalling transduction 
FGFs comprise a family of 22 distinct proteins, numbered consecutively from 1 to 
22 (reviewed in Ornitz and Itoh, 2001). FGF signalling plays important roles in regulate 
developmental processes and adult physiology, and deregulated FGF signalling pathways 
have been shown to be involved in tumorigenesis (Powers et al., 2000). FGFs signal 
through FGF receptors (FGFRs ), which are transmembrane tyrosine kinase receptors. 
There are four FGFRs, designated FGFRl, FGFR2, FGFR3 and FGFR4 (Johnson and 
Williams, 1993). Following ligand binding and dimerization, the receptors phosphorylate 
specific tyrosine residues on their own and each others cytoplamic domains (Lemmon 
and Schlessinger, 1994). The signal cascade is propagated by the recruitment of other 
signalling molecules onto the phosphorylated tyrosine residues of the activated receptors 
resulting in the activation of downstream transduction pathways that eventually lead to 
initiation of a specific set of gene expression (Pawson, 1995). The biological outcome of 
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FGF stimulation depends on a number of factors, including receptors and signalling 
network present in a particular cell. The effects of FGFs on different cellular functions 
are mediated by distinct combinations of signalling pathways including the MAPK 
pathway, phosphoinositide 3 kinase pathway (PI3K), and the phospholipase C-yl 
(PLCy1) pathway (Hawkins et al., 1997; Kamat and Carpenter, 1997; Szebenyi and 
Fallon, 1999). These transduction cascades are initiated by the autophosphorylation of 
the FGFRs upon ligand binding. 
The MAPK pathway is propagated through the recruitment of SH2 domain and/or 
PTB domain docking proteins to the activated FGF receptor. Docking molecules, such as 
FRS2, bind to the phosphorylated receptor and recruit the GRB2-son of sevenless (SOS) 
complex. This puts SOS in close vicinity with RAS, which is also membrane bound. 
SOS promotes the dissociation of GDP from RAS, allowing RAS to acquire GTP 
molecules and to become activated (Ferrell, Jr., 1996). The activated membrane-
associated RAS then recruits and activates RAF-1, a serine-threonine MAPK kinase 
kinase (MAPKKK). In turn, RAF-1 activates MEK, a MAPK kinase (MAPKK), which 
activates MAPK also known as ERK1 (p44) and ERK2 (p42). MAPK can signal directly 
to the nucleus by phosphorylating transcriptional regulators such as Elk1 (Buchwalter et 
al., 2004).. In addition, besides nuclear substrates, MAPK has been found to 
phosphorylate cytosketal proteins, phospholipase, and protein kinases (Ferrell, Jr., 1996). 
Previous reports have established that activation of PI3K, which is a lipid kinase, 
can be achieved either by binding ofPI3K to the receptor complex or by direct binding of 
activated RAS to the catalytic subunit ofPI3K (Cantrell, 2001; Carballada et al., 2001; 
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Ryan eta!., 1998). Activated PI3K phosphorylates the 3 -OH position of the inositol ring 
of membrane phosphatidylinositols (Ptdlns) (reviewed in Lawlor and Alessi, 2001). 3-
phosphorylated Ptdlns in turn act as second messagers to recruit AKT and its regulators 
PDKl and PDK2 to the cell membrane, where PDK1 and PDK2 phosphorylate AKT 
(Scheid and Woodgett, 2003). Activated AKT in turn phosphorylates a number of 
targets, including transcription factors such as transcription factor FOXO (Birkenkamp 
and Coffer, 2003). 
PLCy has been shown to be associated with FGFR and is phosphorylated 
following ligand-dependent activation (Burgess et al., 1990; Gillespie et al., 1992; 
Mohammadi et al., 1991; Ryan et al., 1998; Ryan and Gillespie, 1994). Activated PLCy 
then initiates hydrolysis of phosphatidylinositol 4,5-biphosphate to diacylglcerol (DAG) 
and inositol1,4,5-trisphosphate (IP3). DAG is an activator of protein kinase C (PKC), a 
serine-threonine kinase, and IP3 initiates Ca2+ release from intracellular stores. Second 
messengers, like PKC and Ca2+, activate several molecules including transcription factors 
such as c-FOS and thereby bring about desired cellular responses (Kamat and Carpenter, 
1997; Slootweg et al., 1991). 
1.4.2 Early-response genes 
In a signal transduction cascade, such as that induced by FGFs, communication 
from the extracellular environment to the nucleus results in rapid changes in the steady-
state levels of mRNAs of many genes. These genes are the first genes to be transcribed 
in signal transduction pathways and known as early-response genes or immediate-early 
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genes (reviewed in Thomson et al., 1999). For example, Xbra is a well-characterized 
FGF early-response gene in Xenopus. Expression of Xbra is an early response to 
mesoderm induction by FGFs (Smith et al., 1991). The expression of the early-response 
genes is not dependent on de novo protein synthesis and is normally rapid. The majority 
of early response genes are transcription factors. Their expression can therefore lead to 
the initiation or termination of transcription of other genes that ultimately carry out the 
requirements of functions relayed by the original signal. Therefore, the early response 
genes are considered to be master regulators in signalling transduction, such as FGF 
signalling transduction. Thus, isolation and characterization of early response genes may 
lead to the identification of pivotal points in the signal transduction cascade which 
determine the response of a target cell. 
1.4.3 Isolation of xmi-er 1 
Embryos from the amphibian Xenopus laevis, have been used as a model system 
for studying early response genes in FGF signalling transduction in Paterno and Gillespie 
laboratories (Paterno et al., 1997; Ryan et al., 1998; Ryan and Gillespie, 1994; Teplitsky 
et al., 2003). Most studies were conducted by animal cap experiments in which an 
explant is taken from the prospective ectoderm of a blastula stage embryo and incubated 
with FGF-2 in an attempt to identify the particular early response genes that are active in 
the FGF signalling cascade. The discovery of a novel, developmentally regulated gene 
that was activated by FGF-2 in Xenopus was a result from this search (Paterno et al., 
1997). This gene was designated mesoderm induction ~arly response 1 (mi-erl), since it 
35 
expresses during mesoderm induction and may function as a negative regulator of 
mesoderm induction (Teplitsky et al., 2003). Xenopus mi-er 1 was identified through the 
PCR-based differential display method and demonstrated increased expression levels in 
animal cap explants in response to treatment by FGF-2 (Paterno et al., 1997). The eDNA 
sequence isolated from the differential display was then used to isolate a full-length 2.3 
kilobase-pair (kb) eDNA from a Xenopus blastula library (Paterno et al., 1997). The 
Xenopus mi-er1 eDNA cloned consists of a 1.479 kb single open reading frame (ORF) 
predicted to encode a protein of 493 amino acid residues (Paterno et al., 1997). 
The expression levels of xmi-er 1 were found to increase in Xenopus embryo 
animal cap explants during mesoderm induction by FGF-2. The steady-state levels of 
xmi-er1 were shown to increase 3-4 fold upon treatment with FGF-2. However, the 
increase in xmi-er 1 levels was not due to de novo protein synthesis as cycloheximide, 
which is an inhibitor of protein synthesis, did not affect the FGF-induced increase in xmi-
er 1 levels, thus demonstrated that xmi-er 1 is an early-response gene (Paterno et al., 
1997). 
A database homology search revealed similarity in the predicted xMI-ER1 amino 
acid sequence to rat and human proteins encoded by the metastasis-associated gene 1 
(mta1), a gene that was isolated by differential eDNA library screening and whose 
expression was associated with a metastatic phenotype (Nicolson et al., 2003; Toh et al., 
1994). However, xmi-er1 is not the Xenopus homolog of mta1, since a human homolog 
of xmi-er1, hmi-er1, has been found and is distinct from human mta1 (Paterno et al., 
1997; Paterno et al., 1998). 
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1.4.4 Expression and subcellular localization of xMI-ERl 
Northern blot analysis of RNA extracted from Xenopus laevis embryos showed 
the presence of xmi-er 1 during initial cleavage stages, suggesting that most xmi-er 1 
transcripts may be initially maternally derived. The levels of xmi-er 1 mRNA expression 
were constant during early cleavage, increased slightly at blastula stage and decreased 6-
fold during gastrula, neurula and tailbud stage. The levels then remained below 
detectable levels during subsequent development (Paterno et al., 1997). 
The subcellular localization of endogenous xMI-ER1 protein during Xenopus 
laevis development has been investigated using immunohistochemistry with anti-MI-ER1 
antibody (Luchman et al., 1999). xMI-ER1 is found to be expressed during early stages 
of development, but only localizes to the nucleus around the mid-blastula transition 
(MBT). xMI-ER1 is found exclusively in the cytoplasm during early stages but then is 
found to progressively accumulate in the nuclei of marginal zone cells of stage 8 
blastulae. xMI-ER1 is found exclusively in all nuclei in the animal hemisphere by late 
blastula stage and ubiquitous nuclear localization is observed by early gastrula. Nuclear 
xMI-ER1 staining decreases during tailbud stages (Luchman et al., 1999). Further 
investigation revealed that there is a domain responsible for the cytoplasmic retention of 
xMI-ER1 before MBT, and this retention domain is located between the ELM2 and 
SANT domain (Post et al., unpublished data). 
With forced expression in Nlli 3T3 cells, xMI-ER1 protein is found to be 
constitutively targeted to the nucleus in these cells (Paterno et al., 1997). Analysis of the 
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basic amino acids and comparison of groups of basic amino acids to NLS described in the 
literature showed that xMI-ERl has 4 putative NLSs, which were designated as NLS1, 
NLS2, NLS3, and NLS4 (Paterno et al., 1997; Post et al., 2001). Further investigation 
revealed that NLS4 on the C-terminal region is a functional NLS, and NLS 1 may 
function as a weak NLS for xMI-ERl (Post eta/., 2001). 
1.4.5 xMI-ERl functions as a transcriptional regulator 
As mentioned above, xMI-ER1 was identified as an early response gene induced 
by FGF-2 (see 1.4.3). xMI-ER1 is a nuclear protein (see 1.4.4) (Luchman eta/., 1999; 
Post eta/., 2001). Structurally, xMI-ER1 has conserved domains found in a number of 
transcriptional regulators, including an acid activation domain (Paterno eta/., 1997), an 
ELM2 domain (Solari eta/., 1999) and a signature SANT domain (Aasland eta/., 1996). 
These observations suggested that xMI-ER1 may function as a transcriptional regulator. 
The possibility that xMI-ER1 is a transcriptional regulator was investigated by testing the 
transactivation potential of various regions of the xMI-ER1 protein. Constructs 
containing different regions of xMI-ER1 fused to the GAL4 DNA binding domain were 
used along with a chloramphenicol acetyltransferase (CAT) reporter plasmid in transient 
transfections (Paterno et a/., 1997). Although full-length xMI-ER1 did not activate 
transcription in NIH 3T3 cells, the region consisting of the N-terminal 98 amino acids of 
xMI-ER1 stimulated transcription 80-fold. Fusion with other parts of xMI-ER1 did not 
have any transcriptional activity. These results indicated that the N-terminal region 
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contains a transcription activation domain, and xMI-ER1 has the potential to function as a 
transcription activator (Paterno et al., 1997). 
A recent study revealed that overexpression of xMI-ER1 in Xenopus embryos 
resulted in a dramatic reduction of Xbra expression, suggesting that xMI-ER1 may 
function as a transcription repressor as well (Teplitsky et al., 2003). Xbra is a mesoderm 
induction regulator which is able to induce mesoderm (Cunliffe and Smith, 1994). In 
agreement with the reduction inXbra expression, overexpression ofxMI-ER1 in Xenopus 
embryos significantly inhibited mesoderm induction induced by FGF-2, and resulted in 
truncations of the anteroposterior axis (Teplitsky et al., 2003). These observations 
indicated that xMI-ER1 may be a negative regulator of the FGF signalling pathway, 
perhaps by acting as both a transcriptional repressor on target genes such as Xbra, and a 
transcription activator on other genes. 
1.5 Human homologue of xMI-ER1, hMI-ER1 
1.5.1 hmi-erl isolation and genomic structure 
A human orthologue of xmi-er 1 was previously cloned from human testis eDNA 
library in the laboratory, and designated as hMI-ER1u (Paterno et al., 1998; Paterno et 
al., 2002). Extensive 5 and 3 rapid amplification of eDNA ends (RACE) was 
performed using forward and reverse primers designed against various regions of the 
original published hMI-ER1u sequence in combination with cDNAs from a number of 
human tissues and cell lines (Paterno et al., 2002). Sequence analysis of these RACE 
clones and BLAST comparison to the human genome revealed the structure of the hmi-
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er1 gene and the presence of 12 distinct transcripts. Searches of the human EST database 
revealed that all reported sequences are represented in the eDNA clones obtained in the 
laboratory (Paterno et al., 2002). 
hmi-er 1 is a single copy gene located at 1 p31.2 and spanning 63 kb (Figure 1.4A). 
This gene consists of 17 exons. Most exons are smaller than 160 bp (range 20 bp to 2.5 
kb ), while most introns are several kb in size (range 630 bp to 11.7 kb ). As shown in 
Figure 1.4B, there are a total of 12 distinct transcripts (sequence data in the GenBank 
Database under the accession numbers AF515446, AY124191, AY124194,; AF515447, 
AY124190, AY124193; AF515448, AY124189, AY124192, AY124186, AY124187, 
AY124188) generated by alternative splicing, alternate promoter usage and/or 
polyadenylation signal (PAS) usage (Paterno et al., 2002). The alternate 5 ends result 
from alternate promoter usage or alternate inclusion of exon 3A to generate three distinct 
5 ends encoding three amino terminal regions, N1, N2 and N3. The four variant 3 ends, 
a, bi, bii and biii, result from alternative splicing or alternate PAS usage. The a 3 end 
portion of hmi-er 1 transcripts (Figure 1.4) is predicted to encode the 23 aa a C-terminus 
domain ofhMI-ER1; while the bi, bii and biii 3 portions of hmi-er1 transcripts (Figure 
1.4) are all predicted to encode the same 102 aa ~ C-terminal domain of hMI-ERl 
(Paterno et al., 2002). The production of two distinct C-terminal regions was verified 
using polyclonal antiserum generated against peptides corresponding to hMI-ERla C-
terminus, the ~ C-terminus or the common internal sequence (Paterno et al., 2002). 
As shown in Figure 1.4B, alternate promoter usage and splicing at the 5 end 
results in the generation of mRNAs predicted to encode three distinct N-terminal 
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Figure 1.4 Structure of the human hmi-erl gene and splice variants (adapted from 
Paterno et al., 2002). 
Schematics illustrating the organization of the hmi-er 1 gene and the various hmi-er 1 
transcripts. (A) Exon/intron organization of the hmi-er 1 gene. hmi-er 1 is a single copy 
gene located at lp31.2 (adapted from http://genome-www.stanford.edu/cgi-
bin/genecards/carddisp?MI-ERl). The two alternate starts of translation, ML- and MAE-
are indicated. Exon numbers are indicated below each schematic. (B) Schematics 
illustrating the variant 5' and 3' ends of hmi-er 1 transcripts. Alternate 5' ends result from 
alternate promoter usage or alternate inclusion of exon 3A to generate three distinct 
amino terminal regions, Nl, N2 and N3. The four variant 3' ends, a, bi, bii and biii, 
result from alternative splicing or alternate PAS usage. Scale bar, 500 bp. 
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domains: Nl, N2 and N3. Nl has the same translational start as N2 but includes exon 3A 
sequences, which is inserted after the first 2 amino acid residues (aa). This additional 
sequence is predicted to encode a 25 aa cysteine-rich domain that remains in frame with 
the rest of the hMI-ERl protein. The three distinct N-terminal domains, in combination 
with the two possible C-terminal regions, are predicted to produce six distinct hMI-ERl 
proteins: Nla (457 aa), NIP (536 aa), N2a (433 aa), N2P (511 aa), N3a (433 aa), and 
N3P (512 aa). The predicted sequences were verified using an anti-hMI-ERl antibody to 
immunoprecipitate in vitro translated products (Paterno et al., 2002). 
1.5.2 Protein domains and motifs in hMI-ERl isoforms and their possible function 
Figure 1.5 shows a schematic of the putative functional domains and motifs in 
hMI-ERl isoforms. Putative domains and motifs found in hMI-ERl isoforms were 
identified by computer analysis using software MOTIF (http://www.Motif.genome.ad.jp), 
PSORT (http://www.psort.nibb.ac.jp), Domain Architecture Retrieval Tool (DART; 
http://www.ncbi.nlm.nih.gov/Structure/lexington/lexington.cgi), Protein Families Data 
Base of Alignments (PFAM) at http://pfam.wustl.edu/hmmsearch.shtml. Some of the 
motifs and domains found are indicated in Figure 1.5 and will be described. 
(a) The acidic activation domain 
As shown in Figure 1.5, hMI-ERl isoforms have an acidic activation domain. 
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Acidic activation domains were first described in the yeast GAL4 activator protein (Ma 
and Ptashne, 1987). In the GAL4 protein, transcriptional activation is mediated by acidic 
amino acid residues and transcriptional activation closely correlates with the net negative 
charge. This indicated that acidic amino acids are crucial for transactivation of GAL4. 
Moreover, several studies with acidic activation domains also indicated the importance of 
hydrophobic amino acids for activation (Blair eta!., 1994; Cress and Triezenberg, 1991; 
Lin eta!., 1994). TheN-terminus of xMI-ER1 also has regions rich in acidic residues 
which are important for transcriptional activation function (Paterno et a!., 1997). 
Although full-length :xMI-ER1 did not activate transcription in Nlli 3T3 cells, the region 
consisting of the N-terminal98 amino acids ofxMI-ER1 stimulated transcription 80-fold. 
Fusion with other parts of xMI-ER1 did not have any transcriptional activity. These 
results indicated that the N-terminal region of MI-ER1 contains an acidic activation 
domain, and xMI-ER1 has the potential to function as a transcription activator (Paterno et 
a!., 1997). TheN-terminal acidic sequences are conserved from Xenopus MI-ER1 to its 
human homologue (Paterno et a!., 1998), and suggested a transcriptional activation 
function for this domain in hMI-ERl. 
(b) The EF-hand motif 
As shown in Figure 1.5, hMI-ER1 isoforms have a predicted EF-hand motif. The 
EF-hand motif is involved in binding intracellular calcium (Julenius eta!., 2002). The 
basic EF-hand consists of two 10 to 12 residue alpha helices with a 12-residue loop 
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Figure 1.5 Protein domains and motifs in hMI-ERl isoforms. 
Schematics illustrating the protein motifs common and unique to the hMI-ERl isofonns. 
The acidic activation domain, the EF-hand motif, the ELM2 domain, the SANT domain, 
and the proline rich motif PSPPP are common to the hMI-ERl isofonns. The nuclear 
localization signal (NLS) is localized on the C-tenninal region of hMI-ERla. The 
L:XXLL motif is localized on the C-tenninal region ofhMI-ERlp. 
hMI-ER1 N1a (1-457) 
hMI-ER1 N1P (1-536) 
hMI-ER1 N2a (1-432) 
hMI-ER1 N2P (1-511) 
hMI-ER1 N3a (1-433) 
hMI-ER1 N3P (1-512) 
acidic activation domain 
t 
EFhand ELM2 
LXXLL 
t 
SANT PSPPP NLS 
region between, thereby forming a single calcium-binding site (helix-loop-helix). While 
calcium ions interact with residues contained within the alpha helices, each of the 12 
residues in the loop region is important for calcium coordination. Binding of Ca2+ to the 
EF-hand domains may trigger a conformational change in calcium-binding proteins and 
this change may underlie the Ca2+ -dependent biological effect. One example of Ca2+-
dependent conformational change by EF -hand domain is the downstream regulatory 
element antagonist modulator (DREAM) protein (Craig et al., 2002). DREAM acts as a 
direct transcriptional repressor of c-fos genes (Carrion et al., 1999). The EF-hands 
domain of the DREAM protein senses the intracellular concentration of Ca2+. EF-hand 
occupancy by Ca2+ blocks binding of DREAM to its DNA binding sites. This results in 
relief of the transcriptional repression by DREAM on its target gene such as c-fos 
(Carrion et al., 1999). Moreover, the conformational change of DREAM triggered by 
Ca2+ creates a protein-protein interaction surface for CREB. As a result of the 
interaction, DREAM prevents the recruitment of CBP by CREB and represses CRE-
dependenttranscription (Ledo et al., 2002). 
Activation of most growth factor tyrosine kinase receptors, as well as stimulation 
of G-protein coupled receptors, results in the release of Ca2+ stores from the endoplasmic 
reticulum (reviewed in Soderling, 1999). Ca2+ release is controlled by phosphoinositide-
specific phospholipase C (PLC) isozymes. An increase in intracellular Ca2+ induces 
Ca2+-responsive signalling cascades via the EF-hand domain-containing proteins, 
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resulting in activation or repression a specific set of genes, thus triggering numerous 
biological outcomes. 
(c) The ELM2 domain 
As shown in Figure 1.5, each of the hMI-ER1 isoforms has an ELM2 domain. 
ELM2 consists of approximately 60 amino acid residues and stands for E:G,L-27 and 
MTA1 homology domain ~ (Solari et al., 1999). The ELM2 domain was initially 
identified in the EGL-27 protein as well as in MTA1 (Solari et al., 1999). EGL-27 is a C. 
elegans protein that is involved in embryonic patterning and plays a key role in Wnt 
signalling possibly by regulating HOX gene expression (Herman et al., 1999; Solari et 
al., 1999). MTA1 is known to be part of a protein complex possessing HDAC activities 
(Xue et al., 1998a). However, no function has been ascribed to the ELM2 domain before 
the studies described in this thesis (see Chapter 3). 
Many of ELM2 domain-containing proteins also contain one or more putative 
SANT domains, as predicted by BLAST search (RPS-BLAST 2.2.1, NCBI; 
http://www.ncbi.nlm.nih.gov/Structure/cddlwrpsb.cgi). Interestingly, the ELM2 domain 
is usually found in a position N-terminal to a conserved SANT domain. It is thought that 
there might be some important cooperative function between the two motifs (Solari et al., 
1999). 
46 
(d) The SANT domain 
As shown in Figure 1.5, each of the hMI-ER1 isoforms has a SANT domain C-
terminal to the ELM2 domain. The SANT domain was named for the four transcription 
regulators in which it was first discovered: SWI3, ADA2, nuclear receptor corepressor 
(N-COR), and TFIIIB (Aasland et a!., 1996). The SANT domain consists of 
approximately 50 amino acid residues and is highly related to the DNA binding domain 
(DBD) of the oncoprotein MYB (Aasland eta!., 1996). Like the DBD of MYB, the 
SANT domain has two or three repeated subdomains each resembling the helix-tum-helix 
design in secondary structure. 
Although the function of the SANT domain has not been fully understood, it is 
thought that the SANT domain acts in transcriptional regulation either through DNA 
binding or protein-protein interactions (Aasland eta!., 1996). Recent studies with SANT 
domain proteins have suggested that SANT domains are more likely to function in 
protein-protein interaction. For example, the yeast ADA2 SANT domain has been shown 
to be essential for HAT activity in GCN5-containing complexes and was also found to 
assist GCN5 to bind to histones (Boyer et a!., 2002; Sterner et a!., 2002). Another 
example is CoREST, which is a transcriptional corepressor containing two SANT 
domains (You eta!., 2001). The first SANT domain is important for the co-repression 
function of the protein, by virtue of its interaction with HDACl/2 (You et a!., 2001). 
Similarly, the first SANT domain of N-COR and silencing mediator of retinoic acid and 
thyroid hormone receptor (SMRT) was shown to bind and activate HDAC3 (Guenther et 
a!., 2001). The second SANT domain of SMRT is essential for binding to 
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hypoacetylated histone and therefore may play a role in interpretation of the histone code 
(Yu et al., 2003). Most recently, overexpression ofxMI-ERl, which is a SANT domain 
containing molecule, in Xenopus embryos was found to inhibit mesoderm induction and 
result in truncations of the anteroposterior axis (Teplitsky et al., 2003). However, a 
mutagenesis analysis of the SANT domain revealed that the SANT domain is not 
required for the effects ofxMI-ERl on embryonic development and mesoderm induction 
(Teplitsky et al., 2003). 
(e) The proline rich motif 
As shown in Figure 1.5, each ofhMI-ERl isoforms also has a proline rich motif 
C-terminal to the SANT domain. Proline rich motifs are characterized by the presence of 
the consensus PXXP tetrapeptide, in which the P represents proline and X represents any 
amino acid residue (Alexandropoulos et al., 1995). The proline-rich region of MI-ERl 
fits the consensus for an SH3 recognition motif (Cesareni et al., 2002). As well, it also 
conforms to the consensus SIT -P for a proline-directed phosphorylation site (Teplitsky et 
al., 2003). Since MI-ERl was found not to be phosphorylated in cells (Paterno et al., 
unpublished data), its proline-rich region most likely functions as a SH3 recognition 
motif. In agreement with this, mutagenesis analysis of the proline-rich region of xMI-
ERl e65P366SPPP) revealed that only 365P in the proline-rich region is required for the 
overexpression effects ofxMI-ERl on embryonic development and mesoderm induction 
(Teplitsky et al., 2003). 
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It is known that SH3 domains recognize proline rich motifs (Mayer, 2001). A 
variety of proteins involved in intracellular signal transduction pathways contain SH3 
domains or proline rich motifs. Proline rich motifs are commonly found in situations 
requiring the rapid recruitment of proteins through protein-protein interactions, such as in 
signalling cascades (Kay eta/., 2000). For example, following receptor activation, the 
proline rich region on SOS 1 binds to the two SH3 domains of Grb2, thereby bringing 
SOS 1 to the cell membrane, where SOS 1 in tum activates the RAS pathway (reviewed in 
Williamson, 1994). 
(f) The nuclear localization signals 
Euk:aryotic cells are characterized by distinct nuclear and cytoplasmic 
compartments separated by the nuclear envelope, which is penetrated by nuclear pore 
complexes (NPCs) (Alberts et a/., 2002). Nuclear transport is proving to be a 
fundamental mechanism for regulating protein localization, and protein function (Hood 
and Silver, 2000). Protein nuclear transport in either direction across the nuclear 
envelope through NPCs involves sequential steps mediating the intricate interplay of 
multiple protein components starting from recognition of the protein import/export signal 
by an import or export receptor (Gorlich, 1998; Nigg, 1997). Proteins carrying a NLS 
can be transported into the nucleus. There are several classes ofNLS (Post eta/., 2001). 
Proteins carrying a NES can be transported out of the nucleus (Moroianu, 1999). 
As shown in Figure 1.5, hMI-ER1~ contains a functional NLS in the C-terminal 
region (Paterno et a/., 2002). The hMI-ER1 ~ was found localized in the nucleus, while 
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hMI-ERla shuttles between the nucleus and the cytoplasm (Paterno et al., 2002; Paterno 
et al., unpublished data). 
(g) The LXXLL motif 
The LXXLL motif is characterized by the presence of a consensus LXXLL 
peptide, in which the L represents leucine and X represents any amino acid residue. The 
LXXLL motif is a protein-protein interaction motif that has been implicated in the 
interaction with nuclear hormone receptors. It was also reported to be present in other 
transcription regulators, including the short form of MTAl (MTAls) (Kumar et al., 
2002). This core sequence also has very strong similarity to the Sin3A interaction 
domain (SID) present in the family of MAD (MADl-4) transcriptional repressors 
(Brubaker et al., 2000). The selectivity of the LXXLL motif may depend upon flanking 
amino acid sequences. Many peptides that bind strongly to nuclear hormone receptors 
possess a hydrophobic amino acid in the -1 position relative to the core and a non-
hydrophobic amino acid at the +2 position (Heery et al., 2001). 
The LXXLL domain has been identified in the hMI-ER1a C-terminus and 
contains a core LXXLL motif embedded in an amphipathic helix that is not present in the 
hMI-ER1~ isoform. This domain within hMI-ER1a has a hydrophobic amino acid at 
both the -1 and +2 positions. 
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1.5.3 Expression ofhMI-ERl 
The tissue distribution of the various hmi-er 1 transcripts was examined first by 
Northern blot analysis and then by RT-PCR analysis. A probe hybridizing to the 
common internal region revealed that hmi-er 1 transcripts could be resolved into only four 
bands by Northern blot analysis (Paterno eta/., 2002). This was expected since the three 
5 ends differ little in size. The estimated molecular sizes of the bands, 1.7, 2.5, 3.4 and 
4.8 kb, were consistent with the predicted size of transcripts containing a, bi, bii and biii 
3 ends, respectively. 
Of the 23 human tissues examined by Northern blot analysis, hmi-er 1 transcripts 
were barely detectable or absent in most. Of the five tissues (heart, testis, ovary, thyroid 
and adrenal gland) that showed readily detectable levels of hmi-er 1, testis expressed the 
highest level and was the only tissue in which all four bands were visible. The 4.8 kb 
band was the most widely expressed and could be detected, albeit at low levels, in most 
tissues. The 2.5 kb band was the least abundant and was only visible in a few tissues, 
while expression of the 3.4 kb band was highly variable. The 1.7 kb band was only 
detectable in a few endocrine tissues such as testis, ovary and thyroid (Paterno et al., 
2002). RT-PCR analysis using distinct primers for different isoforms revealed that the 
hmi-er 1 expression pattern is complex as different transcripts were shown to have cell 
type specific expression (Paterno et a/., 2002). hmi-er 1 was found to have ubiquitous, 
but low level, expression in normal human tissues (Paterno eta/., 1998; Paterno eta/., 
2002). Breast carcinoma cell lines and tumours, on the other hand, showed elevated 
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levels (Paterno et al., 1998), suggesting that hmi-erl expression may be associated with 
the neoplastic state in human breast carcinoma. 
1.5.4 Subcellular localization of hMI-ERla and p 
The high degree of similarity (91% overall similarity) shared between the N-
terminal domains of hMI-ER1a protein and xMI-ER1 suggests that they are 
evolutionarily conserved. The C-terminal regions of xMI-ER1 and hMI-ER1a proteins 
have highly divergent sequences (Paterno et al., 1997; Paterno et al., 2002). However, 
the amino acid sequence of the hMI-ERl P C-terminus displayed a high degree of 
similarity (66%) to that of the xMI-ER1 C-terminal domain, suggesting that the published 
xMI-ER1 sequence encodes the orthologue of the hMI-ER1P isoform (Paterno et al., 
2002). Interestingly, although xMI-ER1 contains multiple putative NLSs, it was revealed 
that this C-terminal domain of xMI-ER1 contains the only functional NLS (Post et al., 
2001). Similar to xMI-ER1, hMI-ER1P also contains a functional NLS in the C-terminal 
region. The subcellular localization ofhMI-ER1 was examined by transfecting NIH 3T3 
cells with plasmids expressing Myc-tagged hMI-ER1a or p. Immunohistochemical 
staining with the anti-MYC antibody 9E10 showed that hMI-ER1P was targeted 
exclusively to the nucleus, while hMI-ER1a shuttled between the nucleus and cytoplasm 
(Paterno et al., 2002; Paterno et al., unpublished data). Moreover, hMI-ERl displayed 
less nuclear localization in breast cancer samples, when compared with the normal breast 
tissue (Paterno et al., unpublished data). 
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1.6 Purpose of this study 
hMI-ER1 isoforms localized in the nucleus or shuttled between the nucleus and 
cytoplasm (Paterno et al., 2002; Paterno et al., unpublished data). Structurally, hMI-ERl 
has conserved domains found in a number of transcriptional regulators, including an 
acidic activation domain (Paterno et al., 1997), an ELM2 domain (Solari et al., 1999) and 
a signature SANT domain (Aasland et al., 1996). hMI-ER1 was found to have 
ubiquitous, but low level, expression in normal human tissues (Paterno et al., 1998; 
Paterno et al., 2002). Breast carcinoma cell lines and tumours, on the other hand, showed 
elevated levels (Paterno 1998), suggesting that hmi-erl expression is associated with the 
neoplastic state in human breast carcinoma. Moreover, overexpression of hMI-ER1 in 
NIH 3T3 cells suppressed colony formation efficiency (Paterno et al., unpublished data). 
Depletion ofhMI-ERl in multiple breast cancer cell lines by hmi-erl antisense plasmid 
transfection also results in suppression of colony formation efficiency (Huang et al., 
unpublished data). These results suggested that hMI-ER1 plays an important role in cell 
growth regulation. Therefore, my hypothesis is that hMI-ER1 may be a potent 
transcriptional regulator, and deregulation of its expression and/or functions may 
contribute to tumorigenesis. At the time this study was undertaken, the N3a (the 
GenBank Database accession number AY124188) and N3bii (the GenBank Database 
accession number AY124192) hmi-erl eDNA were the only two cloned isoforms in the 
laboratory. The purpose of this study was to isolate and characterize the promoters of 
hmi-erl, and investigate the role of hMI-ERla (N3a) and hMI-ER1P (N3bii) in 
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transcriptional regulation. To obtain a better understanding of the function ofhMI-ERl, 
different approaches have been used to identify and characterize the hMI-ERla- and 
hMI-ERlj3-interacting proteins, which may be critical for regulating specific cellular 
functions with hMI-ERla and hMI-ERlP. 
Objective 1: Molecular cloning and characterization of the human of hmi-erl 
promoters 
hmi-er 1 was found to have ubiquitous, but low level, expression in normal human 
tissues (Paterno et al., 1998; Paterno et al., 2002). Breast carcinoma cell lines and 
tumours, on the other hand, showed elevated levels (Paterno et al., 1998), suggesting that 
hmi-er 1 expression is associated with the neoplastic state in human breast carcinoma. My 
goal was to study the molecular mechanism for the transcriptional regulation of hmi-er 1, 
through cloning of the 5 promoter region flanking the transcription start sites, and 
identifying regulatory regions important for transcriptional regulation. 
Objective 2: Characterization of the role of hMI-ERl in transcriptional regulation 
Structurally, hMI-ERl shares features with other transcriptional regulators. It 
possesses a putative acidic activation domain, conserved ELM2 domain and conserved 
SANT domain. Although the precise function of ELM2 and SANT domains remain 
unclear, proteins containing these domains were recently found to be present in 
multisubunit complexes with HAT or HDAC enzymatic activity and implicated in 
transcriptional regulation. Examples of these transcription regulators are CoREST, 
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MTAl, MTA2, MTA3, ADA2, N-COR and SMRT. There is evidence that Xenopus 
xMI-ERl can function as a transcriptional regulator (Paterno et al., 1997). Thus, my goal 
was to investigate whether human hMI-ERl functions as a transcriptional regulator 
implicated by these conserved domains in other proteins, and to investigate the molecular 
mechanisms it utilizes to regulate this function. 
Objective 3: Identify and characterize the hMI-ERl-interacting proteins 
To obtain a full picture of hMI-ERl function, it is necessary to perform 
complementary approaches in protein-protein interaction analysis to obtain more specific 
hMI-ERl interacting proteins. Pioneering work toward this goal in this study was 
undertaken using two different approaches. Immunoprecipitation and Western blot 
analysis was used to test the possible interaction between hMI-ERl and predicted 
interacting proteins. I also established the yeast two-hybrid system to screen hMI-ERl-
interacting proteins from a testis eDNA library. My goal was to identify new hMI-ERl-
inteacting proteins that would assist in the elucidation of the regulatory networks in 
which hMI-ERl plays a role in the cell. 
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SECTION H ISOLATION AND CHARACTERIZATION OF THE PROMOTERS 
OFhMI-ERJ 
CHAPTER 2 MOLECULAR CLONING AND CHARACTERIZATION OF THE 
hMI-ER1 P2 PROMOTER: THE ROLE OF SP1 IN PROMOTER ACTIVITY 
REGULATION* 
2.1 Introduction 
It has been revealed that hmi-er 1 transcripts have ubiquitous, but low level, 
expression of hmi-er1 in all normal human tissues (Paterno eta/., 1998; Paterno eta/., 
2002). Breast carcinoma cell lines and tumours, on the other hand, expressed 
significantly elevated levels (Paterno eta/., 1998), suggesting that hmi-er1 expression is 
associated with the neoplastic state in some human breast carcinomas. Cis-regulatory 
elements in the hmi-er 1 promoter( s) would represent an important element for the 
specific expression of this gene. Isolation and analysis of the hmi-er 1 promoter( s) may 
thus shed light to a better understanding of the molecular mechanism for the 
transcriptional regulation of hmi-er 1. To locate the putative promoter, extensive 
CapSelecting rapid amplification of eDNA ends (RACE) was performed, and two 
• Part of this chapter has been published in: Paterno, G.D., Ding, Z., Lew, Y.Y., 
Nash, G.W., Mercer, F.C., and Gillespie, L.L. (2002) Genomic organization of the human 
mi-er1 gene and characterization of alternatively spliced isoforms: regulated use of a 
facultative intron determines subcellular localization. Gene. 295:79-88. 
Part of this chapter has been published in: The SANT domain of human MI-
ER1 interacts with Sp 1 to interfere with GC box recognition and repress transcription 
from its own promoter. J Bioi Chern. 2004 Apr 26 [Epub ahead of print]. 
56 
transcriptional start sites were found in the exons Al and Bl, respectively (section 2.3.1 
and Paterno et al., 2002). The genomic DNA sequences encompassing the two 
transcriptional start sites were then cloned. Two alternative promoters, designated as P1 
and P2, were found (section 2.3.1 and Paterno et al., 2002). Further characterization of 
the promoter focused on the P2 promoter of hmi-er 1. 
2.2 Materials and Methods 
2.2.1 Cell culture 
Human cell lines, HeLa cervical carcinoma cells, C33A cervical carcinoma cells, 
MCF-7 breast carcinoma cells, BT -20 breast carcinoma, SK-OV -3 ovarian carcinoma, 
HEK 293 transformed embryonic kidney cells and U87 glioblastoma cells, were obtained 
from the American Tissue Culture Collection and cultured at 37°C in 5% C02 in DMEM 
containing 10% FCS. 
2.2.2 CapSelecting RACE for hmi-er 1 5' transcriptional start sites 
In order to produce clones with complete 5 ends, eDNA preparations were 
enriched for full-length 5 ends using the CapSelect method (Schmidt and Mueller, 
1999). Multiple clones were obtained by 5 RACE and sequenced. 
57 
2.2.3 Plasmids and constructs 
A 3045 bp genomic sequence, containing 1264 bp of sequence downstream of the 
first transcriptional start site of hmi-er 1 and 1781 bp of genomic sequence upstream of 
the first transcription start site of hmi-er 1 (section 2.3.1 and Paterno et al., 2002) was 
generated by PCR [the PCR product was designated as (-1781)] from human 
endocervical primary cell genomic DNA, using the primer pairs listed in Table 2.1. A 
1460 bp sequence, containing 144 bp of genomic sequence downstream of the second 
transcriptional start site of hmi-er1 and 1316 bp of genomic sequence upstream of the 
second transcription start site of hmi-er1 (section 2.3.1 and Paterno et al., 2002) was 
generated by PCR [the PCR product was designated as (-1316)] from human 
endocervical primary cells, using the primer pairs listed in Table 2.1. The PCR product 
(-1781) and (-1316) was cloned into the pCR2.1 vector [pCR(-1781) and pCR(-1316)], .. 
using the TOPO-TA cloning kit (Invitrogen, Inc.) and sequenced on both strands. The 
sequences were verified by comparison to the previously reported hmi-er 1 sequences 
(Paterno et al., 2002) and to the human genome sequence data (Sanger Centre). The 
pGL3(-1781) plasmid was generated by digestion of pCR(-1781) with KpniiEcoRI and 
subcloning into KpniiSmai sites of the promoterless pGL3-Basic vector (Promega 
Corporation). The pGL3(-1316) plasmid was generated by digestion ofpCR(-1316) and 
subcloning into theXhoi!Hindiii sites of the promoterless pGL3-Basic vector. 
The pGL3(-133) construct was generated by Smal digestion of pGL3(-1316) 
followed by re-ligation. The pGL3(-657) construct was generated by SmaiiBglii 
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Table 1 Table 2.1 PCR primer pairs used for preparing hmi-er 1 promoter 
constructs. 
Construct Forward primer Reverse primer 
(-1781) 5'-TGCAGGTTGGTAGCCTAG 5'-TCCGTCTTGTCTGCATTG 
AAGCAACA-3' AACC-3' 
(-1316) 5'-GACTGTCTGTAGACTCTT 5'-CGTACTGCCGGGTCACAT 
TTCC-3' CTCC-3' 
(-945) 5'-TGAAGATTAGGAAAAAAA 5'-CGTACTGCCGGGTCACAT 
TCCCAGTC-3' CTCC-3' 
(-469) 5'-GATATAGAATTTTACATT 5'-CGTACTGCCGGGTCACAT 
TCCTGTCG -3' CTCC-3' 
(-312) 5'-ACGTATTTTTCCTCTGCT 5'-CGTACTGCCGGGTCACAT 
GTGTCA-3' CTC C-3' 
(-68) 5'-TTTCCCTCCAGTCCAGCC 5'-CGTACTGCCGGGTCACAT 
CAGCCG-3' CTCC-3' 
(+28) 5'-AGTGGCGGCGGGAGCGG 5'-CGTACTGCCGGGTCACAT 
CAGAGA-3' CTCC-3' 
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digestion ofpCR(-1316) and subcloning into the SmaVBamHI sites ofpGL3-Basic. The 
other deletion mutants were constructed by PCR, using the primer pairs listed in Table 
2.1; the PCR products were cloned into pCR2.1, then subcloned into pGL3-Basic, using 
either the Xhoi/Hindlll sites [pGL3(-469), (-312), and (+28)] or the Kpni/Xhol sites 
[pGL3(-945) and (-68)]. 
Full-length human Sp1 eDNA was obtained from Dr. R. Tjian, University of 
California. The Sp 1 expressing construct was generated by PCR from a testis library 
using 5 -CAAGATCACTCCATGGATGAAATGACAG-3 and 5 -TGCCTGATCTCA 
GAAGC CATTGCCA-3 as forward and reverse primers, respectively, and cloned into 
pCR3.1. The GST-Sp1 fusion was constructed by subcloning the EcoRI fragments from 
Sp1-pCR3.1 into the EcoRI sites ofpGEX-4T-2. All plasmids were sequenced to verify 
the junctions and the Sp 1 sequence. 
2.2.4 Computer analysis of the hmi-er 1 promoter region 
To identify regulatory DNA elements in the 1460 bp sequence of P2 promoter 
(-1316), computer-assisted analysis was performed using the following programs: (1) for 
promoter prediction: Promoter Scan (PROSCAN) at http://bimas.dcrt.nih.gov 
/molbio/proscan/ and Neural Network Promoter Prediction (NNPP) at 
http://www.fruitfly.org/seq_tools/promoter.html; (2) for CpG islands: Webgene at 
http://www.itba.mi.enr.it/webgene; (3) for transcription factor binding sites: 
Transcription Factor Binding Site (TFSEARCH) at http://www.cbrc.jp/research 
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/db/TFSEARCHJ.html; Transcription Element Search System (TESS) at 
http://www.cbil.upenn.edu/tess/; and PROSCAN. 
2.2.5 Transfection and reporter assays 
All transfections were performed as previously described (Paterno et al., 1997) in 
duplicate in 6-well plates. 1.5 x 105 cells/well was seeded 18 h prior to transfection and 
cells were harvested after 48 h in culture. Luciferase assays were performed on cell 
lysates using a Monolight 2010 Luminometer (Analytical Luminescence Laboratory) and 
a luciferase assay reagent (Promega), according to the manufacturer s directions. The 
values obtained, in relative luciferase units (RLU), were normalized to the level of 
cellular protein in each sample. Each experiment was repeated three times. 
2.2.6 Western blot analysis 
Western blot analysis was performed as described previously (Ryan and Gillespie, 
1994) with anti-Sp1 monoclonal antibody (dilution 1:100) (Catalog No. 1C6: sc-420, 
Santa Cruz Biotechnology, Inc.). 
2.2. 7 GST -fusion protein production 
GST fusion proteins were expressed in E. coli BL21 and purified according to the 
instructions supplied with the pGEX-4T vector. GST fusion protein level and purity were 
determined by SDS-PAGE. 
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2.2.7 Electophoretic mobility shift assays (EMSAs) 
EMSAs were performed as (Kinzler and Vogelstein, 1990). Briefly, the 
hmi-er 1 P2 minimal functional promoter ( -68) was labelled with r-e2P]ATP and T 4 
polynucleotide kinase, and purified on NucTrap Probe Purification Columns (Stratagene, 
Inc.). The labelled probe was incubated with 2 f.ll ofHeLa nuclear extract (Promega) or 
1 f.lg GST -Sp 1 protein at room temperature for 20 min in 20 f.ll containing 5% glycerol, 5 
mM MgCb, 1 mM dithiothreitol, 50 mM KCI, 10 f.!M ZnS04, 85 f.!g/ml bovine serum 
albumin (BSA), and 50 mM HEPES (pH 7.5). Poly(dl-dC) was used as heterologous 
competitor in the reaction (2 f.!g/reaction). Where indicated, a 20 molar excess of 
unlabelled probe (competitor) was included in the binding reaction to demonstrate 
specificity for the probe. For antibody supershift assays, the extract was incubated for 30 
min at room temperature with 1 f.ll anti-Sp1 polyclonal antiserum (Catalog No. PEP 2 X: 
sc-59, Santa Cruz Biotechnology, Inc.). Bound and free probes were resolved by non-
denaturing electrophoresis on 4% polyacrylamide gels and analyzed by autoradiography. 
2.3 Results 
2.3.1 Cloning of the hmi-er 1 5 regulatory sequences 
In order to obtain eDNA clones with complete ends, eDNA preparations were 
enriched for full-length 5 ends using the CapSelect method (Schmidt and Mueller, 
1999). Multiple eDNA clones were obtained by extensive 5 RACE and sequenced. 
Sequence analysis of these clones and BLAST comparison to the human genome (Sanger 
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Centre) revealed that there are two hmi-er 1 transcription start sites, which designated as 
P1 and P2, in exons A1 and B1, respectively (Figure 2.1A, and Paterno et al., 2002). 
Similarity searches of the human EST database revealed that all reported sequences are 
represented in the eDNA clones obtained. Organization of these two transcriptional starts 
suggested the presence of two distinct promoters of hmi-er 1. 
To provide insight into the regulation of hmi-erl expression, two genomic DNA 
fragments encompassing the two transcriptional start sites were isolated by PCR from 
human endocervical tissue and were subcloned into the promoterless luciferase reporter 
vector, pGL3-Basic. As shown in Figure 2.1A, the genomic DNA fragment 
encompassing the first transcriptional start site contains 3045 bp upstream of the ML 
translational start site. It contains 1264 bp downstream of transcriptional start site ( + 1 to 
+ 1264) and 1781 bp ( -1 to -1781) upstream of transcriptional start site. The genomic 
DNA fragment encompassing the second transcriptional start site in ex on B 1 contains 
1460 bp of sequence upstream of the MAE translational start site. It contains 144 bp of 
sequence downstream of the transcriptional start site ( + 1 to + 144) and 1316bp ( -1 to -
1316) of sequence upstream of the transcriptional start site. 
The. promoter activities of these DNA fragments were analyzed in vivo using 
luciferase reporter assays in HeLa cervical carcinoma cells. As shown in Figure 2.1B, 
the luciferase activity of luciferase reporter construct driven by the genomic DNA 
fragment encompassing the P1 transcription start site [pGL3(-1781)] and the genomic 
DNA fragment encompassing the P2 transcription start site [pGL3(-1316)] was 
significantly higher, compared to the pGL3-Basic vector [pGL3(-)]. These results 
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Figure 2.1 Promoter activities of the DNA fragments encompassing either Pl or P2 
5' flanking sequence. 
(A) Diagrammatic representation to show the two transcriptional start sites, Pl and P2, 
respectively. The two alternate starts of translation, ML- and MAE- are indicated. Exon 
numbers are indicated below each schematic. Two genomic DNA fragments 
encompassing either P1 or P2 isolated by PCR are shown below. (B) Promoter activity 
of the hmi-er 1 Pl and P2 promoters in HeLa cells. HeLa cells were transiently 
transfected with the luciferase reporter vector pGL3-Basic [pGL3(-)] or pGL3-Basic 
containing the DNA fragments of hmi-er 1 5 -flanking the two transcriptional start sites, 
for Pl: 3045 bp (-1781 to -1 and +1 to +1264) [(pGL3(-1781)] and for P2: 1460 bp (-
1316 to -1 and +1 to +144) [pGL3(-1316)]. Following transfection, the cells were 
cultured for an additional 48 h and then lysed in luciferase lysis buffer, and the relative 
luciferase units (RLU) and ~-galactosidase activity were determined. The luciferase 
activity per j.lg protein was then normalized to ~-galactosidase activity per j.lg protein. 
Luciferase activity is presented as the fold increase of luciferase activity from pGL3(-
1316) relative to that from the pGL3-Basic vector control. Shown are the average values 
and standard deviation for three independent experiments. 
A 
+1 P2 
-1781 +1264 -1316 +144 
C1 exon C1 intron 
B 
pGL3(-) 
pGL3(-1781) 
pGL3( ... 1316) 
0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 
Relative luciferase activity 
indicated that these two 5 flanking genomic DNA sequences function as transcription 
promoters, which were designated as hmi-er1 P1 and P2 promoters. 
Further studies were focused on the characterization of the hmi-er 1 P2 promoter 
( -1316), which was located in a relatively shorter DNA fragment. Further experiments 
were performed to test the luciferase activity of hmi-er 1 P2 promoter-driven luciferase 
reporter construct pGL3(-1316) in six different cell lines: C33A, HEK293, BT-20, MCF-
7, SK-OV-3 and U87. Luciferase activity was high in all pGL3(-1316)-transfected cells 
and ranged from 10-fold to 34-fold higher than pGL3-Basic controls (Figure 2.2), 
demonstrating that the hmi-er 1 P2 promoter ( -1316) can function in a variety of cell 
types. 
2.3.2 Location of the hmi-er 1 P2 minimal promoter 
Computer-assisted analysis of the 1460 bp P2 DNA fragment using Web gene at 
http://www.itba.mi.cnr.it/webgene to identify potential cis-regulatory elements predicted 
a CpG island located between nucleotide position -389 and the start of translation (Figure 
2.3A). Further analysis revealed that this GC-rich region does not contain a TATA box; 
nor does it contain an Inr or a DPE sequence, as is often found in TATA-less promoters 
(reviewed in Butler and Kadonaga, 2002). A number of potential transcription factor 
binding sites were identified using TFSEARCH, PROSCAN and TESS, including 2 TEF-
2 sites, an HT4F site, an estrogen response element (ERE) half-site as well as multiple 
binding sites for the Sp 1 family (Figure 2.3B). 
65 
Figure 2.2 hmi-er 1 P2 promoter activities in multiple cancer cell lines. 
hmi-erl P2 promoter-driven luciferase reporter construct pGL3(-1316) was transfected in 
C33A, MCF-7, BT-20, SK-OV-3, U87, and 293K human cell lines. Following 
transfection, the cells were cultured for an additional 48 h and then lysed in luciferase 
lysis buffer, and the level of relative luciferase units (RLU) and ~-galactosidase activity 
were determined. The luciferase activity per J.lg protein was then normalized to P-
galactosidase activity per J.lg protein. Luciferase activity is presented as the fold increase 
of luciferase activity from pGL3( -1316) relative to that from the pGL3-Basic vector 
control. Shown are the average values and standard deviation for three independent 
experiments. 
293K 
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Figure 2.3 Nucleotide sequence of hmi-erl P2 promoter, putative transcription 
factor binding sites and CpG island. 
(A) Diagrammatic representation of hmi-er1 P2 promoter (-1316). The first nucleotide of 
the hmi-erl translation initiation site ATG (+1) is indicated by an arrow. The position of 
a CpG island is shown as a black rectangle. (B) Nucleotide sequence of GC-rich region 
of the hmi-er 1 P2 promoter ( -1316). The number of nucleotides upstream of the first 
nucleotide A ( + 1) of hmi-er 1 P2 transcriptional start site are shown on the left of the 
sequence. The promoter region is designated by the gray region. The GC-rich Sp 1 
binding sites are shown as white nucleotides in black rectangles. Sequence motifs for 
other potential transcription factor binding are underlined and designated. 
A 
-1316 
-389 CpG island + 1 
ATG 
B 
* * * 
-389 TTCTTGCCGCCGTTGCATCACAGCAACATCCGT 
* * * * * 
-356 TTTTCAGCAAATGCATTTCAAAAACGACCTACATGTAAAATATTACGTATTTTTCCTCTG 
Elf-1 
* * 
-296 CTGTGTCAATGCTGGATGTGACTC 
-236 
-116 
-56 CGCG 
* * r+28 * * 
+5 CTCCTGCGCGTTMIIdi(!AGGCAGTGGCGGCGGGAGCGGCAGAGACGGCAGCGGCCGGA 
* * * * * +65 GTCCCGTTGCTGAGTCTCACATCCGGGTTCTGGCCGTGACCCAGCTGCGGCCGCCGCGGA 
* * +125 GATGTGACCCGGCAGTACGGCAAATATG 
To identify the hmi-er1 P2 minimal functional region, a series of 5 deletion 
fragments was constructed in pGL3 and each construct was transiently transfected into 
He La cells. Deletion of nucleotides -1316 to -133 did not result in a significant change in 
luciferase activity. Further deletion to nucleotide -68 reduced, but did not abolish 
luciferase activity, while deletion to nucleotide +28 completely abolished luciferase 
activity (Figure 2.4). These results indicated that the hmi-er1 P2 minimal functional 
promoter is located within the sequence -68/+ 144, contained in the ( -68) construct. 
2.3.3 Spl binds to the hmi-er 1 P2 minimal promoter and activates transcription 
Since the hmi-er 1 P2 minimal promoter ( -68) is predicted to contain four Sp 1 
binding sites, a number of experiments were performed to investigate the possibility that 
Sp 1 would bind to this sequence. EMSAs were performed using a HeLa cell nuclear 
extract and 32P-labelled (-68) as a probe. Two bands representing DNA-protein 
complexes appeared in samples containing nuclear extract (Figure 2.5A, lane 2 band b 
and c), however only the higher band (band b) was specific, as revealed by competition 
with excess nonlabelled (competitor) probe (Figure 2.5A, lane 3). Supershift assays, 
using a Sp 1 antibody that does not cross-react with SP2, SP3 or SP4, resulted in the 
appearance of an additional high mobility band (band a) (Figure 2.5A, lane 4) that 
disappeared in the presence of excess nonlabelled (competitor) probe (Figure 2.5A, lane 
5), thus confirming the presence of Sp1 in the DNA-protein complexes. The binding of 
Sp 1 protein to the hmi-er 1 P2 minimal promoter ( -68) was confirmed by the specific 
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Figure 2.4 Localization of the hmi-erl P2 minimal promoter. 
The diagram on the left represents the luciferase (Luc) constructs made by a series of 
deletions extending from + 144 bp downstream of the P2 transcriptional start site. The 5 
end of the nt of each construct is listed. HeLa cells were transfected with the constructs 
indicated on the left. Following transfection, the cells were cultured for an additional 48 
h and then lysed in luciferase lysis buffer, and the level of relative luciferase units (RLU) 
and ~-galactosidase activity were determined. The luciferase activity per 11g protein was 
then normalized to ~-galactosidase activity per !lg protein. Luciferase activity is 
presented as the fold increase of normalized luciferase activity relative to that from the 
pGL3(-) vector control. Shown are the average values and standard deviation for three 
independent experiments. 
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Figure 2.5 Spl binds to the hmi-erl P2 minimal promoter. 
(A) Shown is a representative EMSA performed using HeLa cell nuclear extracts and a 
32P-labelled the hmi-erl P2 minimal promoter (-68) as a probe e2P(-68)]. In lane 1, the 
labelled probe was incubated without HeLa nuclear extract. In lanes 2-5, HeLa nuclear 
extracts were incubated with (lane 3, 5) or without (lane 2, 4) 20-fold molar excess of 
nonlabelled (competitor) probe and with (lanes 4, 5) or without (lanes 2, 3) 1 f.ll anti-Spl 
antibody. The positions of DNA-protein complexes (band a, b and c) are indicated by 
arrowheads. The position of the free probe is indicated by arrow. (B) Shown is a 
representative EMSA performed using 32P(-68) and the indicated GST-fusion protein, in 
the presence (lanes 2) or absence (lanes 1) of 20-fold molar excess of nonlabelled 
(competitor) probe. The positions of DNA-protein complexes (band a, b) are indicated 
by arrowheads. The position of the free probe is indicated by arrow. 
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retarded bands a and b in EMSAs using purified GST -Sp 1 fusion protein (Figure 2.5B, 
lane 4), which was significantly competed out with nonlabelled (competitor) probe 
(Figure 2.5B, lane 3). In contrast, GST control did not bind to the hmi-er1 P2 minimal 
promoter ( -68) (Figure 2.5B, lane 1 and 2). Thus, these experiments demonstrated that 
Sp 1 binds to the hmi-er 1 P2 minimal promoter ( -68). 
The ability of Sp 1 to regulate transcription from the hmi-er 1 P2 minimal promoter 
( -68) was investigated in vivo using luciferase reporter assays. HeLa cells were co-
transfected with pGL3(-68), along with a Spl expression vector (pCR-Spl) or control 
empty vector (pCR). Overexpression of Sp 1 (Figure 2.6B) resulted in a dose-dependent 
increase in luciferase activity of pGL3( -68), compared to pCR empty vector control 
(Figure 2.6A). However, overexpression of Sp 1 (Figure 2.6C} did not significantly alter 
the luciferase activity of pGL3(-) (Figure 2.6D). These results indicated that Sp1 can 
activate transcription from the hmi-er 1 P2 minimal promoter ( -68). 
2.4 Discussion 
The transcription of a eukaryotic gene is regulated by the combined action of 
general transcription factors, mediators, multiple sequence-specific transcription factors, 
and histone modifiers including histone acetyltransferase and histone deacetylase that 
regulate the activities of the transcription factors and the chromatin structure (reviewed in 
Dynan and Tjian, 1985; Naar et a/., 2001; Pazin and Kadonaga, 1997). hmi-er1 
expression was found to be associated with the neoplastic state in human breast 
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Figure 2.6 Overexpression of Spl enhances hmi-er 1 P2 promoter activity. 
HeLa cells were co-transfected with the indicated promoter-luciferase reporter constructs 
with the pCR3.1 (pCR) empty vector, pCR3.1-Spl (pCR-Spl). The amount of plasmid 
(J..Lg) used for transfection is indicated below each bar. Cells were harvested 48h after 
transfection and the level of relative luciferase units (RLU) was determined, and this 
value was normalized to the level of cellular protein in each sample. For each sample, 
the value is presented as the fold increase over that obtained with the pCR empty vector. 
(A) Shown are the average values and standard deviations from three independent 
experiments with hmi-er 1 P2 minimal promoter-driven luciferase reporter construct 
pGL3(-68). (B) The level of Spl protein expressed in each sample described in panel A 
was determined by Western blot, using anti-Spl antibody. Shown is a representative 
Western blot, and the position of the Spl is indicated by arrow. (C) Shown are the 
average values and standard deviations from three independent experiments with 
luciferase reporter construct pGL3-Basic [pGL3(-)]. (D) The level of Spl protein 
expressed in each sample described in panel C was determined by Western blot analysis, 
using anti-Spl antibody. Shown is a representative Western blot, and the position of the 
Spl is indicated by arrow. 
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carcinoma (Paterno et al., 2002), and plays a role in the regulation of cell growth (Paterno 
et al., 1998; Paterno et al., unpublished data). As a first step toward understanding the 
molecular mechanism of regulation of hMI-ERl expression, the hmi-erl Pl promoter 
( -1781) and P2 promoter ( -1316) were cloned (Figure 2.1 ). Analysis of the P2 promoter 
( -1316) sequence revealed that this sequence contains a CpG island within which a 
number of putative transcription factor binding sites were identified. These included 9 
Spl sites, 2 TEF-2 sites, an HT4F site, an ERE half-site (Figure 2.3). The ERE half-site 
is of particular interest, as many estrogen responsive genes containing 112ERE motifs 
also possess GC boxes in close proximity such that estrogen receptor (ER) protein co-
activator complexes co-operate with Spl to regulate transcription (Sanchez et al., 2002). 
This suggests that hmi-er 1 may be an estrogen responsive gene, and experiments are 
currently being carried out to test this hypothesis (Paterno et al., unpublished data). 
Although transcription regulators, such as Sp3, Sp4 and BTEB3, may compete 
with Spl for binding to GC boxes and repress transcription (Kaczynski et al., 2001), my 
study showed that overexpression of Sp 1 binds to, and enhances transcriptional activity 
from the hmi-erl P2 minimal promoter (-68) (Figure 2.5 and 2.6). Spl is a sequence-
specific transcription factor that binds GC and GT boxes to activate a wide range of viral 
and cellular genes (reviewed in Philipsen and Suske, 1999). Overexpression of Spl 
enhances the transcriptional activity from many gene promoters such as that associated 
with Interleukin-1~ (IL-l~) (Chadjichristos et al., 2003). Spl interacts with dTAFnllO 
(Gill et al., 1994; Hoey et al., 1993) and hTAFnl30 (Tanese et al., 1996) through its 
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activation domain, and with hTAF1155 through its DNA-binding domain (Chiang and 
Roeder, 1995), suggesting that Sp 1 may facilitate the assembly of the general 
transcription machinery via multiple protein-protein interactions with components of 
TFIID. Spl also recruits an additional cofactor complex, CRSP, to mediate synergistic 
activation with SREBP-la on chromatin templates (Naar et al., 1999; Ryu et al., 1999). 
Spl and the transcriptional coactivators CBP/p300 are associated in complexes that 
regulate NGF- and progesterone-mediated induction ofp21 Waf/Cipl (Billon et al., 1999; 
Owen eta/., 1998). In addition to its role as a transcriptional activator, Spl has also been 
reported to repress transcription of murine TK promoter by recruiting histone deacetylase 
activity (Doetzlhofer et al., 1999). Therefore, Spl is important both in transcription 
activation and repression in a promoter context-specific and a cell-type specific manner 
(Bouwman and Philipsen, 2002). 
The presence of a CpG island in the hmi-er 1 P2 promoter ( -1316) indicates that 
promoter activity may also be regulated by DNA methylation. Methyl-CpG binding 
proteins such as MeCP2 and MBD3 recruit chromatin remodelling and modification 
complexes, including the NURD complex (Ng et al., 1999; Tyler and Kadonaga, 1999; 
Zhang et al., 1999). It has been proposed that DNA methylation and histone 
deacetylation might work together to establish a repressive chromatin environment and 
silence gene expression (Cameron et al., 1999). Moreover, Spl has also been linked to 
the maintenance of methylation-free CpG islands (Macleod et al., 1994) and 
hypermethylation around Sp 1 binding sites reduces Sp 1 binding, thereby decreasing 
transcription (Zhu et al., 2003). Aberrant methylation on the promoter CpG islands of 
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genes required for cell growth regulation such as p 16INK4A has been found in certain 
cancers (reviewed in Esteller and Herman, 2002; Nephew and Huang, 2003). For 
example, aberrant methylation of the promoter of the tumour suppressor genes p 16INK4A 
is closely related to tumour growth characteristics (Bender et al., 1998; Cameron et al., 
1999; Issa et al., 1994). Deregulated expression ofhMI-ER1 in some breast carcinomas 
(Paterno et al., 1998; and data at http://genome-www5.stanford.edu/cgi-bin/SMD/ 
source/ expressionSearch ?option=cluster&criteria=Hs.2227 46&dataset=2&organism=Hs) 
thus may be due to aberrant methylation on the promoter CpG island of hmi-er 1. 
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SECTION III INVESTIGATION OF hMI-ERla AND p INTERACTING 
PROTEINS AND hMI-ERla AND JJ FUNCTION 
CHAPTER 3 TRANSCRIPTIONAL REPRESSION BY hMI-ERl 
INVOLVES RECRUITMENT OF IDS TONE DEACETYLASE VIA 
THE ELM2 DOMAIN 
3.1 Introduction 
Structurally, hMI-ERla. and ~ isoforms share a number of features with other 
transcriptional regulators. hMI-ERla. and ~ contain an acidic transcription activation 
domain, an ELM2 domain, and a signature SANT domain. The latter was first identified 
in the transcription factors SWI3, ADA2, N-COR, and TFTIIB, from which the acronym 
SANT is derived (Aasland et al., 1996). Other SANT domain-containing proteins 
include transcriptional regulatory molecules involved in nuclear hormone activity, such 
as N-COR (Aasland et al., 1996) and SMRT (Ordentlich et al., 1999), molecules that are 
components of transcription and chromatin-regulatory complexes, such as MTAl (Tong 
et al., 2002), MTA2 (Wade et al., 1999), MTA3 (Fujita et al., 2003), and CoREST (You 
et al., 2001); and molecules that are important for regulating developmental events, such 
as EGL-27 (Solari et al., 1999). The SANT domain has been implicated in protein-
This chapter has been published in: Ding, Z., Gillespie, L.L., and Paterno, 
G.D. (2003) Human MI-ER1 alpha and beta function as transcriptional repressors by 
recruitment ofHDAC1 to their conserved ELM2 domain. Molecular and Cellular 
Biology, 23: 250-258. 
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protein interactions (Aasland et a/., 1996), including interactions with complexes 
containing HDAC enzymatic activity (Guenther eta/., 2001; You eta/., 2001) and HAT 
activity (Sterner eta/., 2002). The ELM2 (EGL-27 and MTA1 homology 2) domain was 
first described in EGL-27, a Caenorhabditis e/egans protein that plays a fundamental role 
in patterning during embryonic development (Solari eta/., 1999). The ELM2 domain is 
conserved throughout evolution, but to date no function has been ascribed to this motif 
before this study. More interestingly, ELM2 domain-containing proteins, including xMI-
ER1, hMI-ER1, MTA1, MTA2, MTA3 and CoREST, also contain one or more putative 
SANT domains, suggesting that there might be some important cooperative function 
between the two motifs (Solari eta/., 1999). 
Given the potential role ofhMI-ERla and~ as novel transcription regulators and 
their association with tumorigenesis, the role of the hMI-ER1a and ~ isoforms in 
transcriptional regulation was investigated. 
3.2 Materials and Methods 
3.2.1 Cell culture 
HeLa human cervical carcinoma, C33A human cervical carcinoma cells, HEK 
293 human transformed embryonic kidney cells, and mouse NIH 3T3 fibroblast cells 
were obtained from the American Type Culture Collection and cultured at 37°C in 5% 
C02 in DMEM containing 10% FCS. 
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3.2.2 Plasmid.s and. constructs 
The plasmids used in this study include the G5tkCAT reporter plasmid (a kind 
gift from Diane Hayward, Johns Hopkins School of Medicine), which contains 
chloramphenicol acetyltransferase (CAT) linked to five GAU DNA binding sites and the 
herpes simplex virus minimal thymidine kinase (tk) promoter (Hsieh et al., 1999; 
Teodoro and Branton, 1997; Yew et al., 1994); the pM plasmid (Clontech), which 
contains the GAU DBD and an NLS; CS3+MT, containing the Myc epitope tag (a kind 
gift from David Turner, University of Michigan); the pGBKT7 plasmid (Clontech), HA-
HDAC3 (a kind gift from Mark Featherstone, McGill University); and a luciferase T7 
control plasmid encoding full-length luciferase protein (Promega). 
Expression vectors were engineered to contain full-length or deletion mutants of 
hMI-ER1a or P fused to the GAL4 DBD of the pM plasmid or to the Myc epitope tag of 
the CS3+MT plasmid. Specific primers incorporating 5 and 3 Bamm sites were used to 
amplify the entire coding sequence of either hMI-ERla or p, and the digested PCR 
fragments were inserted into the Bgffi site of either the pM or the CS3+MT plasmid. 
Fragments encoding the appropriate amino acid residues of hMI-ERla or P deletion 
mutants were amplified by PCR using the primer pairs listed in Table 3.1. PCR products 
were cloned into pCR3.1 using the TA cloning kit (Invitrogen, Inc.), and EcoRI 
fragments were then inserted into the complementary sites of the pM or pGBKT7 
plasmid. The deletion constructs were named according to the encoded amino acid 
residues of the hMI-ERla or p protein. The GAU-hMI-ER1(164-283) 214W-+A and 
GAL4-hMI-ER1(164-283) 227FL-+AA mutant constructs were generated by site-directed 
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Table 2 Table 3.1 PCR primer pairs used for constructing hMI-ERl and mutating 
hMI-ERl plasmids in PM vector 
Constructa Forward primer Reverse primer 
hmi-erla aa 5-CGGGATCCATATGGCGG 5-CGGGATCCAAAACAAGAC 
1-433 AGCCATCTGTTG-3 CACAGAAGC-3 
hmi-er1~ aa 5-CGGGATCCATATGGCGG 5-CGGGATCCTTAGTCATCT 
1-512 AGCCATCTGTTG-3 GTGTTTTCAAG-3 
aa 1-283 5-CACCATGGCGACATCTG 5-ATCCTCTCTAGCTGCTTTT 
TTGAATC-3 ACA-3 
aa 1-155 5-CACCATGGCGACATCTG 5-CAAAATATTTACATCGACG 
TTGAATC-3 TGGGCG-3 
aa 1-83 5-CACCATGGCGACATCTG 5-TCTTCAGGTAGTCGAACAG 
TTGAATC-3 TAC-3 
aa 83-155 5-CACCATGGAAGAAGATG 5-CAAAATATTTACATCGACG 
AGGAAGAGGAAGAAGAG-3 TGGGCG-3 
aa 83-433 5-CACCATGGAAGAAGATG 5-CGGGATCCAAAACAAGAC 
AGGAAGAGGAAGAAGAG-3 CACAGAAGC-3 
aa 164-433 5-CACCATGGAAGAATCTG 5-CGGGATCCAAAACAAGAC 
AAGAAGATGAAGATT-3 CACAGAAGC-3 
aa287-433 5-CACCATGGTTTGGACAG 5-CGGGATCCAAAACAAGAC 
AGGAAGAGTGTA-3 CACAGAAGC-3 
aa 287-512 5-CACCATGGTTTGGACAG 5-CGGGATCCTTAGTCATCT 
AGGAAGAGTGTA-3 GTGTTTTCAAG-3 
aa 164-283 5-CACCATGGAAGAATCTG 5-ATCCTCTCTAGCTGCTTTT 
AAGAAGATGAAGATT-3 ACA-3 
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Construct' Forward primer Reverse primer 
aa 180-283 5-AAGGAGATTATGGTGGG 5-ATCCTCTCTAGCTGCTTTT 
CTCCATGTTTCAA-3 ACA-3 
aa 164-239 5-CACCATGGAAGAATCTG 5-CTTCTCATCACCTGTTCTT 
AAGAAGATGAAGATT-3 CTAGATGCATC-3 
aa240-283 5-GGTGTAGAAGCAATTCC 5-ATCCTCTCTAGCTGCTTTT 
TGAAGGATCTCAC-3 ACA-3 
aa 164-273 5-CACCATGGAAGAATCTG 5-TCATCTTCTCAATGCTTCT 
AAGAAGATGAAGATT-3 TCTGTATCAAAATTGCA-3 
aa 164-262 5-CACCATGGAAGAATCTG 5-TCATTTAACCAATTCATATA 
AAGAAGATGAAGATT-3 AAGCCTGTTCATTGTC-3 
aa 164-251 5-CACCATGGAAGAATCTG 5-TCATTTTATGTGAGATCCT 
AAGAAGATGAAGATT -3 TCAGGAATTGCTTC-3 
214w~A 5-GATCAGCTCCTGGCGGA 5-GGTAAGTACTCAGGGTCC 
CCCTGAGTACTTACC-3 GCCAGGAGCTGATC-3 
227FL~AA 5-GTGATTATAGCTGCTAAA 5-CCTTCTCATCACCTGTTCT 
GATGCATCTAGAAGAACAG TCTAGATGCATCTTTAGCAGC 
GTGATGAGAAGG-3 TATAATCAC-3 
a Deletion constructs were named according to the encoded amino acid residues of 
the hMI-ERla or~ isoforms 
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mutagenesis mutagenesis using two complementary primers (Table 3.1) (Oligos, Etc.) 
designed to produce the mutation and a QuikChange site-directed mutagenesis kit 
(Stratagene Inc.). All plasmids were sequenced to verify the junctions and the hMI-ER1 
sequence. 
Full-length human hdacl eDNA was amplified by PCR from a testis eDNA 
library by using 5 -ACGGGAGGCGAGCAAGATGGCG-3 and 5 -TCAGGCCAACTT 
GACCTCCTCCTTGAC-3 as forward and reverse primers, respectively, and then cloned 
into pCR3.1 as described above. Plasmid was sequenced to verify the junctions and the 
hdacl sequence (GenBank Database accession numberNM_004964). 
3.2.3 Transfection and reporter assays 
All transfections were performed in duplicate in six-well plates with plasmid 
DNA as previously described (Paterno et al., 1997). A total of 1.5 x 105 cells/well were 
seeded 18 h prior to transfection, and cells were harvested after 48 h in culture. For 
trichostatin A (TSA) treatment, the medium was replaced 24 h after transfection with 
fresh medium with or without the indicated concentration of TSA, and the cells were 
cultured for an additional 24 h. Cell lysates were prepared and assayed for CAT protein 
by using a CAT enzyme-linked immunosorbent assay kit (Boehringer Mannheim) as 
described previously (Paterno et al., 1997). The level of CAT protein expressed in each 
sample was determined using a CAT standard curve supplied by the manufacturer, and 
this value was normalized to the level of cellular protein in each sample. 
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3.2.4 Co-immunoprecipitation (co-IP) and Western blot analysis 
In vitro coupled transcription-translation reactions (TNTs; Promega) were 
performed as described previously (Ryan and Gillespie, 1994). For in vitro co-IP assays, 
50,000 cpm each of 35S-labelled and unlabelled TNT mixtures programmed with the 
appropriate cDNAs were combined and incubated for 3 hat 4°C. Immunoprecipitation 
was performed as described previously (Ryan and Gillespie, 1994) with 10 J!l anti-
HDAC1 polyclonal antiserum (Catalog No. H51: sc-7872, Santa Cruz Biotechnology, 
Inc.) or 10 J!l anti-Myc monoclonal antibody 9E10. For all assays, 1/20 volume of the 
indicated TNT was loaded into the input lanes. All samples were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-P AGE) followed by 
autoradiography. 
For in vivo co-IP assays, either nontransfected HeLa cells or cells transfected with 
Myc-tagged plamid pCS3+MT (pMyc), pCS3+MT-hmi-erla (pMyc-a), or pCS3+MT-
hmi-erl~ (pMyc-~) were used. Cells were lysed in the immunoprecipitation buffer [50 
mM Tris pH 8.0, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 40 mM Sodium 
Pyrophosphate, 50 mM Sodium Fluoride, 1mM Sodium Vanadate ], and the insoluble 
material was removed by centrifugation at 12,000x g for 10 min. For input lanes, one-
third of the total amount of protein in the soluble fraction was used. Supernatants were 
subjected to immunoprecipitation with either 1 J!l anti-hMI-ER1 antibody produced in 
our laboratory (24). 
Western blot analysis was performed as described in section 3.2.4 with anti-Myc 
monoclonal antibody 9E10 (1:100 dilution), anti-HDAC1 monoclonal antibody (1:100 
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dilution) (Catalog No. H-11: sc-8410, Santa Cruz Biotechnology, Inc.), or anti-GAL4 
monoclonal antibody dilution (Catalog No. RK5C1: sc-510, Santa Cruz Biotechnology, 
Inc.). 
3.2.5 HDAC assays 
The eH]acetate-labelled histone substrate for the HDAC enzyme assays was 
prepared from HeLa cells labelled with eH]acetate in the presence of 300 nM TSA as 
described previously (Yoshida et al., 1990). For each sample, 1.5 x 105 HeLa cells were 
transfected with the appropriate construct and, after 48 h, the cells were lysed as 
described previously (Hu et a/., 2000) and insoluble material was removed by 
centrifugation at 12,000 x g for 10 m.m. Supernatants were subjected to 
immunoprecipitation using 1 !J.l anti-GAL4 polyclonal antiserum (Catalog No. 06-262, 
Upstate Biotechnology, Inc.), 10 j..tl anti-Myc monoclonal antibody 9El0, or 10 !J.l anti-
HDAC1 polyclonal antiserum (Santa Cruz Biotechnology, Inc.). The immunoprecipitates 
were analyzed for HDAC enzymatic activity as described previously (Hu et al., 2000) 
with 5,000 cpm of eH]acetate-labelled histone substrate. 
3.3 Results 
3.3.1 hMI-ERla and p function as transcriptional repressors 
In this study, the transcriptional regulatory activity of the hMI-ER1a and p 
isoforms was investigated using the G5tkCAT reporter plasmid. This plasmid contains 
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CAT reporter gene linked to five GAL4 DNA binding sites along with the herpes simplex 
virus (HSV) minimal tk promoter (Hsieh eta/., 1999; Teodoro and Branton, 1997; Yew 
eta/., 1994) to provide a constitutive level of CAT expression; and thereby allows for a 
measure of both activation and repression. HeLa cells were transfected with the reporter 
plasmid along with a plasmid expressing the GAL4 DBD alone or fused to hMI-ER1a 
(GAL4-a) or hMI-ER1P (GAL4-p). Transcriptional regulation was analyzed by 
determining the ability of such fusion proteins to alter the level of CAT expression. 
Overexpression ofhMI-ERla and p (Figure 3.1B) significantly repressed transcription of 
G5tkCAT in a dose-dependent manner (P < 0.05) (Figure 3.1A). Maximum repression 
resulted in a reduction in CAT expression to 10% and 8% of control levels by GAL4-a 
and GAL4-P, respectively. This repression was not unique to HeLa cells, as similar 
results were also obtained with C33A human cervical carcinoma cells, HEK 293 human 
transformed embryonic kidney cells, and NIH 3T3 mouse fibroblasts. As shown in 
Figure 3.2, maximum repression resulted in a reduction in CAT expression to 16% and 
26% of control levels by GAL4-a and GAL4-P respectively in C33A cells; to 28% and 
24% of control levels respectively in 293K cells; to 15% and 39% of control levels 
respectively in NIH 3T3 cells. 
3.3.2 Transcriptional repression by hMI-ERla and p involves recruitment of 
HDAC enzymatic activity 
Recent studies have shown that transcriptional repression is often associated with 
recruitment of HDACs and/or chromatin-regulatory complexes containing HDAC 
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Figure 3.1 hMI-ERla and p function as transcriptional repressors on the 
G5TKCAT promoter in BeLa cells. 
(A) HeLa cells were transfected with the G5tkCAT reporter plasmid alone or with the pM 
plasmid containing an NLS and the GAL4 DBD (GAL4) alone or fused to hmi-erla 
(GAL4-a) or hmi-erl~ (GAL4-~); the amount of plasmid (in )lg) used for transfection is 
indicated below each bar. Cells were harvested 48 h after transfection, and the level of 
CAT protein was determined, and this value was normalized to the level of cellular 
protein in each sample. For each sample, the value is presented as a proportion of the 
value obtained for control G5tkCAT alone (relative CAT expression). Shown are the 
average values and standard deviations from three independent experiments. (B) The 
level of GAL4-a or GAL4-~ protein expressed in each sample was determined by 
Western blot analysis using an anti-GAL4 antibody. Shown is a representative Western 
blot, and the position of the GAL4-a or GAL4-~ is indicated by arrows. 
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Figure 3.2 hMI-ERla and p function as transcriptional repressors on the 
G5TKCAT promoter in C33A, HEK 293 and NIH 3T3 cells. 
C33A, HEK 293 (293K), and NIH 3T3 cells were transfected with the G5tkCAT reporter 
plasmid alone or with the pM plasmid (GAL4) alone or fused to hmi-erla (GAL4-a) or 
hmi-erl~ (GAL4-~); the amount of plasmid (in ).lg) used for transfection is indicated 
below each bar. Cells were harvested 48 h after transfection, and the level of CAT 
protein was determined, and this value was normalized to the level of cellular protein in 
each sample. For each sample, CAT expression value is presented as a proportion of the 
value obtained for control G5tkCAT alone (relative CAT expression). Shown are the 
average values and standard deviations from three independent experiments. 
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enzymatic activity (reviewed in Ayer, 1999). To test whether hMI-ER1a and p repress 
transcription through such a mechanism, HeLa cells were treated with TSA, a specific 
inhibitor of class I and class II HDACs (Yoshida et al., 1990), and the effect was 
examined on hMI-ER1a and P-mediated repression. Addition of TSA to the culture 
medium partially relieved repression of the tk promoter by hMI-ER1a and P (Figure 3.3), 
suggesting that transcriptional repression by hMI-ER1a and P involves recruitment of 
HDAC enzymatic activity. 
To further investigate the nature of the TSA-sensitive repression, co-IP analysis 
was utilized to examine the ability of hMI-ER1a and p to physically associate with 
HDACs both in vitro and in vivo. 35S-labelled Myc-tagged hMI-ERla (Myc-a) and hMI-
ERl p (Myc-P) were synthesized in vitro and mixed with unlabelled in vitro-translated 
HDACI and then subjected to immunoprecipitation with anti-HDACI antibody. Both 
hMI-ERla and hMI-ERIP were detected in HDACI immunoprecipitates, while 
luciferase, a control protein, was not (Figure 3.4A). Reciprocal experiments using anti-
Myc antibody 9El 0 for immunoprecipitation confirmed that HDACI could associate 
with either hMI-ERl isoform (Figure 3.4B). However, there were no interactions 
between either hMI-ERl isoform with HDAC3 in the similar in vitro assay condition 
(Figure 3.4C). 
In vivo analysis involved transient expression of the Myc-tag empty vector, Myc-
a or Myc-P in HeLa cells. Expression of Myc-a and Myc-P was verified by Western blot 
analysis with anti-Myc antibody 9E10 (Figure 3.5A, lane 2 and 3). Cell extracts were 
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Figure 3.3 Transcription repression by hMI-ERla and p occurs through a 
mechanism involving HDAC activity. 
HeLa cells were co-transfected with 0.8 J.Lg of the G5tkCAT reporter plasmid and 0.8 J.lg 
of the GAL4, GAL4-a, or GAL4-~ plasmid and cultured in the presence or absence of 
TSA, a specific inhibitor of class I and class II HDACs. Cells were harvested 48 h after 
transfection, and the level of CAT protein was determined, and this value was normalized 
to the level of cellular protein in each sample. CAT expression values for GAL4-a- and 
GAL4-~-transfected cells are presented as a proportion of the value obtained with the 
GAL4 empty vector (relative CAT expression). Shown are the average values and 
standard deviations from three independent experiments. 
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Figure 3.4 hMI-ERla and fJ physically associate with HDACl in vitro. 
(A) 35S-labelled TNT mixtures programmed with eDNA encoding luciferase (Luc), Myc 
tagged hMI-ERla [Myc-a (a)], or Myc tagged hMI-ERlP [Myc-P (p)] were loaded 
directly on the gel (1/20 of input) (lanes 1 to 3) or incubated with unlabelled TNT 
mixtures programmed with hdacl eDNA and subjected to immunoprecipitation (IP) with 
anti-HDAC1 antibody (lanes 4 to 6). Proteins were resolved by SDS-PAGE and 
visualized by autoradiography. Shown is a representative autoradiograph, and the 
positions of the Myc-a, Myc-p, and luciferase are indicated by arrowheads. (B) 35S-
labelled TNT mixtures programmed with eDNA encoding luciferase or HDAC1 were 
loaded directly on the gel (1/20 of input) (lanes 1 and 2) or incubated with unlabelled 
TNT mixtures programmed with eDNA encoding Myc-a (lanes 3 and 4) or Myc-P (lanes 
5 and 6) and subjected to IP with anti-Myc antibody 9E10; proteins were resolved by 
SDS-PAGE and visualized by autoradiography. Shown is a representative 
autoradiograph, and the positions ofthe HDAC1 and luciferase are indicated by bars. (C) 
35S-labelled TNT mixtures programmed with eDNA encoding luciferase or HDAC3 were 
loaded directly on the gel (1/20 of input) (lanes 1 and 2) or incubated with unlabelled 
TNT mixtures programmed with eDNA encoding Myc-a (lanes 3 and 4) or Myc-P (lanes 
5 and 6) and subjected to IP with anti-Myc antibody 9E10; proteins were resolved by 
SDS-PAGE and visualized by autoradiography. Shown is a representative 
autoradiograph, and the positions of the HDAC3 and luciferase is indicated by arrows. 
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Figure 3.5 hMI-ERla and p physically associate with HDACl in vivo. 
(A) HeLa celllysates from HeLa cells transiently transfected with Myc tag empty vector 
or Myc tagged hMI-ER1a (pMyc-a), or Myc tagged hMI-ER1~ (pMyc-~) plasmid were 
prepared, and either added directly to sample buffer (113 of input) (lanes 1 to 3) or 
subjected to immunoprecipitation (IP) with anti-HDAC1 antibody (lanes 4 to 6); Western 
blot (WB) analysis was performed using anti-Myc antibody 9E10. Shown is a 
representative Western blot. The positions of the Myc-a and Myc-~ proteins are 
indicated by arrowheads. (B) Untransfected HeLa celllysates were subjected to IP with 
pre-immune serum (lane 1) or anti-hMI-ER1 antiserum (lane 2). HDAC1 protein from an 
in vitro TNT mixture was loaded in lane 3. Western blot (WB) analysis was performed 
using anti-HDAC1 antibody. Shown is a representative Western blot. The position of 
the HDAC1 protein is indicated by arrowheads. 
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subjected to immunoprecipitation with anti-HDACl antibody, followed by Western blot 
analysis with anti-Myc antibody 9E10. Both hMI-ERla and ~ isoforms were co-
immunoprecipitated with endogenous HDACl (Figure 3.5A, lane 4 and 5). 
The next set of experiments was designed to investigate whether endogenous 
complexes containing hMI-ERl and HDACl exist in the cell and thus to exclude the 
possibility that the observed interaction was an artifact of overexpression. Co-
immunoprecipitation analysis of extracts from nontransfected HeLa cells was performed 
using anti-hMI-ERl antiserum or pre-immune serum (Figure 3.5B, lane 2). Endogenous 
HDACl protein was detected in hMI-ERl immunoprecipitate but not in the pre-immune 
serum control (Figure 3.5B, lane 1), demonstrating that hMI-ERl can physically 
associate with endogenous HDACl in vivo. 
Next, HDAC enzymatic activity was analyzed from the hMI-ERl 
immunoprecipitates. Cell extracts from HeLa cells transfected with the Myc tag empty 
vector, Myc-a, or Myc-~ were incubated with anti-Myc antibody 9El 0, and the 
immunoprecipitates were assayed for HDAC enzymatic activity. As shown in Figure 3.6, 
both Myc-a and Myc-~ immunoprecipitates with anti-Myc antibody 9E10 contained 
significant levels of HDAC enzymatic activity and this activity was inhibited by TSA. 
On the other hand, immunoprecipitates with anti-Myc antibody 9E10 from mock-
transfected cells or cells transfected with the Myc tag empty vector did not contain 
significant HDAC enzymatic activity (Figure 3.6). Positive control consisted of extracts 
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Figure 3.6 HDAC activities in hMI-ERla and p immunoprecipitates from HeLa 
cells. 
HeLa cells were transiently transfected with Myc tag empty vector or Myc tagged 
hMI-ERla (pMyc-a), or Myc tagged hMI-ERl~ (pMyc-~). Cell extracts were prepared 
48 h after transfection and subjected to immunoprecipitation with anti-HDACl antibody 
or anti-Myc antibody 9E10. Immunoprecipitates were assayed for HDAC enzymatic 
activity in the presence or absence of 300 nM TSA. The histogram shows the average 
values and standard deviations from three independent experiments. 
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from mock-transfected cells immunoprecipitated with anti-HDAC1 antibody and 
contained significant levels of HDAC enzymatic activity (Figure 3.6). Taken together, 
these results demonstrate that hMI-ER1a. and~ isoforms are physically associated with a 
functional HDAC1 protein. 
3.3.3 hMI-ERla and p recruits HDAC enzymatic activity through a region 
containing the ELM2 domain 
To determine which region of hMI-ER1 protein was responsible for recruitment 
of HDAC enzymatic activity, a series of GAL4 DBD-hMI-ERla. and GAL4 DBD-hMI-
ER1 ~ deletion mutants were constructed (Figure 3. 7 A, left panel) and transiently 
expressed in HeLa cells. Expression of all constructs was confirmed by Western blot 
analysis (Figure 3.7B), and immunoprecipitates with anti-GAL4 antibody were tested for 
HDAC enzymatic activity in the presence or absence of TSA (Figure 3.7 A, right panel). 
This deletion analysis revealed that a single 120-aa region common to both hMI-ERla. 
and ~ was sufficient for recruitment of HDAC enzymatic activity. This region is located 
between aa 164 and 283. Sequence analysis of this region using PFAM at 
http://pfam.wustl.edu/hmmsearch.shtml revealed a conserved ELM2 domain located 
between aa 180 and 239 (Appendices 1). 
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Figure 3.7 The region of hMI-ERl containing the ELM2 domain is associated with 
HDAC enzymatic activity. 
(A) The diagram on the left illustrates the deletion mutants of hMI-ER1 fused to GAL4 
DBD in pM vector. The individual domains are identified in the legend below the 
diagram, and the hMI-ERl amino acid residues encoded by each construct are listed. 
HeLa cells were transfected with constructs indicated on the left. Cell extracts were 
prepared 48 h after transfection and subjected to immunoprecipitation with anti-GAL4. 
Immunoprecipitates were assayed for HDAC enzymatic activity in the presence or 
absence of 300 nM TSA. The histogram shown on the right is the average values and 
standard deviations from three independent experiments. (B) The expression of the 
GAL4-hMI-ER1 fusion protein in each sample used in panel A was examined by 
Western blot analysis using an anti-GAL4 antibody. Shown is a representative Western 
blot. Indicated above each lane (lane 1 to 10) are the hMI-ER1 residues encoded by the 
construct as described in panel A. 
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3.3.4 The ELM2 domain functions as a transcriptional repression domain through 
recruitment of HDACl 
The ELM2 domain-containing region is located between aa 164 and 283 and 
contains 16 aa N-terminal sequences and 44 aa C-terminal sequences to the ELM2 
domain (aa 180-239). Further analysis of the region containing aa residues 164 to 283 
was performed to determine the minimum sequence required for recruitment of HDAC1 
and to determine whether this region was important for the transcriptional repression 
activity ofhMI-ERl. Comparison of aa in the ELM2 domain by PFAM (Appendices 1) 
revealed that tryptophan (W) at position 214, and phenylalanine-leucine (FL) at positions 
227 and 228 are highly conserved among the ELM2 domains. Therefore, a site-directed 
mutagenesis approach was employed to specifically examine the role of the ELM2 
domain. For this purpose, 214W and 227FL were changed to alanine (A) to produce two 
mutant GAL4-hMI-ER1(164-283) constructs, 214W~A and 227FL~AA, respectively 
(Figure 3.8A, left panel). Moreover, a series of GAL4-hMI-ER1(164-283) deletion 
mutants were constructed (Figure 3.8A, left panel). All constructs were transfected into 
HeLa cells, and expression of the GAL4 fusion proteins was verified by Western blot 
analysis (Figure 3.8B). Extracts from these cells were assayed for CAT expression and 
HDAC enzymatic activity (Figure 3.8A, right panel). Analysis revealed that mutant 
proteins 214W~A and 227FL~AA, were unable to recruit HDAC enzymatic activity or to 
function in transcriptional repression (Figure 3.8A, right panel), confirming the role of 
the ELM2 domain in mediating these activities. 
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Figure 3.8 The ELM2 domain and an additional 45 aa C-terminal sequence of 
hMI-ERla and JJ recruit HDAC enzymatic activity and repress transcription in 
vivo. 
(A) The diagram on the left illustrates the deletion mutants of hMI-ERl fused to GAL4 
DBD in pM vector. The hMI-ERl amino acid residues encoded by each construct are 
listed. 214W-+A and 227FL-+AA constructs contain residues 164 to 283 with alanine 
substitutions at 21~ and 227FL, respectively. For HDAC enzymatic activity 
measurements, HeLa cells were transfected with constructs indicated on the left. Cell 
extracts were prepared 48 h after transfection and subjected to immunoprecipitation with 
anti-GAL4. Immunoprecipitates were assayed for HDAC enzymatic activity in the 
presence or absence of 300 nM TSA. The histogram shown on the right is the average 
values and standard deviations from three independent experiments. For transcriptional 
repression assays, HeLa cells were transfected with the G5tkCAT reporter plasmid alone 
or with constructs indicated on the left. Cells were harvested 48 h after transfection, and 
the level of CAT protein was determined, and this value was normalized to the level of 
cellular protein in each sample. CAT expression values for all constructs are presented in 
the middle as a proportion of the value obtained with the GAL4 empty vector (relative 
CAT). (B) The expression of the GAL4-hMI-ER1 fusion protein in each sample used in 
panel A was examined by Western blot analysis using an anti-GAL4 antibody. Indicated 
above each lane (lane 1 to 9) are the hMI-ERl residues encoded by each construct. 
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Moreover, deletion of the first 16 aa (aa 164 to 179) of theN-terminus [GAL4-
hMI-ER1(180-283)] resulted in a reduction in the associated HDAC enzymatic activity to 
53% of GAL4-hMI-ER1(164-283), but had no significant effect on transcription 
repression. Further deletion of 60 aa (aa 180-239) ofN-terminal residues reduced HDAC 
enzymatic activity and transcriptional repression to control levels (Figure 3.8A, right 
panel). At the C-terminal end, all deletions, even the one as small as 10 aa from aa 274 to 
283 [GAL4-hMI-ER1(164-273)], completely eliminated HDAC enzymatic activity and 
transcriptional repression. Thus, only GAL4-hMI-ER1(164-283) and GAL4-hMI-
ER1(180-283) showed significant levels of associated HDAC enzymatic activity and 
transcriptional repression. Moreover, these were the only two constructs that were able 
to co-immunoprecipitate HDAC1 (Figure 3.9). These results demonstrate that the 
minimum sequence for recruitment of HDAC1 activity and repression of transcription is 
contained in aa 180 to 283. 
While the ELM2 domain (aa 180 to 239) was shown to be required for HDAC1 
binding and transcriptional repression, it was clear that an additional sequence C terminal 
to this domain was also essential. The ELM2 domain was originally defined on the basis 
of sequence conservation in a small number of available protein sequences (Solari et al., 
1999). A re-examination of the alignment, by using a larger number ofELM2-containing 
proteins, revealed conservation of an additional sequence C terminal to the defined 
ELM2 domain (Figure 3.10A). This highly conserved sequence encompasses aa 256 to 
274 of hMI-ER1 and contains the consensus ALXXLXsDX3ALXXL, in which the 
second and last leucines, 26~ and 274L, are invariant. Secondary-structure analysis of this 
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Figure 3.9 The ELM2 domain and an additional 45 aa C-te:rminal sequence of 
hMI-ERla and p a:re essential fo:r :recruitment of HDACl in vitro. 
35S-labelled TNT mixture programmed With eDNA encoding HDACl was loaded 
directly on the gel (lanes 1) or incubated with unlabelled TNT mixtures programmed with 
Myc tagged hMI-ERl mutants in pGBKT7 plasmid and subjected to 
immunoprecipitation (IP) with anti-Myc antibody 9El0. Proteins were resolved by SDS-
p AGE and visualized by autoradiography. Shown is a representative autoradiograph, and 
the position of the HDACl protein is indicated by arrow. 
1 2 3 4 5 6 7 8 9 10 
Figure 3.10 Alignment of ELM2 domains reveals additional conserved sequence C-
terminal to the ELM2 domain. 
(A) The ELM2 regions of proteins from the PF AM and GenBank databases were aligned 
using ClustalW. Shown is the amino acid sequence from the C-terminal end of the 
ELM2 domain to the beginning of the SANT domain in each protein. Residues 
belonging to these two domains are shaded. Highly conserved residues in the region C 
terminal to the ELM2 domain are shown with white lettering and highlighted in black. 
The consensus sequence is listed below the alignment; X represents any amino acid; <I> 
represents Y, F, or H; and+ represents a charged residue. The numbers listed above the 
alignment correspond to amino acid positions in the hMI-ERl protein sequence. The 
accession numbers for the sequences used in this alignment (from top to bottom) are as 
follows: AF515447, 042194, AB033019, XM_125783, Q9UKLO, XM_127140, 
XM_127140, AJ311849, Q9JMK4, Q9R190, Q13330, 094776, Q9VNF6, Q9VNF6, 
Q9NHX6, Q9P2R6, and Q09228. (B) The amino acid sequence from the C-terminal end 
of the ELM2 domain to the beginning of the SANT domain in hMI-ERl was analyzed 
using HelixDraw vl.OO. Shown is the helical wheel of aa from 256 A to 274E. (C) Shown is 
the helical wheel of aa from 274L to 292E, as described in panel B. 
A 
CONSENSUS: AliXl~XX+AlXXl 
M N SM 
region with the SOPMA at http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=INPSA/ 
npsa_ sopma.html revealed that this region has a propensity to form a-helical structures. 
This regton was further analyzed by HelixDraw vl.OO at 
http://bioinf.man.ac.uk!~gibson/HelixDrawlhelixdraw.html. The charged amino residues 
are clustered on one side, while hydrophobic leucine residues are clustered on the 
opposite face (Figure 3.10B and C). This sequence is predicted to form an alpha-helical 
coiled-coil by NPS@:COILED-COILS PREDICTION at http://npsa-pbil.ibcp.fr/cgi-
binlnpsa_automat.pl?page=/NPSA/npsa_lupas.html which may be important for the 
recruitment ofHDACl activity and transcriptional repression. 
The results presented here illustrate that the previously delineated ELM2 domain 
is not sufficient for transcriptional repression and recruitment of HDAC enzymatic 
activity, but requires an additional sequence further downstream. This additional 
sequence, which is required for recruitment of HDACl activity and transcription 
repression, was found to be highly conserved among ELM2-containing proteins, 
indicating that the functional ELM2 domain extends further downstream than previously 
described and includes aa 180 to 283 in hMI-ERl. 
3.4 Discussion 
In this study, the transcriptional regulatory function of the hMI-ERla and ~ 
isoforms was investigated. Both hMI-ERla and ~ can function equally well as 
transcriptional repressors through recruitment of HDACl and the evolutionarily 
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conserved ELM2 domain (aa 180 to 283), which is common to both, is required for these 
activities. Thus, the two alternate C-terminal domains appear not to be involved in 
HDAC1 activity recruitment and repression. 
Interestingly, the hMI-ERla. isoform was found to shuttle between the nucleus 
and cytoplasm in NIH 3T3 cells (Paterno et al., 2002; Paterno et al., unpublished data). 
Thus, controlling the subcellular localization ofhMI-ER1 by alternate splicing provides a 
mechanism for regulation of its nuclear activities. It is also possible that the hMI-ERla. 
isoform may be transported to the nucleus through regulated interactions with other 
nuclear protein(s), such as HDACl. Co-transport to the nucleus through such a piggy 
back mechanism has been reported for a number of proteins, including RB and HSP90 
(Kang et al., 1994; Zacksenhaus et al., 1999). The C terminus of the hMI-ERla. isoform 
possesses a class III LXXLL motif (NR box), a nuclear hormone receptor interaction 
domain found in a number of transcriptional coactivators and corepressors (Aranda and 
Pascual, 2001; Chang et al., 1999; Heery et al., 1997; Yu, 2002). Thus the C-terminus of 
the hMI-ERla. may be important in regulating the differential subcellular localizations of 
hMI-ER1a. in steroid hormone responsive tissues. In support of this speculation, a variant 
of MTA1, MTA1s, was recently found to contain the LXXLL motif and localize in the 
cytoplasm. MTA1s inhibits nuclear signalling by sequestering ER in the cytoplasm, 
which is distinct from effects ofthe nuclear form ofMTAl (Kumar et al., 2002). 
To date, 18 HDACs have been identified in humans, and their activities have been 
implicated in multiple cellular functions (reviewed in Thiagalingam et al., 2003). Three 
classes ofHDACs have been described based on homology to Saccharomyces cerevisiae 
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RPD3, HDA1 and SIR2 proteins (reviewed in Thiagalingam et a!., 2003). It is believed 
that the different HDACs may have unique temporal and spatial expression patterns that 
contribute to tissue-specific regulation of chromatin- and transcription-regulatory 
complexes. It has been shown that both hMI-ERla and~ interact with HDAC1 and this 
is a native interaction (Figure 3.5), not just an artifact of overexpression by transfection. 
However, it is possible that hMI-ER1 recruits HDAC1 activity either directly or 
indirectly through other proteins in the HDAC1-containing complexes. Since there are 
multiple endogenous proteins in celllysates and in the reticulocyte TNT lysates, I cannot, 
at present, exclude this possibility. Alternative protein-protein interaction assays using 
both purified proteins and then Western blot analysis may address this question. 
There were no interactions between either hMI-ER1 isoform with HDAC3 in 
vitro assay (Figure 3.4C), suggesting some specificity in the interaction ofhMI-ER1 with 
HDAC family members. Specific association with different types of HDACs has been 
reported for other transcription regulators. For example, NCOR and SMRT specifically 
associate with HDAC3 (Guenther eta!., 2001; Yu et al., 2003), while RB interacts with 
both HDACl/2 and HDAC3 (Ferreira et a!., 1998; Lai et a!., 1999). Investigations are 
currently ongoing in the laboratory to determine whether other HDAC family members 
can interact specifically with hMI-ER1 to regulate transcription in the same and/or 
distinct cell types. 
A region from aa 180 to 283, which is common to all hMI-ER1 isoforms and 
containing the ELM2 domain, was found to be responsible for recruiting HDAC1 activity 
(Figure 3.7). Other ELM2-containing proteins, including CoREST, MTA1, MTA2, and 
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MTA3 are present in HDAC-containing complexes (Fujita et al., 2003). While all of 
these are known components of characterized chromatin- and transcription-regulatory 
complexes containing one or more HDACs, most of the interaction domain(s) for 
recruitment of HDACs has not been determined. You et al. concluded that the SANT 
domain of the corepressor CoREST was required for association with HDAC1 (You et 
al., 2001); however, the construct used in that study also contained the ELM2 domain. 
The deletion mutant constructs of hMI-ER1 used in the present study were designed to 
separate the two domains and clearly showed that the SANT domain of hMI-ER1 does 
not recruit HDAC1 activity (Figure 3.7). It is possible that different molecules may 
utilize these domains differently and/or may cooperate in binding HDAC-containing 
complexes. Indeed, the SANT domain of the related corepressor SMRT, which does not 
contain an ELM2 domain, has been implicated in HDAC3 binding (Guenther et al., 
2001). 
The ELM2 containing region (aa 164-283) containing point mutations of the 
highly conserved 214W or 227FL residues on the ELM2 domain were unable to recruit 
HDAC1 enzymatic activity or to function in transcriptional repression (Figure 3.8). 
These results suggested that the conserved aa in the ELM2 domain may play a key role in 
directing the recruitment ofHDAC1 activity. Secondary-structure analysis of this region 
with SOPMA revealed that the ELM2 domain has a propensity to form a-helical 
structures. Although the substitution of214W or 227FL residues on the ELM2 domain with 
alanine did not result in a alteration in the propensity to form a-helical structures, it is 
possible that 21~ or 227FL play a key role in forming an interacting surface for HDAC1 
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or other protein(s) to bridge HDACl. These mutations may result in alteration of the 
structural conformation of the protein These results indicated that the structural integrity 
of the ELM2 containing region (aa 164-283) is critical for recruitment ofHDAC1 activity 
and transcription repression. 
The deletion mutational analysis of the region from aa 180 to 283 revealed that an 
intact ELM2 domain is required for these activities but that additional sequences, not 
previously included in the ELM2 domain as revealed by sequence comparisons (Solari et 
al., 1999) or PFAM alignments, are also critical for recruiting HDAC1 activity and 
transcriptional repression activities (Figure 3.8). A more detailed analysis in the present 
studies of the sequences C-terminal to the ELM2 domain, in hMI-ER1 and other ELM2 
domain-containing proteins, revealed conservation of additional sequences, including the 
consensus sequence AL:XXLX5DX3ALXXL. Secondary-structure analysis of this region 
with SOPMA revealed that this region has a propensity to form a-helical structures. 
Analysis of this region by HelixDraw vl.OO revealed that the charged amino residues are 
clustered on one side, while hydrophobic residues such as leucine are clustered on the 
opposite face (Figure 3.1 OB and C). Secondary-structure analysis of this region with the 
COILS algorithms at http://npsa-pbil.ibcp.fr/cgi-bin/npsa _ automat.pl?page=/NPSA/ 
npsa_lupas.html revealed that residues from 263 to 290 has a high probability of forming 
a coiled-coil. Coiled-coil structures are involved in protein-protein interaction (reviewed 
in Lupas, 1996). For example, the coiled-coil structure in PML is responsible for 
homodimerization (Kastner et al., 1992) and for the specific interaction with Nur77 (Wu 
et al., 2002) and the coiled-coil structure of c-SK.I was shown to recruit mSin3A-HDAC 
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complexes (Nomura et al., 1999). Thus, the structural integrity of this ELM2 domain 
containing region of hMI-ER1 may be critical for the recruitment of HDAC1 and 
transcriptional repression. 
Although the ELM2 containing region (aa 164-283) recruited HDAC1 activity 
and was involved in transcription repression by hMI-ER1, treatment of TSA can only 
partially relieve the transcription repression by hMI-ER1 (Figure 3.3). These results 
suggested that transcriptional repression by hMI-ERla and~ not only may be due to the 
recruitment of HDAC enzymatic activity, but that other mechanisms independent of 
HDAC may also be involved (see Chapter 4). 
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CHAPTER 4 THE SANT DOMAIN CONTAINING REGION OF hMI-ERl 
INTERACTS WITH SPl TO INTERFERE WITH GC BOX 
RECOGNITION AND REPRESS TRANSCRIPTION 
FROM ITS OWN P2 PROMTER 
4.1 Introduction 
hMI-ER1 has conserved domains found in a number of transcriptional regulators, 
including an acid activation domain (Paterno et al., 1997), an ELM2 domain (Solari et 
al., 1999) and a signature SANT domain (Aasland et al., 1996). In a previous study, I 
found that the ELM2 domain functions in the recruitment ofHDAC1 and transcriptional 
repression (Chapter 3 and Ding et al., 2003). The SANT domain is located immediately 
downstream of the ELM2 domain and, in other proteins, has been implicated in protein-
protein interactions (Aasland et al., 1996), including interactions with HDAC1 and 
HDAC3 (Guenther et al., 2001; You et al., 2001) and HAT (Boyer et al., 2002; Sterner et 
al., 2002) containing complexes. To date, no function has been ascribed to the SANT 
domain ofhMI-ER1. 
Studies in our laboratory revealed that overexpression of exogenous hMI-ER1a 
and ~ repress the transcription of endogeneous hMI-ER1 (Paterno et al., unpublished 
data). However, the molecular mechanisms of this transcriptional auto-regulation remain 
This chapter has been published in: The SANT domain of human MI-ER1 
interacts with Sp 1 to interfere with GC box recognition and repress transcription from its 
own promoter. J Biol Chern. 2004 Apr 26 [Epub ahead of print]. 
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unknown. I hypothesized that hMI-ER1a and ~ may function as transcriptional 
repressors on their own promoter, thus forming a negative feedback loop to tightly 
control the activity of hMI-ERl. This would ensure that hMI-ER1 regulates the 
expression of other genes at appropriate times. 
In a previous study of the molecular mechanism for the transcriptional regulation 
of hmi-er 1, the P 1 promoter ( -1781) and the P2 promoter ( -1316) of hmi-er 1 have been 
cloned (Figure 2.1, Chapter 2). This chapter describes experiments to investigate 
whether hMI-ER1a and ~ repress hmi-er1 P2 promoter activity. The molecular 
mechanism of the auto-repression by hMI-ER1a and~ from the hmi-er1 P2 promoter was 
further analyzed. 
4.2 Materials and Methods 
4.2.1 Cell culture 
The human cervical carcinoma HeLa cell line was obtained from the American 
Tissue Culture Collection and cultured at 37°C in 5% C02 in DMEM containing 10% 
FCS. 
4.2.2 Plasmids and constructs 
The pGL3(-1316) and pGL3(-68) plasmids have been previously described 
(section 2.2.3). Myc-tagged plasmids (CS3+MT) containing either full-length hmi-er 1 a 
(pMyc-a) or~ (pMyc-~) have been previously described in section 3.2.2. 
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To obtain GST-hmi-er1a and ~ fusion constructs, eDNA representing the 
appropriate isoform was subcloned in-frame into the pGEX-4T -1 vector (Pharmacia, 
Biotech). A series of hMI-ER1 deletion mutations was generated by amplifying 
fragments encoding the appropriate amino acid residues of hMI-ERla or ~. using the 
primer pairs listed in Table 4.1. PCR products were cloned into pCR3.1 and EcoRI 
fragments were then inserted into the EcoRI sites of the pGEX -4 T -1 plasmid. Deletion 
constructs were named according to the encoded amino acid residues of the hMI-ER1a 
and ~ proteins. The GST -Sp 1 fusion was constructed by subcloning the EcoRI fragments 
from Sp1-pCR3.1 into the EcoRI sites ofpGEX-4T-2. All plasmids were sequenced to 
verify the junctions and the hMI-ER1 or Sp1 sequence. 
4.2.3 Transfection and reporter assays 
All transfection reporter assays were performed as described in section 2.2.5. 
4.2.4 GST -fusion protein production 
GST fusion proteins were expressed as described in section 2.2.6. 
4.2.5 EMSAs 
EMSAs were performed as described in section 2.2.7. 
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Table 3 Table 4.1 PCR primer pairs used for constructing hMI-ERl and mutating 
hMI-ERl plasmids in GST-4Tl-1 vector 
Construct" Forward primer Reverse primer 
hmi-er1a aa 5-CGGGATCCATATGGCGG 5-CGGGATCCAAAACAAGAC 
1-433 AGCCATCTGTTG-3 CACAGAAGC-3 
hmi-er1~ aa 5-CGGGATCCATATGGCGG 5-CGGGATCCTTAGTCATCT 
1-512 AGCCATCTGTTG-3 GTGTTTTCAAG-3 
aa 1-283 5-CACCATGGCGACATCTG 5-ATCCTCTCTAGCTGCTTTT 
TTGAATC-3 ACA-3 
aa 287-433 5-CACCATGGTTTGGACAG 5-CGGGATCCAAAACAAGAC 
AGGAAGAGTGTA-3 CACAGAAGC-3 
aa 325-433 5-CACCATGGCATTCTATTA 5-CGGGATCCAAAACAAGAC 
CATGTGGAAAAAATCT -3 CACAGAAGC-3 
aa 287-410 5-CACCATGGTTTGGACAG 5-CTGGTCCATTAGATGACA 
AGGAAGAGTGTA-3 CTCCA-3 
aa 287-357 5-CACCATGGTTTGGACAG 5-CCGTTACACCAGGATGAA 
AGGAAGAGTGTA-3 GATT-3 
aa 287-330 5-CACCATGGTTTGGACAG 5-CCACATGTAATAGAATGC 
AGGAAGAGTGTA-3 TACA-3 
aa 287-512 5-CACCATGGTTTGGACAG 5-CGGGATCCTTAGTCATCT 
AGGAAGAGTGTA-3 GTGTTTTCAAG-3 
a Deletion constructs were named according to the encoded amino acid residues of the 
hMI-ER1a or~ protein 
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4.2.6 GST pull-down assays 
GST pull-down assays were performed as previously described (Routledge et al., 
2000). Briefly, 1 J..Lg of GST fusion protein was incubated with 50 J.!l of GST -Sepharose 
beads for 1 hat 4°C in 500 J.!l binding buffer (10 mM HEPES pH 7.2,140 mM NaCl, 5 
mM MgCh, 1 mM EDTA, 0.5% BSA and 0.25 % Nonidet P-40). Unbound proteins 
were removed by washing with 1000 J.!l of binding buffer three times. 50,000 cpm of 
e5S]-labelled TNT product was incubated with the GST fusion protein in 500 J.!l binding 
buffer, for 3 h at 4°C. The beads were washed with 1000 J.!l of binding buffer three times, 
1000 J.!l modified binding buffer (without Nonidet P-40) two times, and 1000 J.!l150 mM 
NaCl two times, then boiled 3 min in 40 J.!l SDS sample buffer. The supernatants were 
subjected to SDS-PAGE followed by autoradiography. For all assays, 1/20 of the volume 
of the indicated TNT was loaded into the input lanes. 
4.2.7 Co-IP and Western blot analysis 
In vitro co-IP assays were performed as described in section 3.2.4 with either 10 
J.!l anti-Sp1 polyclonal antiserum (Catalog No. PEP 2 X: sc-59, Santa Cruz 
Biotechnology, Inc.), 10 J.!l anti-Myc monoclonal antibody 9E10. 
In vivo co-IP assays were performed as described in section 3.2.4 with 1 J.!l anti-
hMI-ER1 antibody produced in our laboratory (24), or 10 J.!l anti-Sp1 polyclonal 
antiserum (Catalog No. PEP 2 X: sc-59, Santa Cruz Biotechnology, Inc.). Western blot 
analysis was performed as described in section 3.2.4 with anti-Myc monoclonal antibody 
9E10 (1:100 dilution). 
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4.3 Results 
4.3.1 hMI-ERla and p repress hmi-erl P2 promoter activity through a HDAC-
independent mechanism 
Studies in our laboratory revealed that overexpression of exogenous hMI-ERla. 
and p represses the transcription of endogeneous hMI-ER1 (Paterno et al., unpublished 
data). However, the molecular mechanisms of this transcriptional auto-regulation remain 
unknown. Since hMI-ERla. and p were shown to interact with HDACl and mediate 
transcriptional repression through recruitment of HDAC enzymatic activity, experiments 
were designed to investigate whether hMI-ERla. and p are involved in directing HDAC 
enzymatic activity to hmi-erl P2 promoter (-1316). HeLa cells were co-transfected with 
the hmi-erl P2 promoter-driven luciferase reporter construct pGL3(-1316) with Myc tag 
empty vector alone or fused to hMI-ERa. (pMyc-a.) or hMI-ER1P (pMyc-p). 
Transcriptional regulation was analyzed by determining the ability of such fusion 
proteins to alter the level of luciferase activity, compared to the Myc tag empty vector. 
Overexpression of both hMI-ER1a. and P isoforms (Figure 4.1B) significantly repressed 
luciferase activity of pGL3(-1316), in a dose-dependent manner (Figure 4.1A). 
Maximum repression resulted in a reduction in luciferase activity to 36% and 29% of 
control levels by Myc-a. and Myc-p, respectively. Likewise, overexpression of Myc-a. 
and Myc-P (Figure 4.2B) repressed the activity of pGL3( -68) to 40% and 33% of control 
levels, respectively (Figure 4.2A), while overexpression of hMI-ER1a. and P (Figure 
4.2D) had no significant affect on pGL3-Basic [pGL3(-)] (Figure 4.2C). These results 
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Figure 4.1 hMI-ERla and p repress hmi-erl P2 promoter activity. 
HeLa cells were co-transfected with the hmi-er 1 P2 promoter-driven luciferase reporter 
construct pGL3( -1316) and with the Myc-tag empty vector, pMyc-a or pMyc-~. Cells 
were harvested 48 h after transfection and the level of relative luciferase units (RLU) was 
determined. For each sample, the value is presented as a proportion of the value obtained 
for Myc tag empty vector transfected cells (relative luciferase activity). (A) Shown are 
the average values and standard deviations from three independent experiments. (B) The 
level of Myc-a or Myc-~ protein expressed in each sample as described above in the 
panel A was determined by Western blot, using anti-Myc antibody 9E10. Shown is a 
representative Western blot, and positions of the Myc-a and Myc-~ proteins are indicated 
by arrowheads. 
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Figure 4.2 hMI-ERla and p repress the hmi-erl P2 minimal promoter activity. 
HeLa cells were co-transfected with the hmi-er 1 P2 mimimal promoter-driven luciferase 
reporter construct pGL3(-68) or the pGL3-Basic control vector pGL3(-) and with the 
Myc-tag empty vector, pMyc-u or pMyc-~. Cells were harvested 48 h after transfection 
and the level of relative luciferase units (RLU) was determined. For each sample, the 
value is presented as a proportion of the value obtained for Myc tag empty vector 
transfected cells (relative luciferase activity). (A) Shown are the average values and 
standard deviations from three independent experiments with the reporter construct 
pGL3(-68). (B) The level of Myc-u or Myc-~ protein expressed in each sample with 
pGL3(-68) as described above in the panel A was determined by Western blot, using anti-
Myc antibody 9E10. Shown is a representative Western blot, and the positions of the 
Myc-u and Myc-~ proteins are indicated by arrows. (C) Shown are the average values 
and standard deviations from three independent experiments with the reporter construct 
pGL3(-). (D) The level of Myc-u or Myc-~ protein expressed in each sample as 
described above in the panel C was determined by Western blot, using anti-Myc antibody 
9El0. Shown is a representative Western blot, and the positions of the Myc-u and Myc-~ 
proteins are indicated by arrows. 
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demonstrated that the DNA sequence required for repression by hMI-ER1 is contained 
within the hmi-er 1 P2 minimal promoter ( -68). 
Since hMI-ERl was shown to recruit HDAC1 enzymatic activity, one might then 
speculate that hMI-ERl represses promoter activity by targeting HDAC1 enzymatic 
activity to the promoter. However, other mechanisms may also contribute to repression 
activity, such as competition for DNA binding sites on the hmi-er 1 P2 minimal promoter 
DNA sequence with other transcription regulators or interacting with other transcriptional 
regulators that can bind to the promoter and interfere with their functions. To test 
whether hMI-ER1a. and P repress transcription through recruitment ofHDAC1 enzymatic 
activity, HeLa cells were treated with TSA, and the effect on hMI-ER1a. and P-mediated 
repression was examined. However, addition of TSA to the culture medium did not 
relieve the repression by hMI-ER1a. and P on the luciferase activity of pGL3(-1316) 
(Figure 4.3A), or on the luciferase activity of pGL3(-68) (Figure 4.3B). These results 
suggested that transcriptional repression of the luciferase activity of pGL3 ( -1316) by 
hMI-ERla. and P involves a predominantly HDAC-independent mechanism, unlike what 
was observed with the TKpromoter ofG5TKCAT (Chapter 3). 
4.3.2 hMI-ERla and p do not bind to their own P2 minimal promoter 
To investigate whether hMI-ERl could bind to its P2 minimal promoter (-68) and 
compete for DNA binding sites with other transcription regulators, EMSAs were 
performed using purified GST fusion proteins and 32P-labelled (-68) as a probe. These 
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Figure 4.3 Repression of the hmi-erl P2 promoter by hMI-ERla and p is not 
relieved by treatment with TSA. 
HeLa cells were co-transfected with 0.4 J..tg of the hmi-er 1 P2 promoter-driven luciferase 
reporter construct pGL3(-1316) or the P2 minimal promoter-driven luciferase reporter 
construct pGL3(-68) with the Myc-tag empty vector, pMyc-a or pMyc-~ and cultured in 
the presence or absence of TSA. Cells were harvested 48 h after transfection, and the 
level of relative luciferase units (RLU) was determined. For each sample, the value is 
presented as a proportion of the value obtained for Myc tag empty vector-transfected 
cells (relative luciferase activity). (A) Shown are the average values and standard 
deviations from three independent experiments with the reporter construct pGL3( -1316). 
(B) Shown are the average values and standard deviations from three independent 
experiments with the reporter construct pGL3( -68). 
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assays revealed that hMI-ERla and ~ do not bind to the 32P-labelled (-68) (Figure 4.4, 
lane 6 and 8), while Sp1 does (band a and b) (Figure 4.4, lane 4). These results are in 
agreement with the previous observation that MI-ER has no DNA binding activity 
(Paterno et al., unpublished data), which was determined from an unbiased set of 
degenerate oligonucleotides using CASTing methods (Wright eta!., 1991). These results 
indicated that repression of transcriptional activation on the P2 minimal promoter (-68) is 
not the result of competition for binding to the promoter sequence with other 
transcription factors, such as Sp 1. 
4.3.3 hMI-ERla and p physically interact with Spl in vitro and in vivo 
Since overexpression of Sp 1 was found to activate the luciferase activity of hmi-
er 1 P2 minimal promoter-driven luciferase reporter construct pGL3( -68) (Figure 2.6, 
Chapter 2), experiments were performed to investigate whether overexpression of hMI-
ER1a and ~ alter the luciferase activity of pGL3(-68) stimulated by Spl. HeLa cells 
were co-transfected with pGL3(-68), pCR-Sp1 and either pMyc, pMyc-a, or pMyc-~. 
Luciferase reporter assays revealed that overexpression of both hMI-ER1a and~ (Figure 
4.5B) repressed promoter activity stimulated by Sp 1 in a dose-dependent manner (Figure 
4.5A). 
Four Sp1 binding sites were predicted in the hmi-erl P2 minimal functional 
promoter and Sp1 was also found to bind to this region (Chapter 2). Since hMI-ER1a 
and ~ do not bind to ( -68) (Figure 4.4) but repress the luciferase activity of pGL3( -68) 
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Figure 4.4 hMI-ERla and p do not bind to hmi-erl P2 minimal promoter. 
Shown is a representative EMSA performed using GST fusion proteins and a 32P-labelled 
the hmi-erl P2 minimal promoter as a probe e2P(-68)]. Shown is an EMSA using 
labelled minimal promoter region as a probe. In lanes 1 and 2, the 32p( -68) probe was 
incubated with GST in the presence or absence, respectively, of 20-fold molar excess of 
nonlabelled (competitor) probe. In lanes 3 and 4, the labelled probe was incubated with 
GST-Spl in the presence or absence of 20-fold molar excesses of nonlabelled 
(competitor) probe, respectively. In lanes 5 and 6, the labelled probe was incubated with 
GST-hMI-ERla (GST-a) in the presence or absence of 20-fold molar excesses of 
nonlabelled (competitor) probe, respectively. In lanes 7 and 8, the labelled probe was 
incubated with GST-hMI-ERlP (GST-P) in the presence or absence of 20-fold molar 
excesses of nonlabelled (competitor) probe, respectively. The positions of DNA-protein 
complexes (band a and b) are indicated by arrowheads. The position of the free probe is 
indicated by arrow. 
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Figure 4.5 Overexpression of hMI-ERla and p disrupt hmi-erl P2 promoter 
activity stimulated by Spl. 
(A) HeLa cells were co-transfected with P2 minimal promoter-driven luciferase reporter 
construct pGL3(-68) and pCR3.1-Spl (pCR-Spl) construct with the Myc-tag empty 
vector, pMyc-a or pMyc-~; the amount of plasmid (J.Lg) used for transfection is indicated 
below each bar. Cells were harvested 48h after transfection and the relative luciferase 
units (RLU) was determined. For each sample, the value is presented as a proportion of 
the value obtained for Myc tag empty vector and empty pCR3.1 vector transfected cells 
(relative luciferase activity). (B) The level ofMyc-a or Myc-~ protein expressed in each 
sample was determined by Western blot, using anti-Myc antibody 9E10. Shown is a 
representative Western blot, and the positions of the Myc-a and Myc-~ proteins are 
indicated by arrowheads. 
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stimulated by Spl (Figure 4.5), it is possible that hMI-ERla and ~ may repress the 
activity from this promoter region through interaction with the transcriptional regulator 
Spl. Thus, experiments were performed to see if an interaction between hMI-ERl and 
Sp 1 was possible. Co-immunoprecipitation analysis was utilized to examine the ability 
of hMI-ERia and ~ isoforms to physically associate with Spi both in vitro and in vivo. 
35S-labelled Myc-tagged hMI-ERia (Myc-a) and hMI-ERI~ (Myc-~) were synthesized 
in vitro and mixed with unlabelled in vitro-translated in vitro translated Sp I, then the 
mixture was subjected to immunoprecipitation with anti-Spi antibody. Both hMI-ERia 
and ~ isoforms were detected in Sp I immunoprecipitates while luciferase, a control 
protein, was not (Figure 4.6A). Reciprocal experiments, using anti-Myc antibody 9EIO 
for immunoprecipitation, confirmed that Spi could associate with either hMI-ERI 
isoform (Figure 4.6B). GST pull-down assays again confirmed that in vitro translated 
Spi specifically associated with GST-hMI-ERia or hMI-ERl~, but not with the GST 
control (Figure 4.6C). 
In vivo analysis involved transient expression of the Myc-tag empty vector, Myc-
a or Myc-~ in HeLa cells. Expression ofMyc-a and Myc-~ was verified by Western blot 
analysis with anti-Myc antibody 9EIO (Figure 4.7, lane 2 and 3). Cell extracts were 
subjected to immunoprecipitation with anti-Spi antibody, followed by Western blot 
analysis with anti-Myc antibody 9EIO. Both hMI-ERla and ~ isoforms were co-
immunoprecipitated with endogenous Spi by anti-Spi antibody (Figure 4.7A, lane 7 and 
9), but not in immunoprecipitates with non-immune serum control (Figure 4.7A, lane 6 
and 8). 
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Figure 4.6 hMI-ERla and p interact physically with Spl in vitro. 
(A) 358-labelled TNT mixtures programmed with eDNA encoding luciferase (Luc), Myc 
tagged hMI-ERla [Myc-a (a)], or Myc tagged hMI-ERl~ [Myc-~ (~)] were loaded 
directly on the gel (1/20 of input) (lanes 1 to 3) or incubated with unlabelled TNT 
mixtures programmed with Spl eDNA and subjected to immunoprecipitation (IP) with 
anti-Spl antibody (lances 4-6). Proteins were resolved by SDS-PAGE and visualized by 
autoradiography. Shown is a representative autoradiograph, and the positions of the 
Myc-a, Myc-~ and luciferase proteins are indicated by arrowheads. (B) 35S-labelled 
TNTs programmed with eDNA encoding luciferase (Luc ), or Sp 1 were loaded directly on 
the gel (1/20 of input) (lanes 1, 2) or incubated with unlabelled TNTs programmed with 
eDNA encoding Myc-a (lanes 3, 4) or Myc-~ (lanes 5, 6) and subjected to 
immunoprecipitation (IP) with anti-Myc antibody 9E10. Proteins were resolved by SDS-
p AGE and visualized by autoradiography. Shown is a representative autoradiograph, and 
the positions of the Sp1 and luciferase proteins are indicated by arrowheads. (C) 35S-
labelled TNTs programmed with eDNA encoding Sp 1 was loaded directly on the gel 
(1/20 of input) (lane 1) or incubated with GST (lane 2), GST-hMI-ER1a (GST-a) (lane 
3), GST-hMI-ER1~ (GST-~) (lane 4). Proteins were resolved by SDS-PAGE and 
visualized by autoradiography. Shown is a representative autoradiograph, and the 
position of the Sp 1 protein is indicated by arrowheads. 
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Figure 4.7 hMI-ERla and fJ interact physically with Spl in vivo. 
(A) Cell lysates from HeLa cells, transiently transfected with Myc-tag empty vector, 
Myc-a or Myc-p, were prepared and equivalent amounts of protein from each sample 
were either added directly to sample buffer (113 of input) (lanes 1-3) or subjected to IP 
with anti-Spl antibody (lanes 5, 7, 9), or with non-immune serum (lanes 4, 6, 8); Western 
blot (WB) analysis was performed using anti-Myc antibody 9El0. Shown is a 
representative Western blot, and the positions of the Myc-a and Myc-P proteins are 
indicated by arrowheads. (B) Untransfected HeLa cell1ysates were subjected to IP with 
pre-immune serum (lane 1) or anti-hMI-ER1 (lane 2), or anti-Sp1 antiserum (lane 3). 
Western blot (WB) analysis was performed using anti-Sp1 antibody. Shown is a 
representative Western blot, and the position of the Sp 1 protein is indicated by 
arrowheads. 
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The next set of experiments was designed to investigate whether endogenous 
complexes containing hMI-ER1 and Sp1 exist in the cell to exclude the possibility that 
the observed interaction was an artifact of overexpression of transfected constructs. Co-
immunoprecipitation analysis of extracts from non-transfected HeLa cells was performed, 
using pre-immune serum or an anti-hMI-ER1 antibody. As shown in Figure 4.7B, Sp1 
protein was detected in the hMI-ER1 immunoprecipitate (lane 2), but not in the control 
(lane 1), demonstrating that hMI-ER1 can physically associate with endogenous Sp1 in 
vivo. 
To determine which region of the hMI-ER1 protein is required for interaction 
with Sp1, a series ofGST-hMI-ER1a and~ deletions were constructed (Figure 4.8A) and 
pull-down assays were performed with 358-labelled Spl. The deletion analysis revealed 
that the sequence required for interaction with Sp1 maps to residues 287-357 (Figure 
4.8B, lane 4, 6, 7 and 9). Sequence analysis of this region using PF AM at 
http://pfam.wustl.edu/cgi-bin/getalignment revealed a conserved SANT domain was 
located between aa 288 and 331 (Appendices 2). Further deletion of this region at the C-
terminal end to remove residues from aa 331 to 357 C31K to 357T), which includes a 
highly conserved lysine (K) of SANT domain at position 331 and the C-terminal 26 aa, 
completely abolished interaction with Sp 1 (Figure 4.8B, lane 8). Sp 1 did not interact 
with GST control (Figure 4.8B, lane 6), theN-terminal aa 1-283 deletion mutant ofhMI-
ER1 (Figure 4.8B, lane 3), or the C-terminal aa 325-433 deletion mutant of hMI-ER1 
(Figure 4.8B, lane 5). These results demonstrate the importance of an intact SANT 
domain and the C-terminal 26 aa for the interaction with Sp 1. 
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Figure 4.8 The region of hMI-ERl containing SANT domain interacts with Spl in 
vitro. 
(A) The diagram illustrates the deletion mutants ofhMI-ERl fused to GST in pGEX-4T-
1 vector. The individual domains are identified in the legend below the diagram, and the 
hMI-ERl amino acid residues encoded by each construct are listed. (B) Shown is GST 
pull-down assays of hMI-ER1 deletion mutants with Spl. 35S-labelled TNTs 
programmed with eDNA encoding Spl was loaded directly on the gel (lane 1) or 
incubated with GST (lane 2), GST-(1-283) (lane 3), GST-(287-433) (lance 4), GST-(325-
433) (lane 5), GST-(287-410) (lane 6), GST-(287-357) (lane 7), GST-(287-330) (lane 8), 
and GST-(287-512) (lane 9). Proteins were resolved by SDS-PAGE and visualized by 
autoradiography. The position of the Sp1 protein is indicated by arrowheads. 
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4.3.4 hMI-ERla and p interfere with GC box recognition by Spl 
The finding that GST-hMI-ER1a and P isoforms can associate with Sp1 raises the 
possibility that interaction with Sp1 may affect the ability of Sp1 to bind DNA, thus 
providing a mechanism for the regulation of the hmi-erl promoter by hMI-ERl. To 
examine the effects of GST-hMI-ER1a (GST-1a) and GST-hMI-ER1P (GST-P) on Sp1 
DNA-binding activity, EMSAs were performed using GST-Sp1 with the hmi-erl 
minimal promoter sequence, in the presence or absence of various GST-hMI-ER1 fusion 
proteins (Figure 4.9A). As shown in Figure 4.9B, addition of GST-1a or GST-P to the 
EMSA reaction mixtures resulted in the disruption of the Sp1-DNA complexes (band a 
and b) (lanes 3, 4), while addition of GST alone had no effect (lane 2). Furthermore, 
addition of GST-(287-357), containing an intact SANT domain, disrupted the Sp1-DNA 
complexes (band a and b) (lane 5), while addition ofGST-(287-330) construct, in which 
the last amino acid residue of the SANT domain and C-terminal 26 aa were removed, did 
not (lane 6). An uncharacterized third band (c) appeared in the samples with addition of 
GST-1a, GST-P, or GST-(287-357), but not in the samples with GST alone or GST-(287-
330). 
Next, experiments were performed to examine whether hMI-ER1 could affect the 
ability of Sp 1 to interact with its consensus binding site. EMS As were performed using 
GST-Sp1 and 32P-labelled double-stranded oligonucleotide consisting of the Spl 
consensus sequence (Sp1CS), in the presence or absence of various GST-hMI-ER1 fusion 
proteins (Figure 4.1 OA). As seen with the hmi-er 1 minimal promoter, addition of GST -a, 
GST-P or GST-(287-357) to the EMSA reaction mixtures resulted in the disruption of 
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Figure 4.9 hMI-ERla and p interfere with GC box recognition by Spl to the 
hmi-er 1 P2 minimal promoter. 
(A) The diagram illustrates the deletion mutants ofhMI-ERl fused to GST in pGEX-4T-
1 vector. The individual domains are identified in the legend below the diagram, and the 
hMI-ERl amino acid residues encoded by each construct are listed. (B) Shown is a 
representative EMSA performed using 32P-labelled the hmi-erl P2 minimal promoter 
(-68) as a probe e2P(-68)]. The 32p(-68) probe was incubated with GST-Spl in the 
presence ofGST elution buffer (lane 1), GST (lane 2), GST-hMI-ERla (GST-a) (lane 3), 
GST-hMI-ERl~ (GST-~) (lane 4), GST-(287-357) (lane 5), or GST-(287-330) (lane 6). 
The positions of DNA-protein complexes (band a, band c) are indicated by arrowheads. 
The position of the free probe is indicated by arrow. 
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Figure 4.10 hMI-ERla and p interfere with DNA binding by Spl to the Spl 
consensus oligonucleotide. 
(A) The diagram illustrates the deletion mutants of hMI-ER1 fused to GST in 
pGEX-4T-1 vector. The individual domains are identified in the legend below the 
diagram, and the hMI-ERl amino acid residues encoded by each construct are listed. (B) 
Shown is a representative EMSA performed using labelled consensus Sp 1 oligo 
e2p(Sp1CS)] as a probes. The 32p(Sp1CS) probe was incubated with GST-Sp1 in the 
presence of elution buffer (lane 1), GST (lane 2), GST-hMI-ERla (GST-a) (lane 3), 
GST-hMI-ERl~ (GST-~) (lane 4), GST-(287-357) (lane 5), or GST-(287-330) (lane 6). 
Proteins were resolved by SDS-PAGE and visualized by autoradiography. The positions 
of DNA-protein complexes (band a, b) are indicated by arrowheads. The position of the 
free probe is indicated by arrow. 
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Sp1-DNA complexes (band a and b) (Figure 4.10B, lane 4, 5 and 6), while addition of 
GST and GST-(287-330) had no effect (Figure 4.10B, lane 3 and 7). These results 
confirm that hMI-ERla or~ interferes with the ability for Sp1 to bind to its cognate site 
on DNA. Furthermore, this interference was not due to competition with Sp 1 for binding 
to the Sp1 consensus sequence, as neither hMI-ERl isoform could form a DNA-protein 
complex with the Sp1 consensus oligonucleotide (Figure 4.11, lane 6 and 8). 
4.4 Discussion 
Our previous studies have shown that overexpression of both GAIA tagged hMI-
ERla and hMI-ER1~ significantly repressed transcription from the TK promoter of the 
G5TKCAT reporter plasmid (Chapter 3). Maximum repression resulted in a reduction in 
CAT expression to 10% and 8% of control levels by hMI-ER1a and hMI-ERl~, 
respectively (Figure 3.1). In the studies described in this chapter, overexpression ofboth 
Myc tagged hMI-ERla and hMI-ERl~ also significantly repressed luciferase activity of 
pGL3(-1316), in a dose-dependent manner (Figure 4.1). Maximum repression resulted in 
a reduction in reporter gene expression to 36% and 29% of control levels by hMI-ER1a 
and hMI-ER1 ~, respectively (Figure 4.1 ). 
The DNA sequence required for repression by hMI-ER1 on the luciferase activity 
ofpGL3(-1316) is contained within the P2 minimal promoter (-68) (Figure 4.2). There 
are four putative Sp1 and one TEF-2 binding sites in this region (Figure 2.3). One might 
speculate that hMI-ER1 represses promoter activity on this region by: (1) targeting 
HDAC1 activity to the promoter; (2) competing for DNA binding sites with other 
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Figure 4.11 hMI-ER1a and p do not bind to the Sp1 consensus oligonucleotide. 
Shown is a representative EMSA performed using labelled Sp 1 consensus 
oligonucleotide e2p(Sp1CS)] as a probes. In lanes 1 and 2, 32p(Sp1CS) was incubated 
with 1 J..lg GST fusion protein in the presence or absence, respectively, of 20-fold molar 
excess of nonlabelled (competitor) probe. In lanes 3 and 4, the labelled probe was 
incubated with GST-Sp1 in the presence or absence, respectively, of 20-fold molar 
excesses of nonlabelled (competitor) probe. In lanes 5 and 6, the labelled probe was 
incubated with GST-hMI-ERla (GST-a) in the presence or absence of 20-fold molar 
excesses of nonlabelled (competitor) probe, respectively. In lanes 7 and 8, the labelled 
probe was incubated with GST-hMI-ERl~ (GST-~) in the presence or absence of20-fold 
molar excesses ofnonlabelled (competitor) probe, respectively. The position of the free 
probe is indicated by arrow. 
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transcription regulators such as Spl and/or TEF-2; (3) interacting and interfering with 
other transcriptional regulators such as Spl and/or TEF-2 that can bind to the promoter; 
or (4) changing endogenous Spl concentration and/or activity. The present study showed 
that transcriptional repression ofP2 hmi-erl promoter activity by hMI-ERla and~ is not 
relieved by treatment with TSA (Figure 4.3), unlike what was observed with the TK 
promoter of G5TKCAT (Chapter 3). EMSAs also revealed that hMI-ERla and ~ can not 
bind to the hmi-erl P2 minimal functional promoter (Figure 4.4), suggesting that hMI-
ERl a and ~ may not compete for the DNA binding sites for other transcription factors 
such as Spl and TEF-2. Since our previous study showed that Spl binds to the hmi-erl 
P2 minimal promoter (-68) and enhances the luciferase activity ofpGL3(-68) (Figure 2.5 
and Figure 2.6 in Chapter 2), the study described in this chapter investigated the 
possibility that hMI-ERl interferes with the luciferase activity of pGL3(-68) stimulated 
by Spl. Overexpression of hMI-ERl was shown to repress the luciferase activity of 
pGL3(-68) stimulated by Spl (Figure 4.5). In vitro and in vivo protein-protein interaction 
assays revealed that hMI-ERl indeed interacts with Spl (Figure 4.7). Since the cell 
lysates and the TNT lysate may contain other factors that interact with Spl or hMI-ERl, 
it remains unknown as to whether the interaction ofhMI-ERla and~ with Spl is direct 
or indirect through other proteins. To investigate whether they interact directly, purified 
hMI-ERl and Spl protein from bacterial GST recombinant products will be required for 
pull-down assays, followed by Western blot analysis. 
The interaction between hMI-ERl and Spl interfered with GC box recognition by 
Sp 1 to the hmi-er 1 P2 minimal promoter ( -68) in vitro (band a and b) (Figure 4.9). This 
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result was further confirmed by EMSAs using the consensus Sp 1 binding sequence as a 
probe (Figure 4.10). Interestingly, in the presence of 32P-labelled hmi-erl P2 minimal 
promoter (-68) as a probe, addition of purified hMI-ER1a or~ GST fusion protein to the 
EMSA mixture resulted in the presence of an extra band c (Figure 4.9 lane 3, 4, and 5), 
which is less likely due to the binding of hMI-ERla or ~ themselves, since: (1) hMI-
ERla or~ cannot bind to the hmi-erl P2 minimal promoter (-68) (Figure 4.4); (2) band c 
is on the same position in all the samples with GST-1a, GST-~, or GST-(287-357), which 
have differing molecular weights. Interestingly, this extra band (band c) did not appear 
when the consensus Sp 1 was used as a probe (Figure 4.1 0). Thus this extra band may be 
a specific form ofDNA-Sp1 complexes that bind to the hmi-erl P2 minimal promoter(-
68), but which does not bind to the consensus Sp 1 sequence. Further studies such as 
using anti-Sp1 antibody and/or consensus Sp1 sequence as competitor are required to 
understand the composition of this extra band. 
The present study suggested that the hMI-ER1 interacts with Sp1 and interferes 
with GC box recognition by Sp1 through the SANT domain-containing region (aa 287-
357). These findings support the possibility of a novel mechanism for negative 
regulation of expression from genes containing Sp 1 target promoters, which includes the 
promoter of hmi-erl. However, it is still possible that overexpression ofhMI-ER1 may 
also affect Sp1 concentration in the cells, which in turn affects activity from the hmi-er1 
promoter. Further studies to monitor the cellular level of Sp 1 are required to support or 
refute this scenario. Moreover, it is also possible that overexpression of hMI-ER1 may 
affect Sp 1 activity indirectly through other factors. There are multiple factors that have 
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been reported to regulate Sp 1 activities via several mechanisms: (1) Many transcription 
regulators, such as Sp3, Sp4 and BTEB3 compete with Sp1 for the core cis-acting 
elements and repress promoter activity (Kaczynski et al., 2001; Kwon et al., 1999). (2) 
Sp1 activity was also found to be regulated through protein-protein interactions. Factors 
that interact with Sp1 include E2F1, GATA1, and YY1, all of which act synergistically 
with Sp1 on DNA to increase transcriptional activity (Gregory et al., 1996; Karlseder et 
al., 1996; Lee et al., 1993b; Lin et al., 1996b). (3) Another set of Spl-interacting 
transcription factors that impair Sp 1-mediated transcriptional activity includes p 107, 
PML, FBI-1, TAF-1 and MDM2 (Datta et al., 1995; Johnson-Pais et al., 2001; Lee et al., 
2002; Suzuki et al., 2003; Vallian et al., 1998). (4) Furthermore, Sp1 and the 
transcriptional coactivator CBP/p300 have been shown to be associated in complexes and 
to upregulate the promoter activity of p21Waf/Cip1 (Billon et al., 1999; Owen et al., 
1998). (5) HDAC1-containing complexes can be recruited directly by Sp1 for 
transcriptional repression (Doetzlhofer et al., 1999). (6) While RB has not been shown to 
bind Sp 1 directly, it can increase Sp 1 activity by releasing Sp 1 from MDM2-Sp 1 
complexes (Johnson-Pais et al., 2001). Thus several different kinds of mechanisms of 
regulating Sp 1 transcriptional activity appear to exist, and the change of the concentration 
and/or activity of those proteins may also affect the Sp1-targeted promoter activity. 
The SANT domain is present exclusively in proteins that have an important role 
in the regulation of transcription (Aasland et al., 1996). This domain is related in primary 
and secondary structure to the DNA binding motif of the MYB oncoprotein and other 
MYB-like domains (Aasland et al., 1996). A subset of SANT-containing proteins 
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possesses two or three related repeats of this domain, each of which serves distinct 
functions. For example, the nuclear hormone co-repressor, N-CoR, contains two SANT 
domains. Its N-terminal SANTI domain serves as a deacetylase activation domain 
(DAD) that binds and activates HDAC3 while the C-terminal SANT2 domain functions 
as a histone interaction domain (HID), preferentially targeting non-acetylated histones 
and inhibiting HAT activity (Yu et al., 2003). Thus the two domains function 
synergistically to repress specific regions of chromatin by targeting HDACs and 
inhibiting HAT activity. 
The SANT domains of single SANT proteins, like ADA2, are also involved in 
protein-protein interactions. futerestingly, the single SANT domain of ADA2 has been 
shown to have two different functions in yeast. TheN-terminal portion of the ADA2 
SANT domain is critical for efficient acetylation of histone targets by GCN5, while the 
C-terminal portion of ADA2 SANT domain functions as an interaction domain for GCN5 
(Sterner et al., 2002). fu this chapter, I demonstrated that the SANT domain-containing 
region (aa 287-357) of hMI-ERl interacted with Spl, and the C-terminal deletion from 
331K to 331T eliminated both hMI-ERl interactions with Sp1 (Figure 4.8) and interfered 
with the GC box recognition by Sp 1 (Figure 4.1 0). These results suggest that the SANT 
domain-containing region spanning residues aa 287-357 is an important interaction 
region for hMI-ERl to interact with Spl and interfere with the GC box recognition by 
Sp 1. However, whether an intact SANT domain or the region spanning between the 
SANT domain and its C-terminal 26 aa is critical for the interaction with Sp 1 remains 
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unclear. Site-directed mutagenesis and/or more deletion mutagenesis to this SANT 
domain-containing region (aa 287-357) could be employed to address this question. 
The transcription repression mechanism mediated by the SANT domain of hMI-
ERl is distinct from transcription repression mediated by the ELM2 domain-containing 
region (aa 164-283) which recruits HDAC1 activity to deacetylate the chromatin 
(Chapter 3). Results suggested that hMI-ER1 can function as a transcription repressor via 
both HDAC-dependent and -independent mechanisms through ELM2 and SANT 
domains, respectively. Both HDAC-dependent and -independent transcriptional 
repression mechanisms have been reported for other transcription regulators, such as RB 
(Lai et al., 1999), Stra13 (Sun and Taneja, 2000), LCoR (Fernandes et al., 2003) and 
MTA1 (Yan et al., 2003). 
In summary, hMI-ER1 interferes with DNA recognition by Sp1 on its own 
promoter and represses its own gene promoter activity, thus forming a negative feedback 
loop to tightly control the activity ofhMI-ERl. This ensures that hMI-ERl regulates the 
expression of other genes at appropriate times. 
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CHAPTER 5 A YEAST TWO-HYBRID SYSTEM eDNA LIBRARY SCREENING 
FOR HMI-ERl-INTERACTING PROTEINS: HSP40 AND TRABID WERE 
FOUND TO INTERACT PHYSICALLY WITH HMI-ERl 
5.1 Introduction 
Proteins rarely function by themselves. They normally interact with other proteins 
to execute their functions. Networks of such protein-protein interactions constitute the 
basis for regulation of all cellular functions, including cell growth and cell death 
(reviewed in Figeys, 2002; Tucker eta!., 2001). Thus deciphering of protein interaction 
networks is vital to our understanding of cell growth and cell death as an interacting 
system of molecules. Understanding these protein interaction networks and their roles in 
diseases is critical for successful therapeutic strategies (reviewed in Archakov et a!., 
2003). 
Our previous studies usmg immunoprecipitation, GST -pull down assays, and 
Western blot analysis have identified multiple interacting partners for hMI-ERl, based 
mainly on the observation that hMI-ERl functions as a transcription regulator (Chapter 3 
and 4). These hMI-ERl-interacting proteins include HDACl (Chapter 3), Spl (Chapter 
4), ERa (Savicky eta!., unpublished data), CBP (Blackmore eta!., unpublished data), 
and histone protein (Paterno eta!., unpublished data). 
To obtain a full picture of hMI-ERl function, it is also necessary to perform a 
complementary approach in protein-protein interaction analysis to obtain more unbiased 
representation of hMI-ERl interaction proteins. Such an analysis would expand our 
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knowledge on the interacting partners ofhMI-ERl. Pioneering work toward this goal in 
this study was undertaken using the yeast two-hybrid system eDNA library screening for 
hMI-ERl-interacting proteins. Because of the nature of the reporter system (see section 
5.2.3), positive signals are amplified many-fold, thus making the yeast two-hybrid system 
a very sensitive method for detecting weak and transient protein interactions that are not 
detected by other methods. Since it is performed in yeast, the proteins produced in this 
eukaryotic system are more likely folded properly than those produced in bacterial 
systems and the in vitro reticulocyte TNT lysate system. Thus, the yeast two-hybrid 
eDNA library screening system has advantages over other eDNA library screening 
approaches for studying protein-protein interaction. 
5.2 Materials and Methods 
5.2.1 Plasmids and constructs 
Expression vectors for the yeast two-hybrid system were engineered to contain 
full-length or deletion mutants of hMI-ERla fused to the GAL4 DBD of the pAS2-l 
plasmid (Clontech). Fragments encoding the appropriate amino acid residues of hMI-
ERla deletion mutants were amplified by PCR using the primer pairs listed in Table 3.1 
(Chapter 3). PCR products were cloned into pCR3.1 using the TA cloning kit 
(Invitrogen, Inc.), and EcoRI fragments were then inserted into the EcoRI sites of the 
pAS2-l plasmid. The deletion constructs were named according to the encoded amino 
acid residues of the hMI-ERla protein. All plasmids were sequenced to verify the 
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junctions and the hMI-ER1 sequence. The human testis MATCHMAKER eDNA pACT2 
AD Library of plasmids inserted into the yeast two-hybrid system transcriptional 
activation domain (AD) vector pACT2 was purchased from Clontech. pCMV-Tag2C-
HSP40( 43-340) was generated by subcloning the Bglll fragment from the positive clone 
No. 3764 obtained from the yeast two-hybrid system eDNA library screening (see section 
6.3.2) to the BamBI site ofpCMV-Tag2C vector (Stratagene). pCMV-Tag2C-TRABID 
was generated by subcloning the Bgill fragment from the positive clone No. 3801 
obtained from yeast two-hybrid system eDNA library screening (see section 6.3.3) to the 
BamBI site of pCMV-Tag2C vector. Full-length human HSP40 eDNA was amplified by 
PCR from a human keratinocyte MATCHMAKER eDNA Library (Clontech) by using 
5 -GGG CCG CAG GAG GGG GTC ATG-3 and 5 -CTA TAT TGG AAG AAC CTG 
CTC-3 as forward and reverse primers, respectively, and then cloned into pCR3.1 using 
theTA cloning kit (Invitrogen, Inc.). All plasmids were sequenced to verify the junctions 
and the TRABID or HSP40 sequence. 
5.2.3 Yeast two-hybrid system eDNA library screening 
The yeast two-hybrid system (Fields and Song, 1989; Fields and Stemglanz, 1994) 
was used as a genetic system to isolate hMI-ER1-interacting proteins in vivo. It uses the 
restoration of transcriptional activation to assay the interaction between two proteins. It 
relies on the modular nature of many site-specific transcriptional activators such as 
GAL4, consisting of a DNA-binding domain and a transcriptional activation domain 
(AD). The yeast two-hybrid system is based on the observation that the two domains of 
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the activator need not be a single polypeptide and can be brought together by any two 
interacting fusion proteins, one of which contains the GAL4 DBD (in pAS2-1 vector) 
while the other has the GAL4 AD (in pACT2 vector) (Figure 5.1). The two hybrid 
proteins, often coined as "bait" and "prey," respectively, are assembled onto GAL4 
binding sites [GALl upstream activating sequence (UAS)] in the yeast genome. The 
assembly functionally reconstitutes the GAL4 transcription factor and induces the 
expression of yeast HIS3 and the bacterial /acZ reporter genes integrated in the region 
downstream ofthe GAL4 binding sites (Figure 5.1). The S. cerivisiae strain Y190, which 
is Trp-, Leu- and His-, was used for the yeast two-hybrid system (Clontech). This strain 
harbours the yeast HIS3 and the bacterial/acZ reporter genes, which contain an upstream 
GAL4 binding site. For eDNA library screening, Y190 was co-transformed with pAS2-
1-(287-433) and the human testis MATCHMAKER eDNA pACT2 AD Library, using the 
lithium acetate procedure as described by the manufacturer (Clontech). The 
transformation mixture was then plated on 150-mm petri dishes containing synthetic 
dropout yeast culture medium (SD) lacking tryptophan, leucine, and histidine (SD/-Trp/-
Leui-His) but including 25 mM 3-amino-1,2,4-triazole (3-AT), and incubated at 30 °C for 
5-8 days. The transformants were screened for P-gal activity using a filter lift assay, 
according to the protocol recommended by the manufacturer (Clontech). Briefly, 
colonies were transferred to Whatman filters and cells were permeabilized by freezing for 
10 seconds in liquid nitrogen, and thawing at room temperature. Filters were then 
overlaid onto another Whatman filter saturated with Z buffer/X-gal solution [16.1 mg/ml 
Na2HP04.1H20, 5.5 mg/ml NaH2P04.H20, 0.75 mg/ml KCl, 0.246 mg/ml MgCh.7H20, 
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Figure 5.1 Mechanism of the method of the yeast two-hybrid system eDNA library 
screening for hMI-ERl-interacting proteins. 
The application of this system requires that two hybrid fusion plasmids be constructed for 
expressing DBD and AD fusion proteins: a DBD fused to the bait protein (in this case 
DBD-hMI-ERl from plasmid pAS2-l-hMI-ER1), and an AD fused to the prey proteins 
which may interact with the bait protein (in this case the human testis MATCHMAKER 
eDNA pACT2 AD Library proteins). For eDNA library screening, the two hybrid 
plasmids are co-transformed into a yeast S. cervisiae host strain Y190 harbouring the 
yeast HIS3 and the bacterial lacZ reporter genes, which downstream the GAL4 binding 
site (GALl UAS). The interaction ofhMI-ERl with a novel library protein (marked as ?) 
will activate the HIS3 and the lacZ reporter genes, while library proteins not interacting 
with hMI-ERl will not activate the reporter genes. The transformation mixture was then 
plated on 150-mm petri dishes containing synthetic dropout yeast culture medium (SD) 
lacking tryptophan, leucine, and histidine (SD/-Trp/-Leu/-His) but including 25 mM 
3-amino-1,2,4-triazole (3-AT), and incubated at 30 °C for 5-8 days. The transformants 
were screened for ~-galatosidase (~-gal) activity using a filter lift assay. 
pAS2-1-hMI-ER1 pACT2/human testis 
eDNA library plasmid 
Cotransform plasmids into 
yeast strain Y190 sequentially 
Plate culture on SD/-Trp/-Leu/-His 
l ~-gal filter lift assay 
0.327 mg/ml X-gal, 0.3% (v/v) 2-mercaptoethanol], and incubated at room temperature 3 
h for color development. 
5.2.4 Purification and confirmation of the yeast two-hybrid system positive colonies 
Each of the initial yeast Lacz+ positive colonies was streaked out one to five 
times to segregate multiple pACT2-library plasmids within each single colony and yeast 
two-hybrid ~-gal filter lift assays were repeated on well-isolated colonies. The plasmids 
were then isolated from yeast, transfected into E. coli, and further amplified. These 
pACT2-library plasmids isolated from E. coli were then individually re-transformed into 
yeast strain Y190 to test the specific interaction of the candidate library clones with the 
bait pAS2-l-(287-433), non-related protein pAS2-1-LAM5, and empty pAS2-1 vector. 
Nonspecific interactions (those conferring His+, Lacz+ when paired with pAS2-1 and 
pAS2-1-LAM5) were considered false positives and eliminated, while clones specifically 
interacting with pAS2-1-hMI-ER1 bait fusion were retained. The eDNA obtained were 
sequenced and analyzed for sequence homology using the National Center for 
Biotechnology Information sequence databases through the Basic Alignment Search Tool 
(BLAST) program at http://www.ncbi.nlm.nih.gov/BLAST/. 
5.2.5 GST -fusion protein production 
GST fusion proteins were expressed as described m section 2.2.6. 
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5.2.6 GST pull-down 
GST pull-down assays were performed as described in section 4.2.6. 
5.3 Results 
5.3.1 Yeast two-hybrid system eDNA library screening for hMI-ERl-interacting 
positive colonies 
The yeast two-hybrid ~-gal filter lift assays of the transformants with pAS2-1-
hMI-ER1a and pACT2 empty vector revealed expression of the LacZ reporter gene 
(Figure 5 .2C), while no expression of the LacZ reporter gene was detected in the 
transformants with pAS2-1 vector and pACT2 vector (Figure 5.2B). TheN-terminal (1-
283 aa) and C-terminal (287-433 aa) deletion mutants of hMI-ERla were generated and 
fused to DBD in pAS2-1 vector. ~-gal filter lift assays of the yeast transformants with 
pAS2-1-hMI-ER1(1-283) and empty vector pACT2 revealed the expression of the LacZ 
reporter gene (Figure 5.2D), while pAS2-1-hMI-ER1a(287-433) and AD empty vector 
did not activate the reporter gene (Figure 5.2E). These results indicate that the N-
terminal (1-283 aa) region of hMI-ER1 may interact with the GAL4 AD alone and/or 
recruit the transcriptional machinery of yeast cells to activate the transcription of the 
reporter gene. These results suggest that full-length hMI-ERla and theN-terminal (1-283 
aa) region of hMI-ER1 can not be used as bait in the yeast two-hybrid screening. Thus 
pAS2-1-hMI-ERla(287-433) was used for the yeast two-hybrid eDNA library screening. 
The yeast was transformed with pAS2-l-hMI-ERla(287-433) and the human testis 
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Figure 5.2 Yeast two-hybrid p-gal filter-lift assays of tranformants of empty pACT2 
AD vector with full-length and deletion mutants of hMI-ERla. 
(A) The diagram illustrates the deletion mutants of hMI-ERl fused to GAL4 DBD in 
pAS2-1 vector. The individual domains are identified in the legend below the diagram, 
and the hMI-ERl amino acid residues encoded by each construct are listed. Yeast two-
hybrid ~-gal filter-lift assays of the transformant with pAS2-1 DBD empty vector and 
pACT2 AD empty vector (B); hMI-ERa full-length (1-433 aa) in pAS2-1 DBD vector 
and pACT2 AD empty vector (C); hMI-ERl N-terminall-283 aa in pAS2-1 DBD vector 
and pACT2 AD empty vector (D); or hMI-ERl C-terminal287-433 aa in pAS2-1 DBD 
vector and pACT2 AD empty vector (E). 
A 
pAS2-1 
pAS2-1-a(l-433) 
pAS2-1-(1-283) 
pAS2-1-a(287-433) 
D acidic activation domain 
B ELM2 domain (aa 180-239) 
pAS2-1 
and 
pACT2 
pAS2-1-a(287 -433) 
and 
pACT2 
~ SANT domain (aa 288-331) 
Ill a C-terminus 
pAS2-1-a(1-433) 
and 
pACT2 
pAS2-1-(1-283) 
and 
pACT2 
MATCHMAKER eDNA pACT2 AD Library. Approximately 6.6~106 yeast 
transformants were screened for pAS2-l-hMI-ERla(287-433)-interacting proteins. 
Trp +/Leu+ /His+ colonies were then screened for ~-gal activity using ~-gal filter lift assays, 
and 108 colonies were Lacz+. These positive colonies were then subjected to further 
verification by isolating the pACT2 plasmids from these clones and then individually 
reintroducing them into yeast strain Y190 to test for interaction of the candidate library 
clone against pAS2-1-hMI-ERla(287-433), empty pAS2-1 vector, or non-related protein 
pAS2-1-Lamin. Two positive clones No. 3764 (section 5.3.3) and No. 3801 (section 
5.3.4) were shown to be specific interactions and sequenced. 
5.3.2 HSP40 was found to interact with hMI-ERl in yeast and in vitro 
Yeast two-hybrid ~-gal filter lift assays revealed that the positive clone No. 3764 
specifically interacts with pAS2-1-hMI-ER1a(287-433) (Figure 5.3B), but not with 
empty vector (Figure 5.3C), or a non-related protein pAS2-l-Lamin (Figure 5.3D). The 
eDNA insert of positive clone (No. 3764) was found to contain 1067 bp sequence. 
Subsequent DNA sequencing analysis followed by BLAST at 
http://www.ncbi.nlm.nih.gov/BLAST/ revealed that the sequence of the positive clone 
No. 3764 was identical to the C-terminal of HSP40 encoding a truncated HSP40(43-340) 
(Figure 5.3E, lower blue bar). 
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Figure 5.3 Yeast two-hybrid p-gal filter-lift assays revealed that pAS2-1-hMI-
ERla(287-433) interacts specifically with the positive clone No. 3765 (human 
HSP40). 
pAS2-1-hMI-ERla(287-433) was the bait and pAS2-1 empty vector and pAS2-1-Lamin 
were negative controls to verify the specificity of the interaction between pAS2-1-hMI-
ERla(287-433) and positive clone No. 3765. Yeast two-hybrid ~-gal filter-lift assays of 
the transformant with pAS2-1 empty vector and pACT2 empty vector (A); pAS2-1-hMI-
ERla(287-433) and positive clone No. 3765 (B); pAS2-1 empty vector and positive 
clone No. 3765 (C); pAS2-1-Lamin and positive clone No. 3765 (D); (E) positive clone 
No. 3765 (lower blue bar) is identical to previously known sequences of the C-terminal 
portion of HSP40 (higher blue bar). Translation start codon ATG and stop codon TAG 
are indicated below each bar, and corresponding nt is given. 
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To determine which region of hMI-ER1a interacts with HSP40, four deletion 
mutants were made in frame with GAIA DBD (Figure 5.4A). Yeast two-hybrid ~-gal 
filter lift assays revealed that pACT2-HSP40(43-340) did not interact with the C-terminal 
aa 325-433 deletion mutant of hMI-ER1a (Figure 5.4B). The sequence required for 
interaction with pACT2-HSP40(43-340) maps to hMI-ER1 aa 287-357, which includes 
the SANT domain (Figure 5.4C and D). Further deletion of this region at the C-terminal 
end to remove residues from aa 331 to 357 e31K to 357T), which includes a highly 
conserved lysine (K) of SANT domain at position 331 and the C-terminal 26 aa, 
completely abolished interaction with pACT2-HSP40(43-340) in yeast (Figure 5.4E). 
To confirm the interaction between hMI-ER1 with HSP40(43-340) in vitro, the 
HSP40 eDNA portion isolated from yeast two-hybrid library screening was then 
subcloned into pCMV-Tag2C vector [pCMV-Tag2C-HSP40(43-340)] (see section 5.2.2). 
In vitro translated HSP40(43-340) specifically associated with GST-a (Figure 5.5B, lane 
3) or GST-~ (Figure 5.5B, lane 4), but not with GST control (Figure 5.5B, lane 2). To 
investigate whether the full-length HSP40 interacted with hMI-ERl in vitro, the HSP40 
eDNA encoding full-length HSP40 was amplified from a eDNA library by PCR and 
cloned into pCR3.1. In vitro translated full-length HSP40 (Figure 5.5B, lane 5) 
specifically interacted with GST-a (Figure 5.5B, lane 7) or GST-~ (Figure 5.5B, lane 8), 
but not with GST control (Figure 5.5B, lane 6). 
Further GST pull-down assays with deletion mutants of hMI-ER1 (Figure 5.5A) 
and full-length HSP40 confirmed that the sequences required for interaction with HSP40 
are located in residues spanning aa 287-357, which includes the SANT domain of 
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Figure 5.4 Yeast two-hybrid (}-gal filter-lift assays revealed that a region containing 
SANT domain ofhMI-ERl interacts specifically with HSP40(43-340). 
(A) The diagram illustrates the deletion mutants of hMI-ERl fused to GAL4 DBD in 
pAS2-l vector. The individual domains are identified in the legend below the diagram, 
and the hMI-ERl amino acid residues encoded by each construct are listed. Yeast two-
hybrid ~-gal filter-lift assays of the transformant with pAS2-1-hMI-ERla(325-433) and 
pACT2-HSP40(43-340) (B); pAS2-1-hMI-ER1(287-410) and pACT2-HSP40 (C); pAS2-
l-hMI-ER1(287-357) and pACT2-HSP40(43-340) (D); pAS2-1-hMI-ER1(287-330) and 
pACT2-HSP40(43-340) (E). 
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Figure 5.5 The region of hMI-ERl containing SANT domain interacts with HSP40 
in vitro. 
(A) The diagram illustrates the deletion mutants ofhMI-ER1 fused to GST in pGEX-4T-
1 vector. The individual domains are identified in the legend below the diagram, and the 
hMI-ER1 amino acid residues encoded by each construct are listed. (B) 35S-labelled 
TNTs programmed with eDNA encoding HSP40( 43-340) was loaded directly on the gel 
(1/20 of input) (lane 1) or incubated with GST (lane 2), GST-a (lane 3), and GST-P 
(lance 4). 35S-labelled TNTs programmed with eDNA encoding full-length HSP40 was 
loaded directly on the gel (lane 5) or incubated with GST (lane 6), GST -a (lane 7), and 
GST-P (lance 8). Proteins were resolved by SDS-PAGE and visualized by 
autoradiography. Shown is a representative autoradiograph, and the positions of the 
HSP40(43-340) and the full-length HSP40 are indicated by arrows. (C) 35S-labelled 
TNTs programmed with eDNA encoding full-length HSP40 was loaded directly on the 
gel (1/20 of input) (lane 1) or incubated with GST (lane 2), GST-(1-283) (lane 3), GST-
(287-433) (lance 4), GST-(325-433) (lane 5), GST-(287-410) (lane 6), GST-(287-357) 
(lane 7), GST-(287-330) (lane 8), and GST-(287-512) (lane 9). Proteins were visualized 
by SDS-P AGE and autoradiography. Shown is a representative autoradiograph, and the 
positions of the full-length HSP40 are indicated by arrows. 
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hMI-ER1 (Figure 5.5C, lane 4, 6, 7 and 9). Further deletion of this region at the C-
terminal end to remove residues from aa 331 to 357 e31K to 357T), which includes a 
highly conserved lysine (K) of SANT domain at position 331 and the C-terminal 26 aa, 
completely abolished interaction with HSP40 in vitro (Figure 5.5C, lane 8). HSP40 did 
not interact with the GST control (Figure 5.5C, lane 6), or the N-terminal aa 1-283 
deletion mutant ofhMI-ER1 (Figure 5.5C, lane 3), or the C-terminal aa 325-433 deletion 
mutant of hMI-ER1 (Figure 5.5C, lane 5). These results are consistent with the results 
from the yeast two-hybrid system analysis, and demonstrated the importance of the 
SANT domain-containing region from aa 287-357 for the interaction with HSP40 both in 
the yeast two-hybrid system and in in vitro GST -pull-down assays. 
5.3.3 TRAF-binding domain (TRABIDJ was found to interact with hMI-ERl in 
yeast and in vitro 
Yeast two-hybrid P-gal filter lift assays revealed that another positive clone No. 
3801 specifically interacts with pAS2-1-hMI-ER1a(287-433) (Figure 5.6B), but not with 
empty vector (Figure 5.6C), or a non-related protein pAS2-1-Lamin (Figure 5.6D). The 
eDNA insert of positive clone No. 3801 was found to contain 2173 bp sequence. 
Subsequent DNA sequencmg analysis followed by BLAST at 
http://www.ncbi.nlm.nih.gov/BLAST/ revealed that the sequence of the positive clone 
No. 3801 was identical to TRABID mRNA (Figure 5.6E, lower blue bar). The function of 
TRABID is so far unclear. TRABID shares sequence and structural similarity with A20 
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Figure 5.6 Yeast two-hybrid p-gal filter-lift assays verified that pAS2-1-hMI-
ER1a(287-433) interacts specifically with positive clone No. 3801 (human TRABID). 
pAS2-1-hMI-ERla(287-433) was the bait and pAS2-1 empty vector and pAS2-1-Lamin 
were negative controls to verify the specificity of the interaction between pAS2-1-hMI-
ER1a(287-433) and positive clone No. 3801. Yeast two-hybrid ~-gal filter-lift assays of 
the transformant with pAS2-1 empty vector and pACT2 empty vector (A); pAS2-1-hMI-
ER1a(287-433) and positive clone No. 3801 (B); pAS2-1 empty vector and positive 
clone No. 3801 (C); pAS2-1-Lamin and positive clone No. 3801 (D); (E) positive clone 
No. 3801 (lower blue bar) is identical to previously known sequences of TRABID (higher 
blue bar). Translation start codon ATG and stop codon TAG are indicated below each 
bar, and corresponding nt is given. 
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protein (Evans et al., 2001), which was shown to be involved in TNF receptor associated 
factor (TRAF) signalling pathways (Heyninck and Beyaert, 1999; Lee et al., 2000; Song 
et al., 1996). C-immunoprecipitation studies indicated TRABID was able to interact with 
TRAF6 (Evans et al., 2001). 
To determine which region of hMI-ERla interacts with TRABID, four deletion 
mutants, made in frame with GAL4 DBD in the pAS2-1 vector, were utilized (Figure 
5.7A). Yeast two-hybrid ~-gal filter lift assays revealed that pACT2-TRABID did not 
interact with the C-terminal aa 325-433 deletion mutant ofhMI-ER1a (Figure 5.7B). The 
sequence required for interaction with pACT2-TRABID maps to hMI-ER1 aa 287-357, 
which includes the SANT domain (Figure 5.7C and D). Further deletion of this region at 
the C-terminal end to remove residues from aa 331 to 357 e31K to 357T), which includes a 
highly conserved lysine (K) of SANT domain at position 331 and the C-terminal 26 aa, 
completely abolished interaction with pACT2-TRABID in yeast (Figure 5. 7E). 
To confirm the interaction between hMI-ER1 with TRABID in vitro, the TRABID 
eDNA was subcloned into pCMV-Tag2C vector (pCMV-Tag2C-TRABID) (see 5.2.2) 
which was used to synthesize protein in vitro. In vitro translated TRABID showed two 
bands (Figure 5.8B, lane 1), which may result from two alternative in-frame translation 
start codons in the construct. GST pull-down assays revealed that both in vitro translated 
TRABID products specifically associated with GST-a (Figure 5.8B, lane 3) or GST-~ 
(Figure 5.8B, lane 4), but not with GST control (Figure 5.8B, lane 2), indicating that 
wild-type hMI- ER1a and~ isoforms interact with TRABID. 
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Figure 5. 7 Yeast two-hybrid p-gal filter-lift assays revealed that a region containing 
SANT domain of hMI-ERl interacts specifically with TRABID. 
(A) The diagram illustrates the deletion mutants of hMI-ERl fused to GAL4 DBD in 
pAS2-1 vector. The individual domains are identified in the legend below the diagram, 
and the hMI-ERl aa residues encoded by each construct are listed. Yeast two-hybrid P-
gal filter-lift assays of the transformant with pAS2-l-hMI-ERla(325-433) and pACT2-
TRABID (B); pAS2-l-hMI-ER1(287-410) and pACT2-TRABID (C); pAS2-l-hMI-
ER1(287-357) and pACT2-TRABID (D); pAS2-l-hMI-ER1(287-330) and pACT2-
TRABID (E). 
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Figure 5.8 The region of hMI-ERl containing SANT domain interacts with 
TRABID in vitro. 
(A) The diagram illustrates the deletion mutants ofhMI-ER1 fused to GST in pGEX-4T-
1 vector. The individual domains are identified in the legend below the diagram, and the 
hMI-ER1 amino acid residues encoded by each construct are listed. (B) 35S-labelled 
TNTs programmed with eDNA encoding TRABID was loaded directly on the gel (1/20 
of input) (lane 1) or incubated with GST (lane 2), GST-a(l-433) (lane 3), and GST-~(1-
512) (lance 4). Proteins were resolved by SDS-PAGE and visualized by 
autoradiography. Shown is a representative autoradiograph, and the positions of 
TRABID is indicated by arrows. (C) 35S-labelled TNTs programmed with eDNA 
encoding TRABID was loaded directly on the gel (1/20 of input) (lane 1) or incubated 
with GST (lane 2), GST-(1-283) (lane 3), GST-(287-433) (lance 4), GST-(325-433) (lane 
5), GST-(287-410) (lane 6), GST-(287-357) (lane 7), GST-(287-330) (lane 8), and GST-
(287-512) (lane 9). Proteins were resolved by SDS-PAGE and visualized by 
autoradiography. Shown is a representative autoradiograph, and the positions of 
TRABID is indicated by arrows. 
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Further GST pull-down assays with deletion mutants of hMI-ER1 (Figure 5.8A) 
and TRABID (Figure 5.8C, lane 1) confirmed that the sequences required for interaction 
with TRABID were located in aa 287-357 (Figure 5.8C, lane 4, 6, 7 and 9). Further 
deletion ofthis region at the C-terminal end to remove residues from aa 331 to 357 e31K 
to 357T), which includes a highly conserved lysine (K) of the SANT domain at position 
331 and the C-terminal 26 aa, completely abolished interaction with TRABID in vitro 
(Figure 5.8C, lane 8). TRABID did not interact with the GST control (Figure 5.8C, lane 
6) or theN-terminal aa 1-283 deletion mutant ofhMI-ERl (Figure 5.8C, lane 3), or the 
C-terminal aa 325-433 deletion mutant ofhMI-ER1 (Figure 5.8C, lane 5). These results 
are consistent with the results from the yeast two-hybrid system analysis, and 
demonstrated the importance of the SANT domain-containing region from aa 287-357 for 
interaction with TRABID both in the yeast two-hybrid system and in vitro. 
5.4 Discussion 
From the yeast two-hybrid library screening, hMI-ER1 was found to specifically 
interact with HSP40 (Figure 5.3) TRABID (Figure 5.10). Although the interactions 
between hMI-ER1 and HSP40 or TRABID were also confirmed by in vitro GST pull-
down assays, it is still possible that hMI-ERI interacts with HSP40 or TRABID indirectly 
through other proteins. Since there are multiple endogenous proteins in yeast cells and in 
the reticulocyte TNT lysates, we cannot at present exclude this possibility. Alternative 
protein-protein interaction assays using both purified proteins and then Western blot 
analysis may address this question. 
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In this chapter, I demonstrated that the SANT domain-containing region (aa 287-
357) ofhMI-ER1 interacted with HSP40 and TRABID, and the C-terminal deletion of the 
last 331K of the SANT domain together with downstream 26 aa eliminated both hMI-ER1 
interactions with HSP40 and TRABID (Figure 5.4, 5.9, 5.11, and 5.12). These results 
suggest that the SANT domain-containing region spanning residues aa 287-357 is an 
important interaction region for hMI-ER1 to interact with HSP40 and TRABID. 
However, whether an intact SANT domain or the region spanning the SANT domain and 
its C-terminal 26 aa is critical for the interaction with HSP40 and TRABID remains 
unclear. Site-directed mutagenesis and/or additional deletion mutagenesis to this SANT 
domain-containing region (aa 287-357) could be employed to address this question. 
HSP40 plays a key role with other proteins such as HSP70 in the folding, 
translocation and degradation of proteins in eukaryotic cells (reviewed in Fink, 1999; 
Hartl, 1996). Another important cellular function of HSP40 is to direct the assembly of 
multiple protein complexes, such as nuclear hormone receptor (NR) complexes 
(Hernandez eta/., 2002). Current experiments in the laboratory reveal that hMI-ER1a 
and~ interact with estrogen receptor a (ERa) (Savicky eta/., personal communication). 
Given the important role of HSP40 in NR complex assembly, it is possible that HSP40 is 
critical for the assembly of ERa complexes containing hMI-ERl. Once in the ERa 
complexes, hMI-ER1a and ~ may regulate ERa transcriptional function. There is 
mounting evidence that ERa plays a crucial role in normal breast development and is also 
linked to development and progression of mammary carcinoma (Hortobagyi, 1998; 
Osborne, 1998). However, the molecular mechanisms that regulate ERa transcriptional 
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function are not fully understood. The regulation of the transcriptional activity of ERa by 
hMI-ER1a and pin breast cancer may have potential clinical significance. 
Although the precise function of TRABID remains unknown, co-
immunoprecipitation studies indicated TRABID was able to interact with TRAF6 (Evans 
et al., 2001). Mammalian TRAPs have emerged as the major signal transducers for the 
TNF receptor superfamily and the interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) 
superfamily (reviewed in Chung et al., 2002). TRAF molecules are recruited to 
signalling complexes in response to related extracellular signals such as cytokine 
treatment (Wallach et al., 1999). As shown in Figure 5.9, there are at least three distinct 
ways that TRAF proteins can be recruited to and activated by ligand-engaged receptors. 
Those that contain an intracellular death domain, such as TNFR1, first recruit an adapter 
protein, TRADD, via a death-domain and death-domain interaction (Hsu et al., 1995). 
TRADD then serves as a central platform of the TNFR1 signalling complex, which 
assembles Pas-associating protein with death domain (F ADD) and caspase-8 for the 
induction of apoptosis (Hsu et al., 1996), TRAFs2 and RIP (Hsu et al., 1996; Stanger et 
al., 1995) for survival signalling. Members of the TNF receptor superfamily that do not 
contain intracellular death domains, such as CD40, recruit TRAPs directly via short 
sequences in their intracellular tails (Cheng et al., 1995; Pullen et al., 1998; Rothe et al., 
1994). Members of the IL-1R/TLR superfamily contain a protein interaction module 
known as the TIR domain (Xu et al., 2000), which sequentially recruits MyD88 and 
IRAKs (Cao et al., 1996; Muzio et al., 1997; Wesche et al., 1997; Wesche et al., 1999). 
IRAKs in turn associate with TRAF6 to elicit signalling (reviewed in O'Neill, 2002). 
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Figure 5.9 TRAF signalling pathways and the possible functional implication of 
TRABID and hMI-ERl interaction (adapted from Chung et al., 2002). 
Membrane-proximal events and downstream signalling events for TRAPs in TRAF 
signalling. hMI-ERla and ~ may be activated directly when they are recruited into 
TRABID-TRAF6 complexes. Alternatively, hMI-ERl may regulate the TRAF6-
signalling pathways through assoCiation with TRABID. 
........... 
TRAF signalling appears to be mediated mainly through the activation of transcription 
factors of the NF-KB and AP-1 family. NF-KB is sequestered in the cytoplasm of non-
stimulated cells by binding to inhibitory KB (IKB) molecules. Signalling cascades 
triggered by cytokine stimulation lead to phosphorylation of IKB by the IKB kinase (IKK) 
(reviewed in Karin and Ben-Neriah, 2000; Stancovski and Baltimore, 1997). 
Phosphorylation, followed by ubiquitination and proteosomally mediated degradation of 
IKB occurs and NF -KB is released and translocated to the nucleus to activate transcription 
(reviewed in Karin and Ben-Neriah, 2000; Stancovski and Baltimore, 1997). Signalling 
cascades triggered by cytokine stimulation also lead to the activation of AP-1 by 
mitogen-activated protein (MAP) kinases (Karin, 1996). The stimulation of AP-1 activity 
by MAP kinases may result in expression of AP-1 target genes involved in both cell 
survival and cell death (Shaulian and Karin, 2001). 
The interaction ofhMI-ER1 with TRABID suggested that hMI-ER1 may regulate 
the TRAF signalling pathways through association with the TRABID-TRAF6 complex 
(Figure 5.9). Alternatively, it is possible that TRABID-TRAF6 signalling complexes 
may be important for recruitment and activation of hMI-ERl. hMI-ER1 itself may be 
activated by post-translational modifications such as phosphorylation when it is recruited 
into TRABID-TRAF6 complexes. Although computer-assisted analysis predicted 
multiple phosphorylation sites in hMI-ER1, preliminary studies indicate that hMI-ER1 
may not be phosphorylated in cells under normal growth conditions (Paterno et al., 
personal communication). However, it remains possible that hMI-ER1 would be 
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phosphorylated under a certain cellular condition, such as TNFR activation. Once 
activated, hMI-ERl may function as a transcription regulator on specific target gene 
promoters or it may directly participate in apoptotic pathways (Figure 5.9). The hMI-
ERl sequence was predicted to have a putative BH3 domain in its N-terminal region 
(Paterno et al., personal communication), so it may be a novel BH3-only protein. Proteins 
of the Bcl-2 family are critical regulators of caspase activation and apoptosis, and they 
contain regions of homology (BH1-4) (reviewed in Bouillet and Strasser, 2002). The 
BH3 domain is essential for the binding of BH3-only pro-apoptotic proteins to the anti-
apoptotic members of the Bcl-2 family and for their ability to induce cytochrome c 
release from mitochondria (reviewed in Bouillet and Strasser, 2002). For example, the 
BH3-only protein BAD induces cytochrome c release from mitochondria when it binds to 
BCL-XL or BCL-2 (Kelekar et al., 1997; Yang et al., 1995; Zha et al., 1997). Most 
interestingly, the BH3-only protein, BID protein, is activated by death receptor signalling 
pathway, and is translocated to the mitochondria where it induces cytochrome c release, 
thus providing cross talk from the cell death receptor pathways to the mitochondria death 
pathways (reviewed in Scorrano and Korsmeyer, 2003). In response to cytochrome c 
binding, APAF-1 in the cytoplasm can form a complex with and activate initiator 
caspase-9 to initiate apoptosis (Li et al., 1997; Zou et al., 1997). It may be possible that 
TRABID-TRAFs complexes recruit and activate hMI-ERl, which then translocate to the 
mitochondria and induces apoptosis, analogous to the function of BID transmitting the 
apoptotic signal from the cell death receptors to the mitochondria (Figure 5.9). 
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CHAPTER 6 hMI-ERla AND p WERE FOUND TO INTERACT PHYSICALLY 
WITH THE TUMOUR SUPPRESSOR RB 
6.1 Introduction 
Previous studies revealed that overexpression ofhMI-ERl in Nlli 3T3 fibroblast 
cells suppressed colony forming efficiency (Paterno et al., unpublished data). This assay 
has been previously used to demonstrate, for example, the growth-suppressive activities 
of p53 and p16INK4A (Baker et al., 1990; Lin et al., 1996a). As shown previously in 
colony forming assays with p53 and p16INK4A, the inhibitory effect ofhMI-ER1 in colony 
formation efficiency could be due to an apoptotic-inducing activity or to an ability to 
inhibit cell proliferation (Baker et al., 1990; Lin et al., 1996a). 
Proliferation of mammalian cells is controlled by the cell cycle regulatory 
machinery. The cell cycle regulatory machinery, composed of cyclins, cyclin-dependent 
kinases (CDKs) and their inhibitors (C:I<Is), controls cell cycle progression at particular 
checkpoints, directing the cell towards proliferation, growth arrest or apoptosis (reviewed 
in Alberts et al., 2002). The most thoroughly characterized G 1 checkpoint operates 
through CDK-mediated phosphorylation of Rb and other 'pocket' proteins, which release 
bound transcription factors of the E2F family and allow them to activate genes essential 
for S phase (reviewed in Qu et al., 2003). Thus the CKI-CDK-RB pathway plays a central 
role in determining whether a cell will proceed through the G1 phase of the cell cycle 
(reviewed in Kaelin, 1999). Another important regulator of the cell cycle regulatory 
machinery is p53. p53 functions as a transcription factor that can activate expression of a 
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range of cellular genes involved in arrest of cell cycle and induction of apoptosis. p53 
can arrest cell proliferation or induce apoptosis in response to DNA damage or 
overexpression of oncogenes such as ElA (Sherr, 1998). Both RB and p53 were found to 
form complexes containing HDACl in cells (Luo et al., 2000; Magnaghi-Jaulin et al., 
1998). HDACl was shown to form multi-subunit complexes (reviewed in Ahringer, 
2000; Cress and Seto, 2000; Thiagalingam et al., 2003). Recently, the ELM2 and SANT 
domain-containing protein, MTA2, was shown to form complexes containing HDACl 
and p53 (Luo et al., 2000). Since hMI-ERl associates with HDACl enzymatic activity 
in cells (Chapter 3), it is possible that hMI-ERl is present in the multi-subunit complexes 
containing RB and/or p53. The experiments described in this section were designed to 
investigate if an interaction between hMI-ERl and RB and p53 was possible. 
6.2 Materials and Methods 
6.2.1 Cell culture 
Human MCF-7 breast carcinoma cell line was obtained from the American Type 
Culture Collection and cultured at 37°C in 5% C02 in DMEM containing 10% FCS. 
MCF-7 Tet-On and HeLa Tet-On cell lines were obtained from Clontech, and cultured at 
37°C in 5% C02 in DMEM containing 500 J..lg/ml G418 (Sigma) and 10% Tet system 
approved fetal bovine serum (Clontech). pTRE2, pTREa and pTRE-~ HeLa 
Tet-On cell lines were established in our laboratory (see section 6.2.6), and cultured at 
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37°C in 5% C02 in DMEM containing 500 )!g/ml G418, 200 )!g/ml hygromycin B 
(Clontech) and 10% Tet system approved fetal bovine serum. 
6.2.2 Plasmids and constructs 
Myc-tagged plasmids (CS3+MT) (pMyc) containing either full-length hmi-erla 
(pMyc-a) or~ (pMyc-~) have been previously described (section 3.2.2). GST-hmi-erlu 
(GST-u) or GST-hmi-erl~ (GST-~) fusion constructs were generated as described 
(section 4.2.2). Human p53 eDNA was obtained from Dr. J.G. Church, Memorial 
University of Newfoundland. Full-length human RB eDNA was obtained from Dr. B.L. 
Gallie, University of Toronto. A series of RB deletion mutations were generated by 
amplifying fragments encoding the appropriate amino acid residues of RB, using the 
primer pairs listed in Table 6.1. PCR products were cloned into pCR3.1. All plasmids 
were sequenced to verify the junctions and the RB sequence. 
pTRE2 and pTK-Hyg vector were obtained from Clontech. pTRE2-hMI-ERla 
(pTRE2-a) and pTRE2-hMI-ERl~ (pTRE2-~) were generated by first amplifying entire 
coding sequence of either hMI-ERla or ~. using the primer pairs listed in Table 4.1 
(section 4.2.2). PCR products were cloned into pCR3.1 and BamHI!Xhol fragments were 
then inserted into the BamHJ/Sali sites of the pTRE2 vector. 
6.2.3 GST -fusion protein production 
GST fusion proteins were expressed as described m section 2.2.6. 
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Table 4 Table 6.1 PCR primer pairs used for constructing mutating RB plasmids in 
pCR3.1 vector 
Constructa Forward primer Reverse primer 
RB(1-772) 5-CACCATGGCGCCCAA 5-CACCATGGACTCCAGTTA 
AACCCCCCGAAAAACG-3 GGACTGTTATGAAC-3 
RB(772-928) 5-CACCATGGGCAGAGA 5-GCGGGATCCTCATTTCTC 
CTGAAAACAAATATTTTG-3 TTCCTTGTTTGAGGT -3 
RB(373-772) 5-CACCATGGCTCCAGT 5-CACCATGGACTCCAGTTA 
TAGGACTGTTATGAAC-3 GGACTGTTATGAAC-3 
RB(373-573) 5-CACCATGGCTCCAGT 5-TCAAATAAGATCAAATAA 
TAGGACTGTTATGAAC-3 AGGTGAATCTGAGAG-3 
RB(571-772) 5-CACCATGGATCTTATTAA 5-CACCATGGACTCCAGTTA 
ACAATCAAAGGACCGAG-3 GGACTGTTATGAAC-3 
RB(645-772) 5-CACCATGGCTACCTCTCT 5-CACCATGGACTCCAGTTA 
TTCACTGTTTTATAAAA-3 GGACTGTTATGAAC-3 
a Deletion constructs were named according to the encoded amino acid residues of the 
RB protein 
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6.2.4 GST pull-down 
GST pull-down assays were performed as described in section 4.2.6. 
6.2.5 Co-IP and Western blot analysis 
In vitro co-IP assays were performed as described in section 3 .2.4 with either 10 
J!l anti-RB monoclonal antibody (Catalog No. 14001A: Clone No. G3-245, Santa Cruz 
Biotechnology, Inc.) or 10 J.tl anti-Myc monoclonal antibody 9El0. 
In vivo co-IP assays were performed in MCF-7 cells as described in section 3.2.4 
with 10 J.tl anti-RB monoclonal antibody (Catalog No. 14001A: Clone No. G3-245, Santa 
Cruz Biotechnology, Inc.). Western blot analysis was performed as described in section 
3.2.4 with anti-Myc monoclonal antibody 9El0 (1:100 dilution). 
6.2.6 Establishment of hMI-ERla and p Tet-On cell lines 
The tetracycline induced (Tet-On) gene expression system (Clontech Inc.) takes 
advantage of the high specificity and affinity of the E. coli tetracycline repressor (TetR) 
for its operator sequence (tetO) induced by tetracycline and its derivative antibiotic 
doxycycline (Gossen et al., 1995; Gossen and Bujard, 1992). MCF-7 Tet-On and HeLa 
Tet-On cells were stably transfected with the first regulatory pTet-On plasmid. This 
construct encodes a variant of the tTA protein, the reverse tetracycline transactivation 
(rtTA) protein (Clontech) (Figure 6.1). rtTA can bind to doxycycline and behaves as an 
activator of transcription (Figure 6.1 ). 
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Figure 6.1 Establishment of hMI-ERl HeLa Tet-On cell lines. 
HeLa Tet-On cells were stably transfected with the first regulatory pTet-On plasmid 
which encodes rtTA protein. The second regulatory plasmid is pTRE2-hMI-ERl, in 
which hMI-ERl were under the control of the tetracycline response element (TRE). The 
TRE consists of tetO sequences immediate upstream of a minimal CMV promoter 
(PminCMV). In the absence of doxycycline, rtTA is unable to bind to the tetO, and there 
is no gene expression from the pTRE2-hMI-ER1. When doxycycline is present, 
however, doxycycline binds to rtTA and changes its conformation. rtTA then binds tetO 
to activate transcription ofhMI-ERl. 
PCMV 
pTet-On 
.Dox 
TRE PminCMV 
pTRE-hMI·ER1 
The second regulatory plasmid is pTRE2-hMI-ER1a (pTRE-a) or pTRE2-hMI-
ER1P (pTRE-p), in which hMI-ER1a or hMI-ER1P were under the control of the 
tetracycline responsive element (TRE). The TRE consists of seven repeats of the tetO 
sequence immediately upstream of a minimal CMV promoter (Figure 6.1 ). The minimal 
CMV promoter does not contain any of the enhancer elements of the typical CMV 
promoter, and its activity is controlled by the TRE. In the absence of doxycycline, rtTA 
is unable to bind to the pTRE promoter, and therefore there is no gene expression from 
the pTRE2-hMI-ER1a or p. When doxycycline is present, however, doxycycline binds to 
rtTA and changes its conformation. rtTA then binds tetO to activate transcription of 
hMI-ER1a and p (Figure 6.1). 
To establish hMI-ER1 MCF-7 Tet-On and HeLa Tet-On cell lines which can 
express hMI-ER1a or hMI-ER1P when doxycycline is present, MCF-7 Tet-On and HeLa 
Tet-On cells were co-transfected with the second regulatory plasmid pTRE2 empty 
vector, pTRE2-hMI-ER1a (pTRE2-a) or pTRE2-hMI-ERlp (pTRE2-P) and pTK-Hyg 
vector and selected by hygromycin, according to the protocol recommended by the 
manufacturer (Clontech). The stable clones were isolated and the induced overexpression 
of hMI-ERla or P was screened using Western blot analysis using an anti-hMI-ER1 
antibody produced in our laboratory (24). 
6.2. 7 Colony formation efficiency assays 
For the colony formation efficiency ofHeLa Tet-On cells, 150 cells/plate were seeded in 
50 mm plates 18 h prior 5 Jlg/ml doxycycline (Clontech) induction. The medium was 
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changed every 2 d with fresh medium with or without the indicated concentration of 
doxycycline. Cell colonies were visualized by crystal violet staining 2 weeks later. 
6.3 Results 
6.3.1 hMI-ERla and P associated with RB in vitro and in vivo 
Co-immunoprecipitation analysis was utilized to examine the ability of hMI-
ERlo: and~ isoforms to physically associate with RB and p53 in vitro. RB and p53 were 
synthesized and 35S-labelled in vitro and mixed with unlabelled in vitro translated Myc-
hMI-ERlo: (Myc-o:) or Myc-hMI-ERl~ (Myc-~), followed by immunoprecipitation with 
the anti-Myc antibody 9El0. RB was detected in both Myc-o: and Myc-~ 
immunoprecipitates by anti-Myc antibody 9E10 (Figure 6.2A, lane 2 and 3), indicating 
that RB associates with both isoforms in vitro. The RB immunoprecipitated with hMI-
ERlo: or~ migrated to a higher position on the gel than the direct input of the full-length 
RB TNT (Figure 6.2A, arrow head), suggesting hMI-ERlo: and ~ may be specifically 
associated with a modified RB form, such as phosphorylated RB. In the same assay 
conditions, p53 did not bind to hMI-ERlo: and ~. since p53 was not detected in Myc-
hMI-ERlo: or Myc-hMI-ERl~ immunoprecipitates by anti-Myc antibody 9El0 (Figure 
6.2B, lane 2 and 3). 
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Figure 6.2 hMI-ERla and p interact with RB in vitro. 
(A) 35S-labelled TNTs programmed with eDNA encoding RB were loaded directly on the 
gel (1150 of input) (lanes 1) or incubated with unlabelled TNTs programmed with eDNA 
encoding Myc tagged hMI-ERla (a), or Myc tagged hMI-ERl~ (~)and subjected to IP 
with anti-Myc antibody 9El0 (lane 2-3). Proteins were resolved by SDS-PAGE and 
visualized by autoradiography. Shown is a representative autoradiograph, and the 
positions ofRB are indicated by arrows. (B) 35S-labelled TNTs programmed with eDNA 
encoding p53 were loaded directly on the gel (1150 of input) (lanes 1)) or incubated with 
unlabelled TNTs programmed with eDNA encoding Myc tagged hMI-ER1a (a) or Myc 
tagged hMI-ER1~ (~) and subjected to IP with anti-Myc antibody 9E10 (lane 2-3). 
Proteins were resolved by SDS-P AGE and visualized by autoradiography. Shown is a 
representative autoradiograph, and the positions of p53 are indicated by arrows. (C) 35S-
labelled TNTs programmed with eDNA encoding luciferase (Luc ), Myc tagged 
hMI-ER1a [Myc-a (a)] or Myc tagged hMI-ER1~ [Myc-~ (~)]were loaded directly on 
the gel (1150 of input) (lanes 1-3) or incubated with unlabelled TNTs programmed with 
RB eDNA and subjected to immunoprecipitation (IP) with anti-RB antibody (lanes 4-6). 
Proteins were resolved by SDS-P AGE and visualized by autoradiography. Shown is a 
representative autoradiograph, and the positions of the Myc-a or Myc-~ and luciferase are 
indicated by arrows. 
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Further in vitro and in vivo studies were designed to focus on the interaction with 
RB. Reciprocal experiments, using anti-RB antibody for immunoprecipitation confirmed 
that both hMI-ER1a: and ~ (Figure 6.2A) could associate with RB (Figure 6.2C, lane 4 
and 5), while luciferase, a control protein, did not (Figure 6.2C, lane 6). The basic 
structure of RB consists of the N-terminal, the central region and the C-terminal region 
(Figure 6.3A) (reviewed in Morris and Dyson, 2001). The central region is termed the 
pocket , which folds into a pocket shape to offer a docking site for many interacting 
proteins such as E2F1 (reviewed in Morris and Dyson, 2001). 
The pocket domain of RB contains two regions termed the A-and B-pocket 
domains, that are conserved both across species and among the related proteins (Chow 
and Dean, 1996). These domains are separated by a spacer region that varies in length 
and is not conserved (Chow and Dean, 1996). The human RB A-pocket domain spans 
residues 379 to 572 and the B-pocket domain spans residues 646 to 772 (reviewed in 
Morris and Dyson, 2001). 
To determine which region of RB interacts with hMI-ER1, 35S-labelled in vitro 
synthesized protein using templates encoding only theN-terminal region containing the 
A- and B-pocket domains or the C-terminal region alone were generated (Figure 6.3B, 
lane 1 and 2). GST pull-down assays revealed that the N-terminal region of RB, 
containing the A- and B-pocket domains, interacted with hMI-ER1 (Figure 6.3B, lane 3), 
while the C-terminal region, lacking both A- and B-pocket domains, showed no 
interaction with hMI-ER1 (Figure 6.3B, lane 4). 
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Figure 6.3 Mapping region of RB interacted with hMI-ERl in vitro. 
(A) The diagram illustrates the deletion mutants of RB. The protein pocket A and B 
domains are identified in the legend below the diagram, and the RB amino acid residues 
encoded by each construct are listed. (B) 358-labelled TNTs programmed with eDNA 
encoding RB(1-772) was loaded directly on the gel (1/50 of input) (lane 1) or incubated 
with GST-hMI-ERla (GST-a.) (lane 3); 358-labelled TNTs programmed with eDNA 
encoding RB(772-928) was loaded directly on the gel (lane 2) or incubated with GST-
hMI-ER1a (GST-a.) (lane 4). Proteins were resolved by SDS-PAGE and visualized by 
autoradiography. Shown is a representative autoradiograph, and the positions of RB(1-
722) and RB(722-928) are indicated by arrows. 
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To determine whether the A- and B-pocket domains were required for the 
interaction with hMI-ERl, 35S-labelled in vitro synthesized proteins using templates 
encoding deletion mutants were generated in the region containing the A- and B-pocket 
domains (Figure 6.4A; 6.4B, lane 1 ). GST pull-down assays revealed that this region 
containing both A- and B-pocket domains interacts with hMI-ER1 (Figure 6.4B, lane 4). 
Further experiments revealed that the A-pocket domain of RB was not required for 
interaction with hMI-ER1 (Figure 6.4B, lane 5 and 6), while the B-pocket domain (Figure 
6.4C, lane 1 and 3) interacted with hMI-ER1 (Figure 6.4C, lane 2 and 3). Similar to the 
full-length RB, the RB deletion mutants in the GST-hMI-ER1 pull-down assays exhibited 
a higher molecular form on the gel than the direct input of the in vitro synthesized 
product (Figure 6.4, arrows), which suggested that hMI-ER1a and P may specifically 
associate with a post-translationally modified form ofRB. 
In vivo analysis involved transient expression of the Myc-tag empty vector, Myc-
a or Myc-P in MCF-7 cells. Expression of Myc-a and Myc-P was verified by Western 
blot analysis with anti-Myc antibody 9E10 (Figure 6.5, lane 2 and 3). Cell extracts were 
subjected to immunoprecipitation with anti-RB antibody, followed by Western blot 
analysis with the anti-Myc antibody 9E10. Both hMI-ER1a and p isoforms were co-
immunoprecipitated with endogenous RB by anti-RB antibody (Figure 6.5, lane 7 and 9), 
but not in the immunoprecipitates by the non-immune serum control (Figure 6.5, lane 5 
and 6). 
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Figure 6.4 RB B-pocket domain (aa 645-772) interacted with hMI-ERl in vitro. 
(A) The diagram illustrates the deletion mutants of RB pocket domain. The protein 
pocket A and B domains are identified in the legend below the diagram, and the RB 
amino acid residues encoded by each construct are listed. (B) 35S-labelled TNTs 
programmed with eDNA encoding RB(373-772) was loaded directly on the gel (lane 1) 
or incubated with GST-hMI-ERla (GST-a) (lane 2); 35S-labelled TNTs programmed 
with eDNA encoding RB(373-573) was loaded directly on the gel (1150 of input) (lane 2) 
or incubated with GST-hMI-ERla (GST-a) (lane 4); Shown is a representative 
autoradiograph, and the positions of RB(373-772) and RB(373-573) are indicated by 
arrows. (C) 35S-labelled TNTs programmed with eDNA encoding RB(571-772) was 
loaded directly on the gel (1/50 of input) (lane 1) or incubated with GST-hMI-ERla 
(GST-a) (lane 2); 35S-labelled TNTs programmed with eDNA encoding RB(645-772) 
was loaded directly on the gel (lane 3) or incubated with GST-hMI-ERla (GST-a) (lane 
4). Proteins were resolved by SDS-PAGE and visualized by autoradiography. Shown is 
a representative autoradiograph, and the positions ofRB(571-772) and RB(647-772) are 
indicated by arrows. 
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Figure 6.5 bMI-ERla and p interact with RB in vivo. 
Cell lysates :from MCF-7 cells were transiently transfected with Myc-tag empty vector 
(pMyc), Myc-hMI-ERla (pMyc-a) or Myc-hMI-ERlP (pMyc-p). Cell lysates were 
prepared and were either added directly to sample buffer (1/3 of input) (lanes 1-3) or 
subjected to IP with non-immune serum (lanes 4, 5, 6) or anti-RB antibody (lanes 7, 8, 9). 
Western blot (WB) analysis was performed using anti-Myc antibody 9El0. Shown is a 
representative Western blot, and the positions of the Myc-a and Myc-P proteins are 
indicated. 
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6.3.2 Overexpression of hMI-ERla and p suppresses colony formation efficiency in 
hMI-ERla and p BeLa Tet-On cell lines 
Previous studies revealed that overexpression of hMI-ERla and ~ in NIH 3T3, 
cells suppressed cell colony formation efficiency (Paterno et al., unpublished data). To 
further characterize the cell growth regulatory role ofhMI-ERla and~. experiments were 
designed to establish hMI-ER1a and~ Tet-On cell lines. All hMI-ER1a and ~ Tet-On 
cells would express the same amount ofhMI-ER1a and~ when induced, thus excluding 
the possibility that the observed colony formation was an artifact of transient transfection. 
At the time this study was undertaken, MCF and HeLa Tet-On cell lines were 
commercially available (Clontech). hMI-ER1a and ~ HeLa Tet-On cell lines were 
successfully established in our laboratory (section 6.2.6). However, hMI-ERla and ~ 
MCF-7 Tet-On cell lines have not yet been successfully established. 
In those hMI-ERla and ~ HeLa Tet-On cells, a preliminary study for colony 
formation efficiency assays was conducted after modulating the hMI-ER1a and~ level 
while maintaining all other variables. Induced expression ofhMI-ER1a or hMI-ER1a by 
doxycycline (Figure 6.6B) resulted in significant reduction of cell colony formation 
efficiency in hMI-ER1a or~ HeLa Tet-On cells (Figure 6.6A). Maximum repression 
resulted in a reduction in colony formation efficiency to 38% and 14% of control levels 
by hMI-ER1a and hMI-ER1~, respectively. No significant effect on the colony 
formation efficiency of the pTRE2 control HeLa tet-on cells by addition of doxycycline 
in the culture medium (Figure 6.6A). These results further confirmed that overexpression 
ofhMI-ERla and~ suppresses cell growth in HeLa cells. 
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Figure 6.6 Induced overexpression of hMI-ERla and p by doxycycline significantly 
suppressed the HeLa colony formation efficiency. 
150 cells/plate HeLa tet-on cells were seeded into 50 mm plates. After 24 h of incubation 
cells were followed by changing the medium containing 5 J.lg/J.ll of doxycycline. The 
media with 5 J.lg/J.ll of doxycyline was changed every two days. After 10 days colonies 
were visualized by crystal violet staining. The average values and standard deviations 
from two independent experiments is shown (A). The amount ofhMI-ER1a or P protein 
induced by in each sample was determined 24 h after addition of doxycycline by Western 
blot analysis using anti-hMI-ER1 antiserum. A representative Western blot is shown (B). 
The positions ofhMI-ER1a and hMI-ER1P are indicated by arrows. 
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6.4 Discussion 
The present study revealed that hMI-ER1 can interact with RB. However, it is 
possible that hMI-ER1 interacts with RB either directly or indirectly through other 
proteins in the multi-subunit complexes. Since there are multiple endogenous proteins in 
cells and in the reticulocyte TNT lysates, we cannot at present exclude these possibilities. 
Alternative protein-protein interaction assays using both purified proteins from bacterial 
recombinant products and then Western blot analysis may address this question. 
The A-pocket domain and B-pocket domain of RB is critical in forming a 
transcription repression pocket for E2F (Chow and Dean, 1996; Harbour et al., 1999). As 
shown in Figure 6. 7, subsequent phosphorylation of RB, mediated by cyclin D-
CDK4/6and cyclin E-CDK2 complexes, disrupts the transcription repression pocket for 
E2F and allows for the transcription ofE2F target genes (reviewed in Harbour and Dean, 
2000). In brief, cyclin D-CDK4/6 becomes active during early G1, and phosphorylates 
the C-terminal tail of RB (Figure 6. 7B). This phosphorylated C-terminal tail then folds 
over RB pocket (Figure 6. 7C). During cell cycle progression, cyclin E-CDK2 is activated 
and binds to the C-terminal tail and phosphorylates the pocket domain (S567 was the 
critical residue) (Figure 6.7D). This phosphorylation disrupts the pocket domain structure 
and releases E2F (Figure 6.7E) (Harbour et al., 1999). In this chapter, I demonstrated 
that hMI-ER1 interacted specifically with the B-pocket domain (Figure 6.4). It is 
possible that the interaction of hMI-ER1 with the B-pocket domain stabilizes the 
interaction of A- and B-pocket domains to form the transcription repression pocket for 
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Figure 6. 7 Intramolecular interactions of RB by sequential post-translational 
modification and the possible functional implication of RB and hMI-ERl 
interaction (adapted from Harbour et al., 1999). 
(A) The A- and B-pocket domain interact with each other forming an pocket for 
the E2F binding, thus forming a transcriptional repressive status on the E2F target gene 
promoters. (B) cyclin D-CDK4/6 becomes active early during Gl, and phosphorylates 
RB. (C) Phosphorylated C-terminal tail then folds over the RB pocket. (D) During the 
cell cycle progression, cyclin E-CDK2 is activated and binds to the C-terminal tail and 
phosphorylates the pocket domain CS67S was is the critical residue). (E) Phosphorylation 
of the pocket domain on 567 S was the critical residue disrupts the pocket domain structure 
and releases E2F. (F) hMI-ERl binds to the B-pocket domain (modified form?) ofRB. 
Binding to B-pocket domain by hMI-ERl may inhibit the interaction of C-terminal 
domain ofRB binding to the pocket domain, thus may prevent the phosphorylation of the 
pocket such as on S567 by cyclin E-cdc2 and thus stabilize the RB-E2F repressive 
complexes. 
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E2F (Figure 6. 7F), which requires further study. It would also be very interesting to 
know which region ofhMI-ERl interacts with RB. GST pull-down assays are ongoing in 
the Paterno and Gillespie laboratories in order to study the minimal region of hMI-ERl 
required to interact with RB. 
Although multiple cellular and viral proteins interact with RB, only a few 
proteins, such as Ski, were reported to interact specifically with the B-pocket domain 
(reviewed in Morris and Dyson, 2001 ). Association of Ski with RB represses RB 
activity, and facilitates cell-cycle progression (Medrano, 2003). It is possible that 
interaction ofhMI-ERl with RB inhibits the association of Ski with RB by competing for 
the binding sites in the RB B-pocket domain, thus removing the inhibitory effect on RB 
by Ski and enhancing RB transcriptional repression function. Thus, the interaction of 
hMI-ERl with RB may represent a novel regulatory mechanism for RB transcriptional 
repression function. Since RB plays a pivotal role in the regulation of cell growth and 
tumour suppression, this preliminary finding may have potential clinical significance. 
Further experiments are required to explore this exciting hypothesis. 
The full-length RB TNT immunoprecipitated with the hMI-ERl TNT migrates at 
a higher relative molecular weight on the gel than the direct input of the RB TNT (Figure 
6.2, arrows), suggesting that hMI-ERl may specifically associate with a modified RB 
form. The same is true for the B-pocket domain-containing region mutants (Figure 6.4, 
arrows). Recent studies in our laboratory showed that hMI-ERl recruits multiple 
enzymes, including CBP (Blackmore eta/., unpublished data) and HDACl (Chapter 3), 
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which may modify RB or other associated proteins. Alternatively, RB or RB deletion 
mutants may be modified directly by factors in the reticulocyte TNT lysates. Although 
RB can be phosphorylated (reviewed in Kaelin, 1999; Wright et al., 1991) and acetylated 
(Chan et al., 2001), those well characterized modification sites are not located on the B-
pocket domain (Chan et al., 2001; Kaelin, 1999). The mechanism of binding of hMI-
ERl with a relatively higher molecular weight form of RB B-pocket domain requires 
further investigation. 
hMI-ERl interacts both in vitro and in vivo with RB (Section 6.3.1), which plays 
an important role in cell proliferation regulation (reviewed in Qu et al., 2003). Therefore, 
it is possible that hMI-ER1 inhibits cell proliferation through RB. Induced 
overexpression of hMI-ERl represses colony formation efficiency in hMI-ER1 HeLa 
Tet-On cells (Figure 6.6). In these Tet-On cells, all cells express the same amount of 
hMI-ERla. and~ when induced, thus excluding the possibility that the observed colony 
formation was an artifact of plasmid transfection. These preliminary results suggested 
hMI-ERla. and~ may regulate cell proliferation. However, we cannot at present exclude 
that hMI-ERl could suppress cell proliferation through other RB-independent 
mechanisms. Many different mechanisms could explain our observations. In HeLa cells, 
most wild-type RB is inactivated by HPV18 E7 oncoprotein (Goodwin and DiMaio, 
2000). Repression of E7 in HeLa cells was shown to cause the reactivation of RB 
(Goodwin and DiMaio, 2000). It is, therefore, possible that overexpression ofhMI-ER1 
may enhance the activity of RB through suppression of the expression of E7 oncoprotein. 
Further studies to analyze RB protein levels as well as phosphorylation status before and 
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after the overexpression of hMI-ERla. and P induced by doxycycline would help to 
address this question. 
Most recently, hMI-ERla. or p were found to bind to unacetylated histone protein 
H4 (Paterno et al., unpublished data). Therefore, hMI-ERl may directly bind to E2F-
targeted gene promoters such as cyclin E and repress the transcription of those genes. 
Thus, overexpression of hMI-ERla. and p may result in misregulation of subsets of 
growth-related genes, which ultimately alter cell cycle arrest and/or apoptosis, 
independent of status RB. 
hMI-ERla. and p were recently shown to form complexes containing HDACl and 
have a transcriptional repression function (Chapter 3). In this way, high levels of hMI-
ERla. and p expression could compete for HDACl from other HDACl complexes and 
deregulate a number of other HDACl containing transcriptional regulatory complexes 
such as mSin3A and/or NURD complexes. 
hMI-ERla. and P were also found to interact with the Spl transcription factor, and 
interfere with the DNA binding site recognition by Spl (Chapter 4). Therefore, 
overexpression of hMI-ERla. or p may affect a large set of Spl target genes, many of 
which play important roles in regulating cell growth and cell death (reviewed in Black et 
al., 2001). 
As shown previously in colony forming assays with p53 (Baker et al., 1990), the 
inhibitory effect of hMI-ERl a and p in colony formation efficiency may be also due to an 
apoptotic-inducing activity. We cannot at present exclude the possibility that 
overexpression of hMI-ERl may cause non-specific toxicity to the cells during colony 
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formation. However, overexpression of non-related proteins such as luciferase in HeLa 
cells showed no significant effect on cell colony formation efficiency (Yang et al., 2001). 
Sequence analysis revealed a putative BCL-2 homology (BH)-3 (BH3) domain in theN-
terminal region of hMI-ERl (Paterno et al., personal communication). Proteins of the 
Bcl-2 family are critical regulators of caspase activation and apoptosis, and they contain 
regions of homology (BHl-4) (reviewed in Bouillet and Strasser, 2002). The BH3 
domain is essential for the binding of BH3-only pro-apoptotic proteins to the anti-
apoptotic members of the Bcl-2 family and for their ability to kill cells (reviewed in 
Bouillet and Strasser, 2002). Therefore, hMI-ERla and ~ may be novel BH3-only 
proteins and it is possible that hMI-ERl may interact with Bcl-2 family proteins and 
modulate apoptotic pathways. futerestingly, hMI-ERl was found to interact with 
TRABID, a component of death receptor signalling pathways (see Chapter 5). It is 
possible that hMI-ERl transmits the signal from the cell death receptor signalling 
pathways through TRABID to the mitochondria so as to regulates apoptosis. Therefore, 
it is possible that overexpression of hMI-ERl can induce apoptosis and kill the cell 
during colony formation. 
Although multiple mechanisms arising from the overexpression ofhMI-ERla and 
~ in HeLa Tet-On cells may suppress colony formation efficiency, the establishment of 
the inducible hMI-ERla and ~ Tet-On cell lines would be very useful to further 
investigate the role of hMI-ERl in cell growth regulation. For example, it would be 
interesting to analyze the effect of overexpression of hMI-ERla and ~ on the cell 
proliferation rate of the hMI-ERla and~ HeLa Tet-On cells using approaches such as the 
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MTS assay (Hu et a!., 1999). Moreover, fluorescence activated cell sorting (FACS) 
would be very useful to analyze cell cycle arrest and/or apoptosis of the hMI-ER1a and~ 
HeLa Tet-On cells, before and after doxycycline treatment. 
Since hMI-ER1a and~ may function in a cell type specific manner, it would be 
rewarding to establish more Tet-on cell lines, such as in MCF-7 and/or NIH 3T3 cells, to 
study the role ofhMI-ERla and~ in cell growth regulation. 
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SECTION IV 
CHAPTER 7 GENERAL DISCUSSION, FUTURE DIRECTIONS AND 
CONCLUSION 
7.1 GENERAL DISCUSSION 
7.1.1 The multiple layers of transcriptional regulation of promoter activity of hmi-
erl P2 promoter 
This thesis has described the molecular cloning of the hmi-er1 PI and P2 
promoters (Chapter 2). Further characterization of the hmi-er 1 P2 promoter provided 
information on the transcription regulation of the hmi-er1 P2 promoter (Chapter 2 and 4). 
Studies here bring new insights into molecular mechanisms of the regulation of hmi-er 1 
P2 promoter activity. DNA cis-acting regulatory elements in the hmi-er 1 P2 promoter 
clearly represent an important mechanism for the specific expression of this gene. The 
transcriptional activation of the hmi-er 1 P2 promoter may depend on cell types as well as 
co-expression of transcription regulators such as members of the Spl family (Chapter 2). 
hMI-ERl was found to repress its own promoter activity through interaction with and 
interference with GC box recognition by Spl (Chapter 4), thus forming a negative 
feedback loop to tightly control the activity of hMI-ERla. and B, which function as 
transcriptional regulators (Chapter 3 and 4). 
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The accessibility of promoter elements to transcriptional regulators is also 
regulated at the level of chromatin assembly. The hmi-er 1 P2 promoter has a CpG island, 
and may be subjected to DNA methylation. The state of gene methylation is associated 
with chromatin structure and transcriptional repression (Bird and Wolffe, 1999). Methyl-
CpG binding proteins such as MeCP2 and MBD3 are shown to recruit chromatin 
remodelling and modification complexes, including the NURD complex (Ng et al., 1999; 
Tyler and Kadonaga, 1999; Zhang et al., 1999). It has been proposed that DNA 
methylation and histone deacetylation might work together to establish a repressive 
chromatin environment to silence gene expression (Cameron et al., 1999). Aberrant 
methylation on the CpG island of cell growth regulatory gene promoters has been found 
in certain cancers (reviewed in Esteller and Herman, 2002; Nephew and Huang, 2003). 
For example, aberrant methylation of the promoter of the tumour suppressor genes 
p16INK4A is closely related to tumour growth characteristics (Bender et al., 1998; 
Cameron et al., 1999; Issa et al., 1994). Deregulated expression of hMI-ER1 in some 
breast carcinoma (Paterno et al., 1998; and data at http://genome-www5.stanford.edu/cgi-
bin/SMD/source/expressionSearch?option=cluster&criteria=Hs.222746&dataset=2&orga 
nism=Hs) may be due to aberrant methylation of the promoter CpG island of hmi-er 1 in 
those cancers. 
At the moment, knowledge of the transcriptional regulation of the hmi-er 1 is far 
.from complete. The finding of two promoters (Chapter 2 and Paterno et al., 2002) adds 
additional complexity to the expression regulation of hmi-er 1. Moreover, there may also 
be other enhancers located beyond the DNA region we investigated in this study. 
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7.1.2 hMI-ERl-containing complexes 
It is becoming increasingly clear that protein function is not isolated in cell, but 
rather proteins work together with other associated protein partners in multi-subunit 
complexes. For example, RB was shown to associate with members of the E2F family as 
well as other cellular proteins such as HDAC1 to form transcription repression complexes 
that function in cell growth regulation (reviewed in Morris and Dyson, 2001). Within a 
protein complex, each individual protein may have a particular specialized function that 
contributes to the overall activity of the complex. This specialized function may be 
dependent on the interaction with neighbouring proteins in the complex which may, for 
example, lead to modulation of protein activity through conformational changes and/or 
post-translational modifications. Multi-protein complexes are emerging as important 
entities of biological activity inside cells that serve to create functional diversity by 
contextual combination of gene products and, at the same time, organize the large 
number of different proteins into functional units. 
In the present studies, hMI-ER1 was found to associate with HDAC1-containing 
complexes (Chapter 3). Prominent examples ofHDAC1-containing complexes involving 
chromatin modification and transcriptional regulation are mSin3A, NURD and CoREST 
complexes. The mSin3A complex consists of several core protein components and some 
additional binding protein components. The core is built from mSin3, HDAC1, HDAC2, 
RBAP46, RBAP48, SAP18 and SAP30 proteins. mSin3A itself is a large multi-domain 
protein that most likely forms the scaffold upon which the remainder of the complex 
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assembles (Ayer, 1999). The core protein components of NURD complexes consist of 
Mi-2, HDAC1, HDAC2, RBAP46, RBAP48, and one of the MTA family proteins 
including MTA1, MTA2 and MTA3 (Fujita et al., 2003; Guschin et al., 2000; Knoepfler 
and Eisenman, 1999). The ATPase activityofMi-2 can increase the efficiency of histone 
deacetylation by NURD complexes (Guschin et al., 2000; Tong et al., 1998; Xue et al., 
1998b ), which suggests that chromatin remodelling facilitates the access of the HDACs 
in NURD to the histone tails. Interestingly, MTA1, MTA2 and MTA3, all containing 
ELM2 and SANT domains, have been recently shown to be components of each bona 
fide distinct NURD complexe (Fujita et al., 2003; Tong et al., 1998; Wade et al., 1999; 
Xue et al., 1998b; Yao and Yang, 2003; Zhang et al., 1999). Thus, the NURD complexes 
consist of several distinct forms. Another distinct HDACs-containing complex is the 
CoREST complex. CoREST is an ELM2 and SANT domain-containing protein and 
forms unique complexes different from NURD and mSin3 complexes (You et al., 2001). 
The observations that each ofMTA1, MTA2, MTA3, and CoREST form distinct 
HDAC1 complexes suggested that the ELM2 and SANT domain-containing proteins may 
be sufficient to perform an as yet unknown function (chromatin targeting?) in HDAC1-
containing complexes. Indeed, most recently, the ELM2 and SANT domain-containing 
region of hMI-ER1 was found to bind specifically to unacetylated histone protein H4 
(Paterno et al., unpublished data). Thus, it would be possible that the ELM2 and/or 
SANT domain of MTA1, MTA2, MTA3, or CoREST have similar histone binding 
activity. It is possible that hMI-ER1 is also a key subunit of bona fide unique HDAC1-
containing complex which is different from MTA1, MTA2, MTA3 and CoREST related 
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complexes. To confirm this hypothesis, immunoprecipitation and Western blot analysis 
could be useful to address the presence or the absence of molecular markers of those 
complexes mentioned above, such as MTAl, MTA2, MTA3 and CoREST, in the hMI-
ERl-HDACl complex. Alternatively, this question could also be addressed by the 
combination of classical biochemical fractionation techniques for the enrichment ofhMI-
ERl related complexes with the large-scale purification and identification of distinct 
hMI-ERl complexes by mass spectrometry and bioinformatics (see section 6.2.4). 
hMI-ERl was also found to interact with multiple other proteins, including Spl 
(Chapter 4), RB (Chapter 5), HSP40 (Chapter 5), TRABID (Chapter 5), ERa (Savicky et 
a/., unpublished data), CBP (Blackmore et a/., unpublished data), and core histone 
proteins (Paterno eta/., unpublished data). It is possible that interaction of one of those 
proteins with hMI-ERl may affect the binding of another interacting partner with hMI-
ERl through competition for the binding surface ofhMI-ERl. Thus, hMI-ERl may form 
multiple distinct complexes with each interacting partner. Alternatively, hMI-ERl could 
assemble with all these interacting partners together to form a single transcription 
regulatory complex. Although the interactions of those proteins with hMI-ERl were 
investigated by in vitro and in vivo protein-protein interacting assays, it is still possible 
that some of the interactions between them are indirect, or one may act as a bridge for 
binding of all the others. Since there are multiple endogenous proteins in the cells and in 
the reticulocyte TNT lysates, the interaction detected in these systems may be an indirect 
interaction through other protein(s) in cells or in reticulocyte TNT lysates. It would be 
interesting to know whether interactions of all these proteins with hMI-ERl are direct or 
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indirect. Protein-protein interaction assays using both purified proteins and then Western 
blot analysis may address this question. 
7.1.3 Does hMI-ERl function as transcriptional repressor or activator? 
hMI-ER1 was found to function as a transcriptional repressor through recruitment 
of HDAC1 and interacting with Sp1 and interference with GC box recognition by Sp1 
(Chapter 3 and 4); however, it cannot be excluded that it may function as a transcriptional 
activator under other conditions. TheN-terminal region of hMI-ER1 contains an acidic 
activation domain, which may be implicated in transcriptional activation. Indeed, hMI-
ER1a. fused to GAL4 DBD from pAS2-1-hMI-ER1 alone can activate reporter genes in 
yeast (Figure 5.2B), and this activity was located in theN-terminal region which contains 
the acidic activation domain (Figure 5.2C). These observations suggested that the N-
terminal region ofhMI-ER1 may recruit the transcriptional machinery in yeast, and thus 
is implicated in transcription activation. There is evidence that Xenopus MI-ER1 
functions as a powerful transcriptional activator (Paterno et al., 1997). Recently, theN-
terminal region ofhMI-ER1 was found to interact with the histone acetyltransferase CBP 
(Blackmore et a!., unpublished data). CBP acetylates histone tails and changes the 
conformation of chromatin structure, which is correlated with transcription activation 
(reviewed in Carrozza et al., 2003; Roth et al., 2001). Therefore, the interaction ofhMI-
ER1 with CBP further suggests that hMI-ER1 may function as transcriptional activator 
under certain conditions. Alternatively, it is possible that hMI-ER1 binds to CBP and 
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regulates its HAT activity. It is, of course, also possible that CBP interacts with hMI-
ERl and acetylates hMI-ER1 potentially regulating its functions. 
The ability to both repress and activate transcription has been reported for a 
number of other transcription factors, including the nuclear hormone receptors (reviewed 
in Aranda and Pascual, 2001). In most cases, differential recruitment of coactivator or 
corepressor complexes determines the different effect on transcription by nuclear 
hormone receptors (reviewed in Aranda and Pascual, 2001). It is possible that hMI-ERl 
recruits distinct transcriptional regulatory complexes in response to different signals. The 
transcriptional activation or repression function of hMI-ER1 may be dependent on the 
subunits of the complexes recruited by hMI-ER1, for example, the presence of HDAC1 
and/orCBP. 
Recently, transcriptional activation and repression have been shown to be more 
closely integrated than previously thought. Examples of corepressors and coactivators 
coexisting in a single regulatory unit have been recently described. For example, theN-
CoR and the coactivator CBP have been shown to bind the homeodomain heterodimer 
PBX-HOX simultaneously, while protein kinase A (PKA) stimulation of CBP has been 
found to facilitate the switch from transcriptional repression to activation in this system 
(Asahara et al., 1999; Saleh et a!., 2000). Therefore, it is also possible that hMI-ERl 
associates with corepressors, such as HDAC1, and coactivators, such as CBP, together in 
the same complex in cells, and transcription activation and/or repression may be 
controlled not only by the protein context in a particular cell type but also by signal 
transduction pathways, following growth factor or cytokine stimulation. 
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7.1.4 A model of the regulation of hmi-erl P2 promoter activity and putative 
transcriptional functions ofhMI-ERl 
Figure 7.1 illustrates a model is for the regulation of hmi-er 1 P2 promoter activity 
and transcriptional functions ofhMI-ER1, based on the results obtained in the laboratory. 
Firstly, Sp 1 binds to the hmi-er 1 P2 promoter of hmi-er 1 and activates transcription 
(Chapter 2). hMI-ER1 can recruit with HDAC1 and repress transcription (Chapter 3). 
hMI-ER1 also recruits transcription factor Sp1 and interferes with GC box recognition by 
Sp1, and could thereby regulate Sp1-target gene expression (Chapter 4). hMI-ER1 
interacts with RB (Chapter 5), which may enhance RB s transcriptional repressive 
activity. Interaction ofhMI-ERl with HSP40 (Chapter 5) may be implicated in assembly 
with nuclear hormone receptors such as ERa.. Most recently, hMI-ER1 was found to be 
specifically associated with ERa. (Savicky et al., unpublished data). Association ofhMI-
ERl with ERa. may modulate the transactivation functions of ERa. and regulate essential 
ERa. target gene expression. hMI-ERl interacts with TRABID (Chapter 5), which may 
recruit hMI-ERl into TRABID-TRAF signalling complexes and activate hMI-ERl to 
function as a transcription regulator. hMI-ERl recruits CBP (Blackmore et al., 
unpublished data), which may oppose HDAC1 function to provide precise regulation of 
transcriptional activity. Most recently, hMI-ERl was found to interact with unacetylated 
histone H4 (Paterno et al., unpublished data), and thus may direct multiple subunit 
complexes to target promoters in response to distinct cellular signals. This discovery 
strongly supports the hypothesis that hMI-ERl functions as an important transcription 
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Figure 7.1 Model of putative mechanisms of transcriptional regulation ofhMI-ERl. 
Sp 1 binds to the hmi-er 1 P2 promoter of hmi-er 1 and activate transcription. Interaction 
of hMI-ER1 with HDAC1 results in histone deacetylation and transcription repression. 
hMI-ER1 interacts with transcription factor Sp1 and interferes with GC box recognition 
by Sp1, thus may thereby regulate Spl-target gene expression. Interaction ofhMI-ER1 
with RB may enhance or inhibit RB activity as transcription regulator. HSP40 may direct 
complexes assembling of hMI-ERl with nuclear hormone receptors such as ERa, which 
may regulate essential ERa target gene expression. Interaction of hMI-ER1 with 
TRABID may bring hMI-ERl into TRABID-TRAFs signalling complexes and activate 
hMI-ER1 as transcription regulators. Recruitment of CBP by hMI-ER1 may result in the 
acetylation of histone and activate target gene transcription. Binding ofhMI-ER1 to the 
unacetylated histone protein H4unacetylated histone may direct multiple subunit 
complexes to the target promoter. hMI-ER1 was also found to interfere with DNA 
recognition by Sp 1 to its own P2 promoter and repress its own P2 promoter activity, thus 
forming a negative feedback loop to tightly control the activity ofhMI-ERl. 
~···· 
Transcriptional regulation of target genes 
regulator and could target chromatin and regulate gene transcription. Finally, hMI-ER1 
interferes with DNA recognition by Sp 1 on its own promoter and represses its own gene 
promoter activity (Chapter 4), thus forming a negative feedback loop to tightly control 
the activity of hMI-ERl. This ensures that hMI-ER1 regulates the expression of other 
genes at appropriate times. 
7.2 Future directions 
This thesis has described the molecular cloning of hmi-er 1 promoters. 
Characterization of the hmi-er 1 P2 promoter provided information on its transcriptional 
regulation (Chapter 2). In the present study, hMI-ER1 was found to repress transcription 
on the TK minimal promoter of G5TKCAT through recruiting HDAC1 activity (Chapter 
3). Moreover, hMI-ER1 was found to repress promoter activity on its own P2 promoter 
through interacting with Sp1 and interfering with GC box recognition by Sp1 (Chapter 4). 
Furthermore, multiple hMI-ER1 interacting protein partners were identified using 
different approaches (Chapter 5 and 6). Most interestingly, overexpression of hMI-ER1 
was found to have a profound impact on cell growth (Chapter 6 and Paterno et al., 
unpublished data). However, at the moment we are just able to see the tip of the iceberg. 
To fully understand the molecular mechanisms of hMI-ERl expression and function, 
more experiments must be. 
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7.2.1 Further characterization of hmi-erl promoters 
Cloning and characterization of the hmi-er 1 P2 promoter revealed that Sp 1 binds 
to the promoter and plays a positive role in the regulation of promoter activity (Chapter 
2). Besides Sp 1 binding sites, other transcription regulator binding sites, including two 
TEF-2 sites, an HT4F site, and an ERE half-site, were also predicted in the P2 promoter 
(Chapter 3). Approaches such as EMSA (Chapter 2 and 4) and chromatin 
immunoprecipitation (ChiP) (Mazumdar et al., 2001) can be used to investigate whether 
the related transcription factors such as TEF-2, HT4T and ERa bind to the promoter in 
vitro and in vivo. The ERE half-site in the hmi-er 1 P2 promoter, which suggests that 
hmi-er 1 may be an estrogen-responsive gene, is particularly interesting. Many estrogen-
response genes, such as MTA3, were found to be downregulated in ER-negative breast 
tumours (Fujita et al., 2003). Since hMI-ER1 was found to interact with ERa and 
regulate ERa-mediated transcription (Savicky et al., unpublished data), hMI-ER1 may 
play an important role in estrogen-signalling pathways. It would be important to know 
whether the ERa-hMI-ERl pathway is deregulated in hormone-resistant cancers, and 
whether the expression of hMI-ERl is correlated to the status of ERa in breast 
carcinomas. It would therefore be very interesting to analyze the expression ofhMI-ER1 
and the correlation with ERa status in more breast carcinomas samples. This is presently 
under investigation in our laboratory. 
To investigate whether other unpredicted transcription regulators bind to the hmi-
er 1 P2 promoter region and regulate the promoter activity of hmi-er 1, an expression 
eDNA library screening approach (Vinson et al., 1988) may be conducted to identify and 
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isolate the hmi-erl promoter-binding protein(s) using the labelled P2 promoter as a 
probe. Moreover, it would be rewarding to characterize the hmi-erl P1 promoter using 
similar approaches. 
7.2.2 Functional implication of the interactions with HSP40, TRABID and RB 
Pioneering work in this study revealed that hMI-ER1 interacts with RB, HSP40 
(Chapter 5), TRABID (Chapter 5) and RB (Chapter 6). These preliminary studies 
provided more clues to study the function of hMI-ERl. ERa plays a crucial role in 
normal breast development and is also linked to development and progression of 
mammary carcinoma (Hortobagyi, 1998; Osborne, 1998). The transcriptional activity of 
ERa is regulated by hMI-ER1 (Savicky et al., personal communication). Since HSP40 
may play a critical role in assembling an ERa-regulatory complex with hMI-ERl, the 
interaction of hMI-ERl and HSP40 may be a critical event in regulation of ERa 
functions, and thus may have potential clinical significance. Further study of the 
interaction with HSP40 would involve investigating: (1) if hMI-ER1 interacts with 
HSP40 in mammalian cells and thus to exclude the possibility that the observed 
interaction was an artifact of overexpression; (2) if HSP40 directs ERa complex 
assembly with hMI-ER1; (3) the role of the hMI-ER1-HSP40-ERa pathway in ERa 
signalling; (4) ifER-resistant cancer results from the misregulation ofhMI-ER1-HSP40-
ERa pathway. Similarly, 
hMI-ER1 interacts with TRABID, which may be involved in the regulation of cell 
death through the TRABID-TRAF signalling pathway. Further studies examining the 
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interaction with TRABID would involve determining: (1) whether hMI-ER1 interacts 
with TRABID in mammalian cells and thus to exclude the possibility that the observed 
interaction was an artifact of overexpression; (2) whether TRABID-TRAF signalling 
complexes recruit hMI-ERl and activate hMI-ER1; and (3) whether overexpression of 
hMI-ER1 would sensitize cells to cytokine-induced apoptosis, through the TRABID-
TRAF-dependent pathway. 
Further study of the interaction with RB would involve investigating: (1) if 
endogenous complexes containing hMI-ER1 and RB exist in the cell, thus excluding the 
possibility that the observed interaction was an artifact of overexpression; (2) what post-
translational modification of the RB B-pocket domain allow interactions with hMI-ER1; 
(3) which domain ofhMI-ER1 interacts with RB; (4) whether hMI-ERla and~ affects 
the cell cycle-dependent interaction of RB with E2F on E2F binding sites; (5) whether 
hMI-ER1 affects the E2F target gene such as cyclin E expression; (6) whether hMI-ER1 
binds to the E2F target promoters through RB-dependent and/or -independent 
mechanisms; and (7) whether the cell growth regulation by hMI-ER1 is dependent on the 
interaction with RB, i.e. a form ofhMI-ER1 that fails to interact with RB may affect the 
cell growth regulation. 
7.2.3 hMI-ERl transcriptional target genes 
The functional study of hMI-ER1 revealed that hMI-ER1 functions as a 
transcriptional regulator (Chapter 3 and 4; Savicky et al., unpublished data; Blackmore et 
al., unpublished data). Thus, a systematic approach may be used to identify the 
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transcriptional targets of hMI-ERl. The global v1ew of gene expresswn profiles 
regulated by hMI-ERla. and~ may provide further clues about their transcriptional target 
genes in cells. Microarray and/or serial analysis of gene expression (SAGE) approaches 
(Pollock, 2002) may be utilized to assess changes in RNA expression upon hMI-ERla. 
and~ overexpression in cells. Recently, hMI-ERla. and~ HeLa Tet-On cell lines were 
successfully established in the laboratory (Chapter 6). These cell lines would be very 
useful for the purpose of studying global gene expression profiles affected by induced 
hMI-ERla. and ~ overexpression. Recently, new technologies have been developed to 
identify novel target gene promoters for transcription factors in mammalian cells, such as 
modified ChiP (Johnson and Bresnick, 2002; Weinmann and Farnham, 2002). 
7.2.4 Do hMI-ERla and p complexes have distinct components? 
Quite often proteins participate in more than one complex, or do so in different 
subcellular compartments. Different subcellular compartments contain compartment-
specific subsets of gene products in order to provide suitable biochemical environments, 
in which they exert their particular function. 
hMI-ERl~ is a nuclear protein, while hMI-ERla. shuttles between the nucleus and 
cytoplasm, which may suggest distinct functions for the two isoforms (Paterno et a/., 
2002 and unpublished data). Thus, the identification of subsets of protein complexes of 
hMI-ERla. and ~ at the subcellular level would also provide more clues towards the 
understanding of the precise function ofhMI-ERla. and~· Interestingly, hMI-ERla. has 
the LXXLL NR binding motif in its C-terminal region, which may function to interact 
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with and sequester NR in the cytoplasm. Recently, a variant of MTAl, MTAls, was 
found to contain the LXXLL motif and localize in the cytoplasm. MTAls inhibits nuclear 
signalling by sequestering ERin the cytoplasm, which is distinct from the nuclear form 
of MTAl (Kumar et a/., 2002). However, so far, proteins that have been identified as 
interacting partners, including ERa., have been found to interact with both hMI-ERla. and 
f3. Therefore, isolation of the distinct subcellularly localized hMI-ERla. and f3 complexes 
may help to distinguish their different components and functions. Approaches to isolate 
the protein complexes include recombinant proteins, epitope-tagged proteins and 
antibody methods (reviewed in Bauer and Kuster, 2003). Since specific antibodies 
against the C-terminal portion of distinct hMI-ERla. or f3 have been generated in the 
laboratory, the antibody immunoprecipitation method for the isolation ofhMI-ERla. or f3 
related complexes would be very useful and feasible. Moreover, GST fusion proteins 
containing the distinct C-terminal portions ofhMI-ERla. or f3 also have been generated in 
the laboratory. Therefore, GST pull-down isolation methods are also suitable for the 
isolation of distinct hMI-ERla. and f3 complexes in the laboratory. The combination of 
classic biochemical techniques for the isolation of hMI-ERla. or f3 related complexes 
from particular subcellular structures with the large-scale purification and identification 
of distinct hMI-ERla. and f3 complexes by mass spectrometry and bioinformatics would 
provide more information on their components. 
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7.2.5 Role in cell growth control and tumorigenesis 
Overexpression of hMI-ERla. and p suppresses colony formation efficiency in 
multiple cell lines (Paterno et al., unpublished data; Huang et al., personal 
communication). Recently, hMI-ERla. and p HeLa Tet-On cell lines were established in 
the laboratory and preliminary studies showed that the induced expression ofhMI-ERla. 
and p suppressed cell colony formation efficiency in these cells (Chapter 6). Further 
studies are required to determine whether upregulated hMI-ERla. and p induce inhibition 
of proliferation and/or cell death. It would be particularly interesting to know whether 
induced expression of hMI-ER1a. and p by doxycycline would inhibit tumour growth in 
nude mice. 
It would be rewarding to know which domain and functions of hMI-ER1 are 
critical for colony formation efficiency inhibition. The ELM2 and SANT domains of 
hMI-ER1 were shown to play a role in transcriptional repression through distinct 
mechanisms (Chapter 3 and 4). The mutant forms of aa 214W and 227FL in the ELM2 
domain fail to recruit HDAC1 activity and repress transcription (Chapter 3). A deletion 
mutant retaining the SANT domain region (aa 287-357) was found to interact with Sp1, 
while further deletion of this region at the C-terminal end to remove residues from aa 331 
to 357 e31K to 357T), which includes a highly conserved lysine (K) within the SANT 
domain at position 331 and the C-terminal 26 aa, completely abolished the interaction 
with Spl and the interference with the GC box recognition by Sp1 (Chapter 4). If the 
transcription repression ofhMI-ERl is important for its role in cell growth regulation, the 
mutant form ofhMI-ER1 in the ELM2 domain and/or SANT domain may then affect the 
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cell growth regulation function by hMI-ERl. Most recently, mutagenesis analysis of the 
proline-rich region of Xenopus MI-ER1 e65PSPPP) revealed that 365p in the proline-rich 
region is required for the effects ofxMI-ER1 on embryonic development and mesoderm 
induction (Teplitsky et al., 2003). Therefore, it would be interesting to investigate the 
role of the ELM2 domain, the SANT domain, and the proline-rich PSPPP motif in cell 
growth regulation through deletion or point mutation of those conserved residues 
including aa 214W, 227FL, 331K, and 376psppp ofhMI-ERl. 
hMI-ER1 was found to have ubiquitous, but low level, expression in normal 
human tissues (Paterno et al., 1998; Paterno et al., 2002). Breast carcinoma cell lines and 
tumours, on the other hand, showed elevated levels (Paterno 1998), suggesting that hmi-
er 1 expression is associated with the neoplastic state in human breast carcinoma. 
However, it remains to be determined whether the high levels of hmi-erl expression 
observed are causative or correlative in the tumorigenesis. That overexpression of hMI-
ERl a and ~ in cancer cells suppresses colony formation efficiency is quite unexpected 
and may be a very complicated consequence ofhMI-ERla. and~ functions. However, it 
is clear now that there are at least 12 transcripts which encode 6 distinct hMI-ER1 protein 
isoforms. The expression of these transcripts is complex, as well as the subcellular 
localization of proteins in normal tissues and tumour tissues (Paterno et al., unpublished 
data). Moreover, each protein isoform may have different, or even opposite functions. 
For example, p73, which is a member of the p53 family, was shown to have multiple 
isoforms which play different roles in cell growth regulation (reviewed in Irwin and 
Kaelin, 2001). Two of hmi-erl isoforms (N1a. and N1~) contain a 25 aa cysteine-rich 
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region at the N-terminus (Paterno et al., 2002), which may function in protein-protein 
interactions (Park et al., 2001) or form zinc fingers (Laity et al., 2001). It would be 
rewarding to investigate whether these cysteine-rich-region-containing isoforms have 
similar or distinct cell growth functions with hMI-ERla (N3a) and hMI-ERl~ (N3~) 
isoforms, which lack this cysteine-rich region and which were used in this study. 
To obtain a better understanding of the role ofhMI-ERla and~ in tumorigenesis, 
it would be rewarding to examine the protein expression and subcellular localization of 
each protein isoform ofhMI-ER1, as well as correlate with other related molecules such 
as RB and ERa in more tumour and normal tissue samples. Tissue microarray 
approaches may be very useful for this purpose to examine a large number of samples in 
more efficient ways (Packeisen et al., 2003). 
7.2.6 Knockout specific hMI-ERl isforms in mice 
Although preliminary observation indicated that overexpression ofhMI-ER1a and 
~ suppresses colony formation efficiency (Paterno et al., unpublished data), the role of 
physiological levels of these hMI-ER protein isoforms is unknown. Gene-targeting 
studies are which would address the role of mouse MI-ER1 in cell growth regulation. 
Initial studies would be to disrupt the mouse MI-ERla or ~ isoforms by targeting the 
appropriate C-terminus-encoding exon, leaving potential expression of the other mouse 
MI-ER1 isoforms intact. Although exogenously expressed MI-ERla or ~ protein 
isoforms both suppress colony formation efficiency, it is possible that MI-ERla and ~ 
carry out specialized, non-overlapping functions in vivo. 
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Xenopus MI-ER1 was induced as an early response gene by FGF treatment and 
functions as negative regulator of the FGF pathway (Paterno eta!., 1997; Teplitsky eta!., 
2003). An increased expression of hMI-ER1a. induced by FGF was observed in 
mammalian cells (Paterno eta!., personal communication), suggesting that hMI-ERl may 
play a role in the FGF signaling pathway in mammalian cells as well. Since FGF 
signalling pathways are involved in many biological processes including embryonic 
development and angiogenesis (reviewed in Wilkie et a!., 2002), it would be interesting 
to investigate whether mouse mi-erl knock-out would also affect those FGF signalling 
pathways. 
7.3 Conclusion 
The study of the hmi-er 1 P2 promoter has provided some insight into its structure 
and regulation The functional study of hMI-ERla. and ~ isoforms revealed that hMI-
ER1a. and ~ function as transcriptional repressors on the G5TKCAT promoter by 
recruitment of HDACl via the ELM2 domain. hMI-ER1a. and ~ also function as 
transcriptional repressors on their own promoter, through interaction with Sp 1 and 
interference with the GC box recognition by Sp 1 via the SANT -domain-containing 
region. In the present study, hMI-ERla. and~ were also found to interact with HSP40, 
TRABID and RB, which have distinct functions. There is also preliminary evidence that 
hMI-ER1 plays a role in cell growth regulation. A likely scenario is that hMI-ERl 
coordinates multiple interacting protein partners, thereby linking signal transduction, 
transcription and cell growth regulation. Further study of hMI-ER1a. and ~ related 
complexes and function may help to decipher the composition of multi-protein signalling 
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complexes involving hMI-ERla and ~, which would eventually contribute to 
reconstruction of signal transduction pathways and benefit the specific therapeutic 
targeting of diseases such as cancer. 
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APPENDICES 
Appendice 1 Alignment ofELM2 domains by PFAM. Accession number PF01448 
hMI-ERl/180-239 
MTAl HUMAN/165-226 
MTAl MOUSE/165-226 
MTAl RAT/165-226 
MTA2 HUMAN/145-206 
MTA2 MOUSE/145-206 
MTA3 HUMAN/148-209 
MTA3 MOUSE/148-208 
EG27 CAEEL/224-281 
Q8BND7/174-234 
Q8BSS0/147-207 
Q86YG8/174-233 
Q8NA13/111-170 
Q9VWH3/90-153 
Q8MSX7/1-38 
Q9P2K3/24-86 
QBVDZ0/1-61 
Q8N5U3/57-119 
Q9JMK4/2-63 
QBC796/44-107 
QBIZ40/44-107 
Q90WN5/50-113 
QBCFE3/1-63 
Q15044/14-78 
Q86VG5/100-164 
Q9UKL0/100-164 
Q9VHD1/1619-1679 
Q9U6X3/230-291 
KEIMVGSM.FQAEIPVGICRYKENEKVYEND---DQLLWDPE.---- YLPEDKVIIFLKDASR---RTGDEK 
GEIRVGNR.YQADITDLLKEGEEDGRDQSRL---ETQVWEAH.-.--NPLTDKQIDQFLVVARS--VGTFARA 
GEIRVGNR.YQADITDLLKEGEEDGRDQSKL---ETKVWEAH.-.--NPLVDKQIDQFLVVARS--VGTFARA 
GEIRVGNR.YQADITDLLKDGEEDGRDQSKL---ETKVWEAH.-.--NPLVDKQIDQFLVVARS--VGTFARA 
GEIRVGCK.YQAEIPDRLVEGESDNRNQQKM---EMKVWDPD.-.--NPLTDRQIDQFLVVARA--VGTFARA 
GEIRVGCK.FQAEIPDRLAEGESDNRNQQKM---EMKVWDPD.-.--NPLTDRQIDQFLVVARA--VGTFARA 
GEIRVGPR.YQADIPEMLLEGESDEREQSKL---EVKVWDPN.-.--SPLTDRQIDQFLVVARA--VGTFARA 
GEIRVGPK.YQADIPDMLP-EDSDEREQSKL---EVKVWDPN.-.--SPLTDRQIDQFLVVARA--VGTFARA 
YAIRVGTS.FQATLPPMAECSVGDDSDR------DELLYRPN.-.---SIESGEEEDYIKLARC--YRTYTLS 
REIMIGLE.YQAEIPPYLGEYNGDDEKAYEN-E-DQLLWHPG.-.---VLLESKVKEYLVETS---LRTGNEK 
REIMIGLE.YQAEIPPYLGEYNGDDEKAYEN-E-DQLLWHPG.-.---VLLESKVKEYLVETS---LRTGNEK 
KEIMIGLQ.YQAEIPPYLGEYDGNEKVYENE---DQLLWCPD.-.---VVLESKVKEYLVETS---LRTGSEK 
KEIMIGLQ.YQAEIPPYLGEYDGNEKVYENE---DQLLWCPD.-.---VVLESKVKEYLVETS---LRTGSEK 
EKIRVGRD.YQAVCPPLVPEAERRPEQMNER---ALLVWSPT.-.--KEIPDLKLEEYISVAKEKYGYNGEQA 
--------.------------------MNER---ALLVWSPT.-.--KEIPDLKLEEYISVAKEKYGYNGEQA 
VGMRVGAE.YQARIPEFDPGATKYTDKDN----GGMLVWSPY.-.--HSIPDAKLDEYIAIAKEKHGYNVEQA 
--MRVGAE.YQARIPEFDPGATKYTDKDN----GGMLVWSPY.-.--HSIPDAKLDEYIAIAKEKHGYNVEQA 
VGMRVGAE.YQARIPEFDPGATKYTDKDN----GGMLVWSPY.-.--HSIPDARLDEYIAIAKEKHGYNVEQA 
--IRVGTN.YQAVIPECKP--ESPARYSNKELK-GMLVWSPN.-.--HCVSDAKLDKYIAMAKEKHGYNIEQA 
SMIRVGTN.YQAVIPECKP--ESPARYSNKELK-GMLVWSPN.-.--HCVSDAKLDKYIAMAKEKHGYNIEQA 
SMIRVGTN.YQAVIPECKP--ESPARYSNKELK-GMLVWSPN.-.--HCVSDAKLDKYIAMAKEKHGYNIEQA 
GGMRVGLQ.YQAVVPEFDQ-EVAKNCQEREN--LGMLVWSPN.-.--QNISEAKLDEYISVAKEKHGYNMEQA 
--MRVGPQ.YQAAVPDFDPAKLARRSQERDN--LGMLVWSPN.-.--QSLSEAKLDEYIAIAKEKHGYNMEQA 
GGMRVGPQ.YQAVVPDFDPAKLARRSQERDN--LGMLVWSPN.-.--QNLSEAKLDEYIAIAKEKHGYNMEQA 
GGMRVGPQ.YQAVVPDFDPAKLARRSQERDN--LGMLVWSPN.-.--QNLSEAKLDEYIAIAKEKHGYNMEQA 
GGMRVGPQ.YQAVVPDFDPAKLARRSQERDN--LGMLVWSPN.-.--QNLSEAKLDEYIAIAKEKHGYNMEQA 
SKVNLGST.YQAQIPSCRPLEEALRDSP-----GAEMMWNPE.-.--VQEDEKILMRYIDLSKS-SAVPMGSH 
GEIRVGSR.YQCDIPAKLKDTATDDRKLEEL---ESLVWTPE.-.--HSLTDRKIDQFLVVSRS--IGTFARA 
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Q9VNF6/230-291 
Q9VNF7/194-255 
Q9PUN0/145-206 
Q7ZUE1/148-209 
QBOUI1/161-222 
Q86SW2/139-200 
Q86TR6/79-140 
075046/16-75 
Q9P2R6/284-343 
Q96PN7/779-843 
Q9NQ72/535-599 
Q9NQ73/535-599 
QBBXJ2/785-849 
Q810H8/784-848 
Q8BUZ9/713-778 
Q7ZV74/167-229 
Q960H5/216-275 
Q9V4M4/272-331 
Q8N344/159-220 
Q9ULM7/194-255 
SPR1 CAEEL/107-170 
Q9LDD4/372-427 
082364/372-428 
Q84JT7/358-414 
P91437/126-188 
Q19306/20-82 
018691/129-193 
GEIRVGSR.YQCDIPAKLKDTATDDRKLEEL---ESLVWTPE.-.--HSLTDRKIDQFLVVSRS--IGTFARA 
GEIRVGSR.YQCDIPAKLKDTATDDRKLEEL---ESLVWTPE.-.--HSLTDRKIDQFLVVSRS--IGTFARA 
GEIRVGSK.YQAEIPDQLAEGESDNRNQQKM---EIKVWDPE.-.--NPLTDRQIDQFLVVARA--VGTFARA 
GEIRVGPR.FQADVPEMLQEGEADDRDQSKL---EMKMWDPE.-.--CPLTNKQIDQFLVVARA--VGTFARA 
GEIRVGNR.YQADITDLLKEGEEDGRDQSKL---ETKVWEAH.-.--NPLVDKQIDQFLVVARS--VGTFARA 
GEIRVGNR.YQADITDLLKEGEEDGRDQSRL---ETQVWEAH.-.--NPLTDKQIDQFLVVARS--VGTFARA 
GEIRVGNR.YQADITDLLKEGEEDGRDQSRL---ETQVWEAH.-.--NPLTDKQIDQFLVVARS--VGTFARA 
GEIRVGPS.HQAKLPDLQP-FPSPDGDT-VTQH-EELVWMPG.-.----VNDCDLLMYLRAARS--MAAFAGM 
GEIRVGPS.HQAKLPDLQP-FPSPDGDT-VTQH-EELVWMPG.-.----VNDCDLLMYLRAARS--MAAFAGM 
PRINIGLR.FQAEIPELQDISALAQDTHK-----ATLVWKPWp-eLENHDLQQRVENLLNLCCS-SALPGGGT 
PRINIGLR.FQAEIPELQDISALAQDTHK-----ATLVWKPWp-eLENHDLQQRVENLLNLCCS-SALPGGGT 
PRINIGLR.FQAEIPELQDISALAQDTHK-----ATLVWKPWp-eLENHDLQQRVENLLNLCCS-SALPGGGT 
PRINIGLR.FQAEIPELQDVSALAQDTHR-----ATLVWKPWp-eLENQALQQQVENLLNLCCS-SALPGGGT 
PRINIGLR.FQAEIPELQDVSALAQDTHR-----ATLVWKPWp-eLENQALQQQVENLLNLCCS-SALPGGGT 
PRINVGTR.FQAEIPMMRD-RALAAFDPHK----ADLVWQPWeHlESSWEKQRQVDDLLTAACS-SIFPGAGT 
KEIMVGSM.YQAETPVGLCKYKDNEKVYEND---DQLLWNPE.-.---LLPEEKVEEFLTEASKRSGDEAGVD 
KIIMVGHD.YQAEIPEGLSQYGDILPYENE----DQLIWEPS.-.---QVSEREVEEYLAKIQE--TRSIVPP 
KIIMVGHD.YQAEIPEGLSQYGDILPYENE---DQLIWEPS.-.---QVSEREVEEYLAKIQE.--TRSIVPP 
KEIMVGPQ.FQADLSNLHLNRHCEKIYENE----DQLLWDPS.-.---VLPEREVEEFLYRAVKRRWHEMAGP 
KEIMVGPQ.FQADLSNLHLNRHCEKIYENE----DQLLWDPS.-.---VLPEREVEEFLYRAVKRRWHEMAGP 
KEINVGTE.FQAKIADLNLNDKACNEDR-DDQ--DELIWNTP.-.--ETIDDEKLEAFIRESSDRYLIPIDRA 
RCIKVGHQ.HQAQVDEWTESGVDSDSKW-----LGTRIWPPE.-.-----NSEALDQTLGNDL---VGKGRPD 
PCALVGSK.FQAKVPEWTGITPESDSKW-----LGTRIWP--.-.---LTKEQTKANLLIERDR--IGKGRQD 
PCALVGSK.FQAKVPEWTGITPESDSKW-----LGTRIWP--.-.---LTKEQTKANLLIERDR--IGKGRQD 
RSIRVDPVlFQADVPLFNE--ATVEESARED---DTILWT-Id-.QTNQPSDEVIDNYLKDVVG--LRKAHDQ 
RSIRVDPVlFQADVPLFNE--ATVEESARED---DTILWT-Id-.QTNQPSDEVIDNYLKDVVG--LRKAHDQ 
LENAVGRE.HQAHVGPFKKLRGRDEEEDR-----DERMWCPPd-dDQNLDYDLLKNAYWRAIWR-QFENHIPM 
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Appendice 2 Alignment of SANT domains by PFAM. Accession number PF00249 
hMI-ER1/288-331 
MTA1 HUMAN/285-331 
ADA2 HUMAN/72-118 
ADA2 YEAST/62-108 
EG27 CAEEL/334-380 
YGN1 YEAST/557-602 
075046/125-171 
YDBJ SCHP0/248-293 
SNT1 YEAST/670-716 
NCR1 HUMAN/437-482 
NCR2 HUMAN/429-474 
YKZ6 CAEEL/215-260 
061907/481-527 
Q15044/103-148 
042194/274-320 
Q20733/562-607 
NCR1 HUMAN/625-670 
P70413/224-268 
TRF1 CRIGR/380-428 
TRF2 MOUSE/442-490 
DOT6 YEAST/72-117 
YBF4 YEAST/75-120 
065366/59-104 
064877/47-101 
048523/13-66 
Q9SJW0/17-68 
Q98807/189-240 
Q9FH42/25-76 
Q9FK47/47-98 
---WTEEECRNFEQGLKAYGKD--------FHLIQANK------.-VRTRSVGECVAFYYMWK 
MEEWSASEANLFEEALEKYGKDFTDIQ ... QDFLPWKSL ............. TSIIEYYYMWK 
DPSWTAQEEMALLEAVMDCGFG ....... NWQDVANQMCTK ......... TKEECEKHYMKHF 
CPDWGADEELQLIKGAQTLGLG ....... NWQDIADHIGSR ......... GKEEVKEHYLKYY 
VDNMTQDDAKKFAKGIKQLGKNFSRIH ... RELLPHHSR ............. EQLVSYYYLWK 
EPSFTAVEIRKFEEAVEKFGSE ........ LRPVCEYVG ......... TQPMSMIVRFYYNWK 
EKCWTEDEVKRFVKGLRQYGKNFFRIR ... KELLPNKET ............. GELITFYYYWK 
PDIWNEEQHSIFVQQFILHGKKFGKI .... AEAVPGKNS ............. KECVLHYYLTK 
SDNFTDHEHSLFLEGYLIHPKKFGKI .... SHYMGGLRSP ............ EECVLHYYRTK 
MNVWTDHEKEIFKDKFIQHPKNFGLI .... ASYLERKSV ............. PDCVLYYYLTK 
MNMWSEQEKETFREKFMQHPKNFGLI .... ASFLERKTV ............. AECVLYYYLTK 
LEEWSPEERSLFKSRQADHVKI ........ FHGLTEFFV ......... DKTASDLVLFYYMNK 
LEEWSTPEMNLFEDALDKVGKDFNEIR ... AEYLPWKSI ............. RDIVEYYYLMK 
PDEWTVEDKVLFEQAFSFHGKT ........ FHRIQQMLP ......... DKSIASLVKFYYSWK 
LSVWTEEECRNFEQGLKAYGKD ........ FHLIQANKVR ........ TRSVGECVAFYYMWK 
SVLWTPDEIYQFQDAIYQSEKD ........ FDKVAVELP ......... GKSVKECVQFYYTWK 
TSRWTEEEMEVAKKGLVEHGRNWAAI .... AKMVGTKSE ............. AQCKNFYFNYK 
VGKYTPEEIEKLKELRIKHGND ........ WATIGAALG .......... RSASSVKDRCRLMK 
RQAWLWEEDKNLRSGVRKYGEG ....... NWSKILLHYKFN ....... NRTSVMLKDRWRTMK 
KQKWTIEESEWVKDGVRKYGEG ....... NWAAISKSYPFV ....... NRTAVMIKDRWRTMK 
PSSWDPQDDLLLRHLKEVKKMG ........ WKDISQYFP ......... NRTPNACQFRWRRLK 
PSSWDPSDDIKLRHLKEIKNLG ........ WKEIAHHFP ......... NRTPNACQFRWRRLK 
KESLTQEEQILVINLQAKHGNK ........ WKKIAAEVP ......... GRTAKRLGKWWEVFK 
TQAWGTWEELLLACAVKRHGFG ....... DWDSVATEVRSRS.SLSHLLASANDCRHKYRDLK 
KQTWSTWEELLLACAVHRHGTE ....... SWNSVSAEIQKLSPNLCSLTASA .. CRHKYFDLK 
RLRWTHELHERFVDAVAQLGGPD .... RATPKGVLRVMG ....... VQGLTIYHVKSHLQKYR 
RLRWTPELHNRFVNAVNSLGGPD .... KATPKGILKLMG ....... VDGLTIYHIKSHLQKYR 
RLRWTADLHDRFVDAVAKLGGAD .... KATPKSVLKLMG ....... LKGLTLYHLKSHLQKYR 
RLKWTPDLHERFVEAVNQLGGGD .... KATPKTIMKVMG ....... IPGLTLYHLKSHLQKYR 
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Q9FG27/193-244 
Q9MOH0/227-278 
Q9LSH8/243-294 
Q9MA23/25-76 
Q9SIZ5/84-135 
082801/56-104 
Q9FJV5/107-158 
Q9ZPZ8/88-139 
Q9XEB2/16-67 
Q9FGT7/193-243 
Q9FXD6/195-246 
Q9FTT8/220-267 
Q9LTH4/143-193 
Q9LZJ8/213-268 
Q9FX84/197-245 
Q9FPE8/214-262 
081713/24-69 
004605/59-104 
004322/118-165 
Q62187/564-608 
YD3A SCHP0/55-105 
024251/16-68 
P78793/32-81 
REB1 KLULA/338-382 
Q12457/345-389 
REB1 SCHP0/313-357 
065366/4-53 
062208/356-402 
Q00658/7-54 
MYB1 NEUCR/9-55 
Q9ZTD7/6-52 
RIRWTQDLHEKFVECVNRLGGAD .... KATPKAILKRMD ....... SDGLTIFHVKSHLQKYR 
RMRWTPELHEAFVEAVNSLGGSE .... RATPKGVLKIMK ....... VEGLTIYHVKSHLQKYR 
RMRWTPELHESFVKAVIKLEGPE .... KATPKAVKKLMN ....... VEGLTIYHVKSHLQKYR 
RLRWTPELHRSFVHAVDLLGGQY .... KATPKLVLKIMD ....... VKGLTISHVKSHLQMYR 
RLRWTPELHICFLQAVERLGGPD .... RATPKLVLQLMN ....... VKGLSIAHVKSHLQMYR 
RLRWTPDLHLRFVRAVERLGGQE .... RATPKLVRQMMN ....... IKGLSIAHVKSHLQ .. . 
RMRWTSTLHAHFVHAVQLLGGHE .... RATPKSVLELMN ....... VKDLTLAHVKSHLQMYR 
RLRWSSDLHDCFVNAVEKLGGPN .... KATPKSVKEAME ....... VEGIALHHVKSHLQKFR 
RMHWTDDLDIRFIQVIEKLGGEES .... ATPKRILSLMG ....... VRDLTISHVKSHLQMYR 
RVVWSQELHQKFVSAVQQLG.LDK .... AVPKKILDLM ....... SIEGLTRENVASHLQKYR 
RVVWSFELHHKFVNAVNQIGCDHK .... AGPKKILDLM ....... NVPWLTRENVASHLQKYR 
... WTPELHRRFVQAVEQLG.IDK .... AVPSRILELM ....... GIECLTRHNIASHLQKYR 
RLVWTPQLHKRFVDVVAHLG.IKN .... AVPKTIMQLM ....... NVEGLTRENVASHLQKYR 
RMQWTPELHHKFEVAVEKMGSLEK .... AFPKTILKYMQEEL ... NVQGLTRNNVASHLQKYR 
... WNPELHRRFVDALQQLGGPG .... VATPKQIREHMQ ....... EEGLTNDEVKSHLQKYR 
... WSPELHRRFLHALQQLGGSH .... VATPKQIRDLMK ....... VDGLTNDEVKSHLQKYR 
RERWTEDEHERFLEALRLYG ........ RAWQRIEEHIG ....... TK .. TAVQIRSHAQKFF 
RENWTDQEHDKFLEALHLFD ........ RDWKKIEAFVG ....... SK .. TVVQIRSHAQKYF 
GVPWTEEEHRLFLVGLQKLGKG ....... DWRGISRNYVT ........ SRTPTQVASHAQKYF 
KGRYNEEDTKKLKAYHSLHGND ........ WKKIGAMVA .......... RSSLSVALKFSQIG 
RVKWTEKETNDLLRGCQIHGVG ....... NWKKILLDERFH ..... FTNRSPNDLKDRFRTIL 
KQKWTAEEEEALKAGVKKHGMG ....... KWKTILVDPDFATA ... LTHRSNIDLKDKWRNLG 
RKQFTPEEDERLLEGFFLHGPC ........ WTRISKDANLG ..... LQNRRSTDLRDRFRNAF 
RGKWTPEEDAELARWCAEKE.G ....... QWSN .. IGKVLG ........ RMPEDCRDRWRNYV 
RGKWTPEEDQELARLCLEKE.G ....... HWTE .. VGKLLG ........ RMPEDCRDRWRNYM 
RCVWSKEEDEELRKNVVEHG.K ....... CWTK .. IGRKMA ........ RMPNDCRDRWRDVV 
RQRWRPEEDALLRAYVKEYGPR ....... DWHLVTQRMN ...... KPLNRDAKSCLERWKNYL 
HGRWTDQEDVLLVCAVSRYGAK ....... DWAKVAQAVQ ......... NRNDSQCRERWTNVL 
RGPWVPEEDQLLLQLVREQGPNNN ...... WVRISQHMH ......... YRSPKQCRERYHQNL 
RGPWSAGEDQRLIKLVKDLGPGN ....... WVNVARILG ......... TRTPKQCRERWHQNL 
RGHWRPAEDEKLKDLVEQYGPHN ....... WNAIALKLP ......... GRSGKSCRLRWFNQL 
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Q42575/55-101 
022179/13-59 
004192/50-96 
065263/69-118 
001719/93-139 
MYB DROME/136-182 
065528/26-72 
MYBH DICDI/201-247 
MYBA CHICK/87-133 
Q96463/12-59 
Q9ZTC3/10-57 
023891/14-61 
MYBC MAIZE/14-61 
049538/14-62 
Q38850/25-72 
023892/22-69 
P81394/14-61 
049744/14-61 
MYB2 PHYPA/14-61 
049649/14-61 
Q43597/14-61 
Q39153/14-61 
MYB1 MAIZE/16-63 
004109/14-61 
049782/15-62 
049765/14-61 
Q38739/14-61 
023618/15-62 
004141/14-61 
Q40920/14-61 
MYBP MAIZE/14-61 
KGPWSKEEDDVLSELVKRLGARN ....... WSFIARSIP ......... GRSGKSCRLRWCNQL 
KGPWSPEEDDLLQSLVQKHGPRN ....... WSLISKSIP ......... GRSGKSCRLRWCNQL 
KGPWLPEQDEALTRLVKMCGPRN ....... WNLISRGIP ......... GRSGKSCRLRWCNQL 
KGAWKKEEDELLSELVKDYMENDR .... PPWSKISKELP ......... GRIGKQCRERWHNHL 
KGPWTTEEDERVVELVREHGPKR ....... WSLISKFLV ......... GRTGKQCRERWHNHL 
KGPWTRDEDDMVIKLVRNFGPKK ....... WTLIARYLN ......... GRIGKQCRERWHNHL 
KGPWSKEEDNTIIDLVEKYGPKK ....... WSTISQHLP ......... GRIGKQCRERWHNHL 
KGAWTKDEDDKVIELVKTYGPKK ....... WSDIALHLK ......... GRMGKQCRERWHNHL 
KGPWTKEEDQRVIELVQKYGPKR ....... WSLIAKHLK ......... GRIGKQCRERWHNHL 
GVPVDAAECKILVAHIHSHGHG ....... NWRALPKQA ........ GLLRCGKSCRLRWINYL 
KGAWTAEEDSLLRLCIDKYGEG ....... KWHQVPLRA ........ GLNRCRKSCRLRWLNYL 
RGAWTAMEDDILVSYIAKHGEG ....... KWGALPKRA ........ GLKRCGKSCRLRWLNYL 
RGAWTSKEDDALAAYVKAHGEG ....... KWREVPQKA ........ GLRRCGKSCRLRWLNYL 
KGPWSPEEDAKLKDYIENSGTGG ...... NWIALPQKI ........ GLRRCGKSCRLRWLNYL 
RGPWTVEEDEILVSFIKKEGEG ....... RWRSLPKRA ........ GLLRCGKSCRLRWMNYL 
RGPWTPEEDEVLARFVAREGCD ....... RWRTLPRRA ........ GLLRCGKSCRLRWMNYL 
RGPWTEEEDQKLTSYVLKNGIQ ....... GWRVIPKLA ........ GLSRCGKSCRLRWMNYL 
RGPWTPEEDQILVSFILNHGHS ....... NWRALPKQA ........ GLLRCGKSCRLRWMNYL 
RGPWTSEEDQKLVSHITNNGLS ....... CWRAIPKLA ........ GLLRCGKSCRLRWTNYL 
KGPWTVEEDKKLINFILTNGHC ....... CWRALPKLA ........ GLRRCGKSCRLRWTNYL 
KGAWTPEEDKLLVDYIQVNGHG ....... SWRLLPKLA ........ GLNRCGKSCRLRWTNYL 
KGPWSAEEDRILINYISLHGHP ....... NWRALPKLA ........ GLLRCGKSCRLRWINYL 
RGSWTPQEDMRLIAYIQKHGHT ....... NWRALPKQA ........ GLLRCGKSCRLRWINYL 
KGPWTPEEDIILVSYIQEHGPG ....... NWRSVPINT ........ GLMRCSKSCRLRWTNYL 
KGAWTPEEDQKLLSYLNRHGEG ....... GWRTLPEKA ........ GLKRCGKSCRLRWANYL 
KGAWTAEEDKKLISYIHEHGGG ....... GWRDIPQKA ........ GLKRCGKSCRLRWANYL 
KGPWTVDEDQKLLAYIEEHGHG ....... SWRSLPLKA ........ GLQRCGKSCRLRWANYL 
KGPWLPEEDDKLTAYINENGYG ....... NWRSLPKLA ........ GLNRCGKSCRLRWMNYL 
KGPWTPEEDEKLIAYIKEHGQG ....... NWRTLPKNA ........ GLSRCGKSCRLRWTNYL 
KGAWSAEEDSLLGKYIQTHGEG ....... NWRSLPKKA ........ GLRRCGKSCRLRWLNYL 
RGRWTAEEDQLLANYIAEHGEG ....... SWRSLPKNA ........ GLLRCGKSCRLRWINYL 
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MYB1 HORVU/14-61 
Q43524/14-61 
MYB3 HORVU/16-63 
049018/14-61 
049017/15-62 
080883/20-67 
023893/43-90 
Q39028/22-69 
050069/10-57 
P92986/20-67 
049020/22-69 
Q39550/29-76 
022684/22-69 
GL1 ARATH/16-63 
BAS1 YEAST/169-214 
065263/12-63 
MYB DROME/85-130 
001719/41-87 
MYBB XENLA/31-77 
MYBB CHICK/31-77 
MYBA XENLA/35-80 
MYB BOVIN/40-86 
MYBA CHICK/35-81 
Q9ZPU2/40-86 
MYBH DICDI/149-195 
BAS1 YEAST/116-161 
015816/427-474 
064502/30-76 
CEF1 YEAST/10-56 
Q21119/8-54 
CC5 SCHP0/6-52 
KGAWTKEEDDRLTAYIKAHGEG ....... CWRSLPKAA ........ GLLRCGKSCRLRWINYL 
RGLWSPEEDEKLIRYITSHGYG ....... CWSEVPEKA ........ GLQRCGKSCRLRWINYL 
KGLWSPEEDEKLYNHIIRHGVG ....... CWSSVPRLA ........ ALNRCGKSCRLRWINYL 
KGAWTAEEDRKLAEVITVHGAK ....... RWKTIPSIA ........ GLNRCGKSCRLRWMNYL 
KGSWTAEEDRRLAKYIEIHGAK ....... RWKTIAIKS ........ GLNRCGKSCRLRWLNYL 
KGPWTTTEDAILTEYVRKHGEG ....... NWNAVQKNS ........ GLLRCGKSCRLRWANHL 
KGPWTSWEDSILEKYIKKHGER ....... NWKLVQKNT ........ GLLRCGKSCRLRWMNHL 
KGPWTEEEDAILVNFVSIHGDA ....... RWNHIARSS ........ GLKRTGKSCRLRWLNYL 
KGPWTEQEDILLVNFVHLFGDR ....... RWDFVAKVS ........ GLNRTGKSCRLRWVNYL 
KGPWTAEEDRLLIDYVQLHGEG ....... RWNSVARLR ........ GLKRNGKSCRLRWVNYL 
KGPWTEEEDSMLRAYVNIHGEG ....... RWNAVARLS ........ GLRRTGKSCRLRWLNYM 
RGPWTVDEDFTLINYIAHHGEG ....... RWNSLARFA ........ GLKRTGKSCRLRWLNYL 
KGPWTMEEDLILINYIANHGDG ....... VWNSLAKSA ........ GLKRTGKSCRLRWLNYL 
KGLWTVEEDNILMDYVLNHGTG ....... QWNRIVRKT ........ GLKRCGKSCRLRWMNYL 
LREWTLEEDLNLISKVKAYGTK ........ WRKISSEME ......... FRPSLTCRNRWRKII 
KPFFHLMQDQILTNVVKKYQGR ....... NWKRIAECLPGSE .... ENRRNDVQCQHRWLKVL 
GKRWSKSEDVLLKQLVETHG.E ....... NWEIIGPHFK ......... DRLEQQVQQRWAKVL 
RARWTKDEDDMLRQAIEVHGTL ....... DWKLIGSFFP ......... NRSELQCFHRWQKVL 
KVKWTPEEDETLKALVKKHGQG ....... EWKTIASNLN ......... NRTEQQCQHRWLRVL 
KVKWTQEEDEQLKMLVRHYGQN ....... DWKFLASHFP ......... NRSDQQCQYRWLRVL 
KLRWTKDEDDKVKKLVEKHG.E ....... DWGVVARHFI ......... NRSEVQCQHRWHKVL 
KTRWTREEDEKLKKLVEQNGTD ....... DWKVIANYLP ......... NRTDVQCQHRWQKVL 
RVKWTRDEDEKLKKLVEQNGTD ....... DWAFIASHLQ ......... NRSDFQCQHRWQKVL 
KGGWTPEEDETLRRAVEKYKGK ....... RWKKIAEFFP ......... ERTQVQCLHRWQKVL 
KGKWTSEEDQILIKAVNLHNQK ....... NWKKIAEHFP ......... DRTDVQCHHRYQKVL 
KGKWTQEEDEQLLKAYEEHGPH ........ WLSISMDIP ......... GRTEDQCAKRYIEVL 
PNKWTKEESQNLIKLVTENGDK ....... QWKKIATKLG ........ GGKTGAQCAQHWKRVL 
IVTWSPEEDDILRKQISLQGTEN ....... WAIIASKFN ......... DKSTRQCRRRWYTYL 
GGVWTNVEDQILKAAVQKYGTH ....... QWSKVASLLQ ......... KKTARQSELRWNEYL 
GGVWKNTEDEILKAAIMKYGKN ....... QWSRIASLLH ......... RKSAKQCKARWFEWL 
GGAWKNTEDEILKAAVSKYGKN ....... QWARISSLLV ......... RKTPKQCKARWYEWI 
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062208/301-350 
CEF1 YEAST/62-106 
CC5 SCHP0/58-102 
Q01073/213-264 
014108/327-371 
022059/35-80 
Q00658/60-105 
MYB1 NEUCR/61-106 
064502/82-127 
Q9ZTD7/58-103 
Q9ZTD6/3-48 
065528/78-123 
065263/124-169 
Q42575/107-152 
022179/65-110 
004192/102-147 
MYBH DICDI/253-298 
MYB DROME/188-233 
MYBA CHICK/139-184 
080883/73-118 
065898/13-58 
023893/96-141 
065720/14-59 
P81394/67-112 
004110/67-112 
Q9ZR24/33-78 
Q43524/67-112 
049019/67-112 
022264/67-112 
Q9ZQS3/10-55 
MYBC MAIZE/67-112 
SKEWSQDEDTKLIALTKITSING .... HIQWDKVAQCMP ......... GRTRQQVRTRFSHTL 
FTEFSKEEDAQLLDLARELPNQ ........ WRTIADMM .......... ARPAQVCVERYNRLL 
KTEWSREEDEKLLHLAKLLPTQ ........ WRTIAPIV .......... GRTATQCLERYQKLL 
KSSFTKEEDEFILDVVRKNPTKR .. TTHTLYDEISHYVP ......... NHTGNSIRHRFRVYL 
RNAWEESELKKLYTLVEQEGTR ........ WNSIANKLG .......... TSPAACMSQWRFVV 
AVKMSEEEEDLISRMYKLVGDR ........ WELIAGRIP ......... GRTPEEIERYWLMKH 
RDPISAEEGLAIERMVNEMGRC ........ WAEIARRLG ......... NRSDNAVKNWWNGNM 
HGPMTQEEAAIIVREVDLKGPR ........ WADIARKLQ ......... GRSDNAVKNYWNGLN 
RGGWSPEEDTLLCEAQRLFGNR ........ WTEIAKVVS ......... GRTDNAVKNRFTTLC 
RNPFTEEEEERLLAAHRIHGNR ........ WSIIARLFP ......... GRTDNAVKNHWHVIM 
KRAFTEEEEFRLLAAHRAYGNK ........ WALISRLFP ......... GRTDNAVKNHRHVIM 
KNAWTQEEELTLIRAHQIYGNK ........ WAELMKFLP ......... GRSDNSIKNHWNSSV 
KSPWTREEELILVQAQRGNGNK ........ WAEIAKLLP ......... GRTENNIKNHWNCSV 
RNSFTEVEDQAIIAAHAIHGNK ........ WAVIAKLLP ......... GRTDNAIKNHWNSAL 
HRGFTAEEDDTIILAHARFGNK ........ WATIARLLN ......... GRTDNAIKNHWNSTL 
RKPFSDEEEHMIMSAQAVLGNK ........ WSVIAKLLP ......... GRTDNAIKNHWNSNL 
KEAWSDEEDQIIRDQHAIHGNK ........ WAEIAKFLP ......... GRTDNAIKNHWNSSM 
KTAWTEKEDEIIYQAHLELGNQ ........ WAKIAKRLP ......... GRTDNAIKNHWNSTM 
KSSWTEAEDRVIYEAHKRLGNR ........ WAEIAKLLP ......... GRTDNSIKNHWNSTM 
KGSFTPDEEKIIIDLHAKLGNK ........ WARMASQLP ......... GRTDNEIKNYWNTRM 
KGAFSQEEEQLIVEMHAKMGNK ........ WAQMAEHLP ......... GRTDNEIKNYWNTRI 
KGAFSKEEENKIINLHRKMGNK ........ WSRMAADLP ......... GRTDNEIKNYWNTRI 
RGGFTDAEEDRIMELHSQLGNR ........ WSKIASHFS ......... GRTDNEIKNHWNTKI 
KGPLTEMEENQIIELHAHLGNR ........ WSKIALHIP ......... GRTDNEIKNYWNTHI 
RGLLSETEEKTVIDLHEQLGNR ........ WSKIASHLP ......... GRTDNEIKNHWNTHI 
RGPFSTEEEKLVIQLHGILGNR ........ WAAIASQLP ......... GRTDNEIKNLWNTHL 
RGRFTPEEEKLIISLHGAVGNR ........ WAHIASHLP ......... GRTDNEIKNYWNSWI 
RGNFTSQEEEVIINLHATLGNR ........ WSLIASYLP ......... GRTDNEIKNYWNSHL 
RGNITPEEEELVVKLHSTLGNR ........ WSLIAGHLP ......... GRTDNEIKNYWNSHL 
RGKFSVDEEELMIKLHALLGNR ........ WSLIAGRLP ......... ERTDNEVKNYWNSHM 
RGNISYDEEDLIIRLHRLLGNR ........ WSLIAGRLP ......... GRTDNEIKNYWNSTL 
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022685/67-112 
MYB3 HORVU/69-114 
Q9ZTE9/14-59 
MYB2 PHYPA/67-112 
004108/67-112 
004140/67-112 
MYB1 MAIZE/69-114 
Q9ZTC8/3-48 
MYB1 HORVU/67-112 
049782/68-113 
049765/67-112 
Q02992/67-112 
023618/68-113 
064399/67-112 
004109/67-112 
Q39156/35-80 
Q9ZTC3/63-108 
GL1 ARATH/69-114 
050069/63-108 
049020/75-120 
022684/75-120 
049780/14-59 
049770/14-59 
Q9ZTE4/14-59 
049538/68-113 
Q61866/451-507 
YMA9 CAEEL/215-264 
Q94216/533-582 
DJC1 MOUSE/492-541 
015816/480-525 
REB1 SCHP0/365-418 
RGAFSQDEESLIIELHAALGNR ........ WSQIATRLP ......... GRTDNEIKNFWNSCL 
RGCFSQQEEDHIVALHQILGNR ........ WSQIASHLP ......... GRTDNEIKNFWNSCI 
RGPFSEEEEETILTLHSSLGNK ........ WSRIAKYLP ......... GRTDNEIKNYWHSYL 
RGIFSEAEENLILDLHATLGNR ........ WSRIAAQLP ......... GRTDNEIKNYWNTRL 
RGNFTADEEDLIVRLHNSLGNR ........ WSAIAAQMP ......... GRTDNEIKNVWHTHL 
RGNFSKEEEDTIIHLHELLGNR ........ WSAIAARLP ......... GRTDNEIKNVWHTHL 
RGNFTDEEEEAIIRLHGLLGNK ........ WSKIAACLP ......... GRTDNEIKNVWNTHL 
RGRFSFEEEETIIQLHGIMGNK ........ WSAIAARLP ......... GRTDNEIKNYWNTHI 
RGNFSHEEDELIIKLHSLLGNK ........ WSLIAGRLP ......... GRTDNEIKNYWNTHI 
RGEFTEDEERSIISLHALHGNK ........ WSAIARGLP ......... GRTDNEIKNYWNTHI 
RGEFSYEEEQIIIMLHASRGNK ........ WSVIARHLP ......... KRTDNEIKNYWNTHL 
RGKFTLQEEQTIIQLHALLGNR ........ WSAIATHLP ......... KRTDNEIKNYWNTHL 
RGKFSDGEESTIVRLHALLGNK ........ WSKIAGHLP ......... GRTDNEIKNYWNTHM 
RGEFSPEEDDTIIKLHALKGNK ........ WAAIATSLA ......... GRTDNEIKNYWNTNL 
RGNFTAHEEGIIVHLQSLLGNR ........ WAAIASYLP ......... QRTDNDIKNYWNTHL 
QRNFSKDEDDLILKLHALLGNR ........ WSLIAGRLP ......... GRTDNEVRIHWETYL 
RGRLSNDEVDLLLRLHKLLGNR ........ WSLIAGRLP ......... GRTANDVKNYWNTHL 
KGNFTEQEEDLIIRLHKLLGNR ........ WSLIAKRVP ......... GRTDNQVKNYWNTHL 
RGKMTPQEERLVLELHAKWGNR ........ WSKIARKLP ......... GRTDNEIKNYWRTHM 
RGNISLEEQLLILELHSRWGNR ........ WSKIAQHLP ......... GRTDNEIKNYWRTRV 
RGNITPEEQLIIMELHAKWGNR ........ WSKIAKHLP ......... GRTDNEIKNFCRTRI 
RGKFTPQEEEEIIQLHAVLGNR ........ WAAMAKKMQ ......... NRTDNDIKNHWNSCL 
HDSFSTQEEELIIECHRAIGSR ........ WSSIARKLP ......... GRTDNDVKNHWNTKL 
HGDFTEEEDNIIYSLFASIGSR ........ WSVIAAHLQ ......... GRTDNDIKNYWNTKL 
HGGFSEEEDNIICNLYVTIGSR ........ WSIIAAQLP ......... GRTDNDIKNYWNTRL 
SKNWSEDDLQLLIKAVNLFPAGTN .... SRWEVIANYMNIHSS .. SGVKRTAKDVISKAKSLQ 
EDDWSQAEQKAFETALQKYPKGTD .... ERWERISEEIG ......... SKTKKQVMVRFKQLA 
EDVWSATEQKTLEDAIKKHKSSDP .... ERWEKISTEVG ......... TKSKKACIRRFKYLV 
EEAWTQSQQKLLELALQQYPKGAS .... DRWDKIAKCVP ......... SKSKEDCIARYKLLV 
KGSWDEAEEELLFQLVDKHGQS ........ WKNVAIEIK ......... TRTDIQCRYQYFKAI 
RNAWSLEEETQLLQIVAELRNREDLSSDINWTLVAQMLG ......... TRTRLQCRYKFQQLT 
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SWI3 YEAST/524-569 
022811/225-270 
YFK7 YEAST/312-358 
013788/290-335 
014470/247-292 
Q9VF03/671-716 
023486/88-134 
062208/409-455 
022895/127-173 
TBF1 YEAST/409-456 
042961/405-451 
SNT1 YEAST/889-934 
Q19953/77-125 
080435/19-68 
TFC5 YEAST/417-462 
094481/365-410 
YDPA SCHP0/71-116 
Q15044/294-339 
SPR1 CAEEL/483-528 
DENWSKEDLQKLLKGIQEFGAD ........ WYKVAKNVG ......... NKSPEQCILRFLQLP 
KPEWSDKEILLLLEAVMHYG ........ DDWKKVASHVI ......... GRTEKDCVSQFVKLP 
KKNWSDQEMLLLLEGIEMYE ........ DQWEKIADHVGG ........ HKRVEDCIEKFLSLP 
DDTWTAQELVLLSEGVEMYS ........ DDWAKVASHVN ......... TKSVEECILKFLNLP 
EKPWSNQETLLLLEAIETYG ........ DDWNQIALHVG ......... SRTKEQCLIHFLQIP 
AREWTDQETLLLLEGLEMHK ........ DDWNKVCEHVG ......... SRTQDECILHFLRLP 
CPDWSADDEMLLLEGLEIYGLG ....... NWAEVAEHVGTK ......... SKEQCLEHYRNIY 
NERFTLVEDEQLLYAVKVFGKG ....... NWAKCQMLLP ......... KKTSRQLRRRYLQLI 
DSVWTKEETDQLFEFCQNFDLR ........ FVVIADRFP ........ VSRTVEELKDRYYSVN 
KRTWSKEEEEALVEGLKEV.GP ....... SWSKILDLYGPG ....... GKITENLKNRTQVQL 
RRSWTKEEEEALLDGLDLVKGP ....... RWSQILELYGPG ....... GKKSEVLKYRNQV .. 
TSYWSVRESQLFPELLKEFGSQ ........ WSLISEKLG ......... TKSTTMVRNYYQRNA 
AMSWTHEDEFELLKAAHKFKMG ....... NWGEIAESIG ....... RGRKDGHNCKDYFEKHF 
GTKWTAEENKKFENALAFYDKDTP .... DRWSRVAAMLP ......... GKTVGDVIKQYRELE 
TDPWTVEEMIKFYKALSMWG ........ TDFNLISQLY ........ PYR.SRKQVKAKFVNEE 
PEKWNAMDTEKFYKALSQWG ........ TDFALIANMF ........ PTR.NRRQIKLKFKQEE 
GTYWSAEEKELFFQAVARNGKR ....... DLDLIAYSIP ......... SKSAVQIERYINAL. 
NARWTTEEQLLAVQAIRKYGRDFQAI .... SDVIGNKSV ............. VQVKNFFVNYR 
SQDWTQLERSQVIRCFNMYGAH ........ FEHIADVIG ......... TKTPDQVYQFYLENQ 
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